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Bone is a metabolically active tissue being throughout life continuously remodeled.1 During 
growth bone mass is accumulated until bone modeling ends with epiphyseal closure. After 
that bone remodeling takes place, old bone being removed by osteoclastic resorption and 
replaced with new bone by osteoblastic bone formation. These two processes are regulated by 
systemic hormones and several systemic or paracrine growth factors and cytokines, and they 
are tightly coupled. When the regulation of remodeling detoriates, the processes are no longer 
coupled and as a result a disease state develops, more often a state where bone resorption 
exceeds bone formation, and bone mass is thus lost. 
As early as 1920’s alkaline phosphatase activity was found to be elevated in bone diseases,2
and for decades it was the only laboratory parameter reflecting bone formation. 
Electrophoretic and chromatographic methods enabled the assessment of bone specific 
isoform of the enzyme, at least semiquantitavely.3, 4. Hydroxyproline has been used until 
recently as a resorption marker.5, 6 This amino acid is formed during type I collagen 
breakdown, but it can also originate from other tissues and even from the diet.  
The increasing knowledge of bone matrix components, the characterization of the bone 
specific peptide, osteocalcin,7 and the development of assay techniques, especially sensitive 
immunoassays, led to the description of a radioimmunoassay method for measuring serum 
osteocalcin concentration in 1980.8 In this assay bovine osteocalcin was used as an antigen to 
raise the polyclonal antibody of the assay, later monoclonal antibodies were raised against 
both bovine and human osteocalcin, and different immunoreactive forms of osteocalcin were 
characterized.9 The early osteocalcin assays measured the intact molecule and to a differing 
extent several of its breakdown products. For almost ten years osteocalcin was the only 
marker believed to reflect bone formation, and it is still widely used as a marker of bone 
formation. Numerous methods have been described and are commercially available, the more 
recent ones using human osteocalcin as antigen, monoclonal antibodies raised against specific 
fragments of the molecule or against the intact molecule, and immunometric assay 
principle.10, 11, 12.
During the last ten years several biochemical markers of both bone formation and resorption 
have been introduced. Most of these markers are derived from type I collagen, the most 
abundant component of bone organic matrix. Ten years after the first assay for osteocalcin 
was published a radioimmunoassay method was described for the carboxy-terminal 
propeptide of type I procollagen, PICP.13 This large protein, rather than a peptide, is liberated 
into the circulation during type I collagen formation, and thus its serum concentration reflects 
bone formation rate. Several methods for measuring the extension peptide from the amino-
terminal end of the type I procollagen, PINP, have also been described.14, 15, 16 These assays 
give somewhat discordant results, and their clinical value has not been fully elucidated. 
Immunoassays for measuring specifically bone isoform of alkaline phosphatase have also 
been introduced. One of these assays measures the mass concentration of the enzyme,17 the 
other assay measures the activity after immunoextraction of the isoform.18 Both of these 
assays crossreact to some extent with the liver isoform of alkaline phosphatase, the other 
isoform of the enzyme normally found in the circulation. 
7Markers of bone resorption are almost solely type I collagen breakdown products. In addition 
to hydroxyproline measurement, in late 80’s a high performance liquid chromatographic 
method was described for quantitating urinary excretion of pyridinium crosslinks, present in 
mature collagen.19 Several immunoassays have later been introduced to measure different 
type I collagen breakdown products, either their excretion to urine or their concentrations in 
serum. The first immunoassay for measuring type I collagen breakdown product was 
described in early 90’s for the measurement of serum concentration of the carboxy-terminal 
telopeptide of type I collagen (ICTP).20 This antigen contains the pyridinium crosslink, and 
attached to it, two alpha-1 peptide chains from the non-helical telopeptide region of one 
collagen molecule and one alpha-1 or -2 peptide chain from the helical region of the adjacent 
collagen molecule. The molecular weight of the antigen is approximately 10 kDa. Assays for 
measuring urinary excretion of smaller breakdown products of type I collagen were 
introduced somewhat later, first an ELISA method which measured free pyridinoline and 
deoxypyridinoline crosslinks and small peptides containing these crosslinks (Pyr),21 and 
shortly after an ELISA method measuring urinary free deoxypyridinolines, the more bone 
specific of the two crosslinks (DPD).22 ELISA methods for measuring urinary excretion of 
two crosslink peptides, cross-linked amino-terminal telopeptides of type I collagen (NTX)23
and for a peptide from the crosslink region of the carboxy-terminal telopeptide of type I 
collagen (CTX),24 were also introduced, and serum assays for both of these telopeptides have 
become available recently.25, 26
Tartrate resistant acid phosphatase is produced by the osteoclast, and the osteoclast specific 
isoenzyme has been suggested to be used as a marker reflecting osteoclast activity. Most 
methods published so far have been, however, disappointing. Only recently an 
immunoextraction method for the osteoclast isoform of the enzyme was introduced.27
The markers of bone turnover have been widely used in research and clinical trials, and a 
huge and continuously increasing number of articles have been published, dealing with the 
use of the markers in diagnosis of metabolic and metastatic bone diseases, in the follow-up of 
the response to treatment of these disorders, as well as their use as prognostic factors for both 
benign and malignant bone disorders.28, 29, 30, 31, 32 It has been shown that markers of bone 
turnover decrease as response to efficient treatment after one to six months on treatment 
whereas the change in bone mineral density (BMD) can be seen after one to two years after 
the treatment has been started. There is also evidence that high bone turnover correlates with 
increased fracture risk. The results have, however, been conflicting, and the use of the 
markers in normal clinical practice has not been widely accepted. 
The aim of the present study was to evaluate some commercial methods for type I collagen-
derived markers as to their performance, and to evaluate the value of these marker 
measurements in different clinical situations – in healthy persons, in children with asthma and 
on corticosteroid treatment, in patients with previous differentiated thyroid carcinoma on and 
off thyroxine treatment, in metastatic bone disease, and in the follow-up of treatment response 
in postmenopausal osteoporosis. The effect of smoking on the markers in postmenopausal 
women was also studied. 
82 Review of the literature 
2.1 Bone composition 
Bone is composed of mineral and organic matrix. Two thirds of bone dry weight is mineral, 
mostly hydroxyapatite. Other minerals, like magnesium, carbonate and sodium, are absorbed 
on the hydroxyapatite crystals. The major part of the body calcium (99 %), of the phosphate 
(80 %) and of the other minerals, mentioned above, are stored in the skeleton, from where 
they are released when needed. The major component of bone organic matrix is type I 
collagen, comprising about 90 % of it. In addition to collagen, bone organic matrix contains a 
wide variety of non-collagenous proteins. The most abundant of these proteins are osteocalcin 
and bone sialoprotein. In addition, proteins involved in cell adhesion are produced by 
osteoblasts. Bone matrix contains several growth factors and cytokines, needed for bone cell 
differentiation, and synthesized either by the cells in the bone marrow or by osteoblasts. Cells 
take up about two percent of the bone organic matrix.33
2.1.1 Osteoblasts
The bone forming cells, cuboidal osteoblasts are responsible for the formation of the bone 
extracellular matrix components, and they have a major role in regulating the mineralization 
of the osteoid, the newly formed unmineralized bone matrix. Osteoblasts also produce factors 
essential for osteoclast differentiation.34 Osteoblasts originate from multipotent mesenchymal 
stem cells, which in addition give rise to adipocytes, myocytes, fibroblasts and cartilage 
cells.35 Osteoblasts contain a large oval nucleus, well-developed endoplasmic reticulum and 
Golgi apparatus. They are clearly polarized, several cells producing simultaneously on basal 
aspect the unmineralized organic matrix. Most osteoblast products are similar to fibroblast 
products, due to their similar origin, but the relative abundance and the combined production 
are typical to the differentiated cell type.33 Only two osteoblast specific products have been 
identified to date, one being a transcription factor36 and the other one osteocalcin.37 Typically 
osteoblasts contain bone specific isoform of alkaline phosphatase, anchored on to the outer 
side of their cell membrane.38
2.1.2 Osteoclasts
Large multinuclear osteoclasts, the bone resorbing cells, cleave bone matrix by their 
proteolytic enzymes in acidic environment, provided by osteoclastic enzyme carbonic 
anhydrase II, which produces the protons, and vacuolar ATPase, which pumps the protons to 
the extracellular space.39, 40 Osteoclasts originate from hematopoietic mononuclear progenitor 
cells, which differentiate and fuse to cells of several unique features.41, 42  Typically 
osteoclasts contain several nuclei, the number of which in man is normally under ten but can 
be as high as 100 in pathological conditions. In addition, osteoclasts contain lysosomes and 
several mitochondria. An iron-containing 35 kDa enzyme tartrate-resistant acid phosphatase 
(TRACP), is expressed in osteoclasts early during their development, and has for long been 
used as their biomarker.43, 44 Unique to osteoclasts is the ruffled border, a specific area of the 
membrane, which comprises of many cytoplasmic extensions, facing the surface of the bone 
to be resorbed and allowing close contact to the resorption area. The ruffled border is 
surrounded by a clear zone, an organelle free cytoplasmic area containing contractile proteins 
like actin, and involved in anchoring the osteoclast to the bone surface undergoing 
9resorption.45 Osteoclast membrane also has several integrins, which can bind to RGD 
(arginine-glycine-aspartic acid) sequences of the adhesion proteins in the bone matrix, the 
most important one of them being the ανβ3 integrin.46, 47, 48 In addition to resorbing bone, 
osteoclasts remove the bone matrix degradation products via endocytosis along the ruffled 
border, transfer the degradation products via transcytosis to their basolateral membrane, and 
release them to the extracellular space.49, 50
2.1.3 Osteocytes and lining cells 
In addition to bone forming and resorbing cells, stellar-shaped osteocytes can be found 
imbedded to the bone matrix and flattened lining cells on bone surfaces. Both of these cells 
form from mature osteoblasts. Osteocytes are connected to each others and to other bone cells 
by gap junctions.51 They function in sensoring mechanical stress and signaling it to other cells 
in bone by generating signaling molecules such as nitric oxide and prostaglandins. 52, 53 When 
bone forming is completed lining cells are formed from osteoblasts, covering the bone surface 
during the quiescence phase. They have a role in starting the remodeling cycle.54
2.2 Bone biochemistry 
Osteoblast lineage cells produce the extracellular matrix of bone, which is a unique storage of 
various growth factors, in addition to the components which give bone its structure and 
strength.
2.2.1 Type I collagen 
Collagens are extracellular matrix proteins, which are of crucial importance for the normal 
structure and function of vertebrate connective tissues. To date some twenty different 
collagens are known. Typical to collagen structure is the repeat triplet amino acid sequence 
glycine-X-Y, where X and Y stand often for proline or hydroxyproline. This repetitive 
sequence is the basis of collagen structure, a stable semirigid triple helical molecule of three 
collagenous polypeptide chains.55, 56
Type I collagen, one of the interstitial fibrillar collagens, is the major organic component of 
bone matrix, comprising about 90 percent of it. Although not specific to bone, type I collagen 
of bone has specific features, not found in type I collagen of other tissues. Type I collagen is a 
heterodimer of two alpha 1(I) and one alpha 2(I) chains, and in addition to the large helical 
middle part the molecule has short non-helical telopeptide regions at each end of the 
molecule. Osteoblasts start to synthesize type I preproalphachains in an early phase of 
osteoblast differentiation.57, 58 COL1A1 gene on chromosome 17 and COL1A2 gene on 
chromosome 7 code for alpha 1(I) and alpha 2 (I) preprocollagen chains, respectively. The 
preprochains pass to the rough endoplasmic reticulum, where the leader sequence at the 
amino-terminal end is cleaved off, and the proalpha chains are post-translationally modified 
by several enzymes.59 Certain prolyl and lysyl residues are hydroxylated, some hydroxylysyl 
residues are glycosylated to form galactosyl or glucosyl-galactosyl hydroxylysyl residues. N-
linked glycosylation occurs in the carboxy-terminal non-collagenous area and phosporylation 
of serine residues in the N-terminal extension peptide area. These post-translational 
modifications of type I collagen are tissue specific. The three chains are then assembled 
together, starting from the carboxy-terminal end of the chains by interchain disulfide bond 
formation. The modification of the procollagen chains goes on during the assembly of the 
chains. Type I procollagen molecule, which is about 1.5 times the size of type I collagen, has 
large extension peptides at both ends of the molecule. The carboxy-terminal propeptide 
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(PICP) is globular in structure; the amino-terminal propeptide (PINP) is partly helical, partly 
globular. After the procollagen molecule has been assembled it is secreted into the 
extracellular space via the Golgi complex.57 The propeptide moieties are then cleaved off 
from the molecule by specific endoproteinases. The C-terminal propeptide (PICP) is removed 
first by a specific endopeptidase (bone morphogenetic protein 1, BMP-1),60 after which the 
molecule is layered onto the collagen fibrils as type I pN-collagen. The amino-terminal 
propeptide is then cleaved off after some delay by another specific endopeptidase.61
The type I collagen molecules, approximately 360 kDa in molecular weight, 300 nm long and 
1.5 nm in diameter, are layered on the surface of another fibril in a longitudinally staggered 
quarterly array, forming collagen fibers. Collagen fibers are then stabilized by crosslink 
formation.62, 63, 64 The first step is the deamination of the ε-amino groups of specific 
telopeptide lysine or hydroxylysine residues to corresponding aldehyde derivatives, catalyzed 
by the enzyme lysyl oxidase, a copper-dependent enzyme acting only upon certain telopeptide 
lysine residues. After the first enzymatic step in crosslinking immature divalent ketoimine 
crosslinks are formed by condensation of the aldehyde with a helical lysine or hydroxylysine. 
Part of the divalent crosslink undergoes maturation to a trivalent pyridinium or pyrrole 
crosslink, which occurs by further reaction of the ketoimine with a telopeptide aldehyde. The 
nature of the crosslinks is determined by the post-translational modifications of the alpha 
chains, especially the hydroxylation of specific lysine residues. In bone the level of lysyl 
hydroxylation is relatively low as compared to that in non-mineralized tissues. Hydroxylysyl 
pyridinoline is the most abundant crosslink in a variety of tissues, but not in bone, where lysyl 
pyridinoline predominates, being almost specific for calcified tissue.65 There is also evidence 
that some of the mature trivalent crosslinks are pyrrole cross-links, formed from the reaction 
of a telopeptidyl lysine aldehyde and an immature crosslink hydroxylysino-5-
ketonorleucine.66, 67, 68 These pyrrole crosslinks probably form between three adjacent 
collagen molecules whereas the pyridinium crosslinks connect two collagen molecules 
together.63, 69
Collagen crosslinking is of utmost importance to the biomechanical properties of bone, to the 
strength of bone,70 and to the mineralization of bone.71 The decrease in the number of both 
mature trivalent and immature divalent crosslinks reduces bone strength and decreases its 
mineral density.72 In addition to enzymatic crosslinking, formation of nonenzymatic linkages 
by glycation and accumulation of glycation end products can take place with ageing of 
collagen,73 affecting the properties of bone. 
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Figure 1: Type I procollagen / collagen molecule and formation of fibrils according to ref. 61, with 
permission.
2.2.2 Non-collagen proteins 
About ten percent of bone organic matrix is taken up by several non-collagenous proteins 
such as proteoglycans, glycoproteins, arginine-glycine-aspartic acid-sequence (RGD) 
containing attachment proteins and gammacarboxy glutamic acid (gla)-containing proteins.61
These proteins are produced by the osteoblasts at different stages of bone formation and 
matrix mineralization, and they have specific functions during bone remodeling processes, 
though some of these activities still remain to be elucidated. 
2.2.2.1 Proteoglycans 
Proteoglycans take up about ten percent of the non-collagen proteins in the bone matrix. At 
sites where bone formation is about to take place a large chondroitin sulfate proteoglycan is 
found. This protein with an apparent molecular weight of one million Da has a core protein of 
approximately 390 kDa and chondroitin sulfate (CS) sidechains of 40 kDa attached to it. Its 
proposed function is to capture space for bone formation. In a later phase of bone formation 
this large proteoglycan degrades and is replaced by decorin and biglycan in the mineralized 
matrix. Decorin with an apparent molecular weight of about 130 kDa has a core protein of 46 
kDa and one CS sidechain attached to it, while biglycan (MW about 270 kDa) with a similar 
size core protein has two glycosaminglycan side chains. Both of these proteins have 24 amino 
acid leucine rich repeats (10 in decorin, 12 in biglycan), also found in other connective tissue 
proteins, and believed to function in sequestering transforming growth factor beta (TGF-β)
and modulating its activity.74
These two proteoglycans are differently located in bone. Decorin location coincides that of 
collagen, and its function is proposed to be in regulating fibril diameter.75 Both decorin and 
biglycan are produced by osteoblasts during bone formation, but only biglycan expression has 
been located in osteocytes. 
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Some cell surface-associated proteoglycans like heparan sulfate proteoglycan, syndecan, and 
another proteoglycan, betaglycan, have been shown to have a role in mediating responses to 
growth factors e.g. fibroblast growth factors (FGFs) and TGFs in the developing bone.76, 77
Bone cell cultures have been shown to synthesize hyaluronan, an unsulfated 
glycosaminoglycan, which might have a role in bone morphogenesis.61
2.2.2.2 Bone glycoproteins 
Alkaline phosphatase is a ubiquitously expressed enzyme, having at least four genes coding 
for it in different tissues.38 The bone enzyme (Bone ALP) is one isoform of the 
bone/liver/kidney or tissue non-specific enzyme, being differently glycosylated in different 
tissues and even within one tissue. In bone two differently glycosylated isoforms have been 
found.78 Alkaline phosphatase is a dimeric ectoenzyme with a molecular weight of 
approximately 130 kDa, and it is attached to the cell membrane by a glycosyl-
phosphatidylinositol (GPI) anchor. For eighty years it has been known to be involved in bone 
mineralization, and it is considered to be a hallmark of osteoblast lineage cells.79 Bone ALP is 
expressed by osteoblasts, starting in early mineralization phase of bone development,80 and it 
is known to be involved in matrix mineralization, though the exact mechanism is as yet 
unresolved. It is found in high concentrations in extracellular matrix vesicles, where it is 
proposed to provide sufficient amounts of phosphate for the mineralization to proceed by 
hydrolyzing it from proteins or pyrophosphates.81 Some of the enzyme is released from the 
membrane and liberated into the circulation, where, in addition to the two isoforms of Bone 
ALP, also a minor form of the isoform containing the GPI anchor is found.78
Osteonectin (or SPARC or B-40) is a glycated and phosphorylated protein with a molecular 
weight of approximately 45 kDa, expressed by osteoblasts somewhat later than Bone ALP.80
In addition to calcified tissues it has been located in other sites e.g. parietal endoderm, some 
basement membranes and platelets. It is an acidic and cysteine rich protein, capable of 
binding calcium.61 Its exact function is not known, but according to in vitro studies a role in 
regulation of cell proliferation, cell-matrix interactions, angiogenesis and metalloproteinase 
expression has been proposed.82
2.2.2.3 Bone RGD proteins 
Bone matrix contains several cell attachment proteins, which have in common the RGD 
(arginine-glysine-aspartic acid) amino acid sequence, responsible for mediating the 
attachment of these proteins to cell surface integrins.61 The interaction of cells with the 
extracellular matrix is essential for their proliferation, migration and differentiation. 
Thrombospondins (TSPs) are complex proteins composed of three identical subunits with a 
molecular weight of 150 kDa.83 In addition to the RGD sequence they have several domains 
capable of binding matrix proteins, and the molecule has also a calcium binding sequence. 
TSP is found primarily in basement membranes. In bone it is produced by osteoblasts and 
located in the osteoid, where one of its functions is to activate TGF-β.84
Fibronectin is another large ubiquitous RGD protein (MW 250 kDa).61 Fibronectin is 
composed of two unidentical subunits, both having nine domains for different functions – for 
binding different matrix proteins, DNA and cell surfaces independently of RGD - in addition 
to the RGD sequence. Fibronectin is either synthesized locally in bone during early phase of 
osteogenesis or brought to bone by vasculature. Vitronectin or S-protein of serum is a 
monomer of molecular weight of 70 kDa.61 It is synthesized primarily in the liver, and low 
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amounts are found in calcified tissues. Vitronectin, too, can bind several matrix and serum 
proteins.
Osteopontin is a cell adhesion protein with a core protein of approximately 32 kDa.61 The 
protein is posttranslationally modified to a differing extent, both phosphorylated at serine 
residues and glycosylated by both N- and O-linkages. It was first isolated from bone, but has 
since been found in other tissues, too. It can be produced by both osteoblasts and osteoclasts, 
and it is synthesized during different phases of bone remodeling. Its RGD sequence is situated 
in the mid region of the molecule, and it binds with great affinity the ανβ3 integrin, and it also 
binds calcium. It has been shown to function as an inhibitor of mineralization and as a 
mediator of cell-matrix and matrix-matrix/mineral adhesion.85 Osteopontin is typically found 
in cell- and matrix-matrix interfacial structures. 
Bone sialoprotein (BSP) is an RGD containing protein with a molecular weight of 
approximately 75 kDa.61 It is highly glycosylated, about half of its molecular weight comes 
from carbohydrate, and 12 percent of the carbohydrate is sialic acid. One third of the serine 
residues of BSP are phosphorylated, and the protein can also be sulphated at tyrosine 
residues. In addition to the RGD sequence the molecule has other sequences capable of 
binding cells at the tyrosine-rich domains of the amino- and carboxy termini of the 
molecule.86 BSP is specific to mineralized tissues, and it has been shown to be expressed in 
advanced breast cancer, in atherosclerotic plaques and in trophoblasts. In bone it is mainly 
produced by osteoblasts during the mineralization phase of bone formation, but also 
osteoclasts have been shown to have mRNA for BSP. BSP makes about 15 % of non-
collagenous organic matrix of bone.  
Another sialic acid containing protein in bone is bone acid glycoprotein-75, an acidic 
glycosylated and phosphorylated protein with 30 % sequence homology with osteopontin in 
the amino-terminus of the molecule. It binds calcium, and there is some evidence that it 
inhibits bone resorption. 
2.2.2.4 Bone gla-proteins 
Osteocalcin (OC) or bone gla-protein (gammacarboxy glutamic acid) is a 49 amino acid 
polypeptide with a molecular weight of 5700 Da.8 It makes about 15 % of the non-
collagenous proteins in bone matrix. The molecule, which is synthesized under the 
stimulation of vitamin D as pro-osteocalcin, contains three glutamic acid residues, which are 
posttranslationally carboxylated in an enzymatic vitamin K dependent reaction. The 
propeptide is cleaved off simultaneously with secretion to the extra cellular matrix, where OC 
binds via calcium to hydroxyapatite. This causes a conformational change in the molecule, 
which becomes partly α-helical in nature, and enhances the accumulation of OC in the bone 
matrix. OC is considered to be one of the two bone specific proteins,37 and it is produced 
mainly by osteoblasts during the late mineralization phase, but some OC is also expressed in 
osteocytes.87 OC function is still unknown, but roles in mineralization and regulation of bone 
resorption have been suggested. Recent evidence indicates that osteoblasts express an 
osteocalcin receptor, and OC may be a signaling molecule for osteoblasts to stop bone 
formation.88
Matrix gla protein (MGP) is another gla-protein in bone matrix.61 It is larger than OC, its 
molecular weight being approximately 15 kDa, and it contains five gla residues. It is 
synthesized in an earlier phase of bone formation than OC, and its function has not been 
established. 
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2.2.3 Growth factors and cytokines 
Bone matrix contains a large variety of growth factors and cytokines, polypeptides with 
molecular weights varying from 7.5 kDa to 30 kDa. They are produced mainly by the 
osteoblasts, to some extent by osteoclasts and cells in the bone marrow, and they have 
autocrine or paracrine effects on bone cells. These molecules are essential for the 
morphogenesis and development of bone, as well as the regulation of bone (re)modeling. In 
addition, arachidonic acid metabolites such as prostaglandins are produced by bone cells. All 
these factors exert their effect by binding to their specific receptors, which starts a signaling 
cascade by activating specific kinases to phosphorylate specific transcription factors. 
2.2.3.1 Growth factors 
Several members of the transforming growth factor-β (TGF-β) superfamily, such as the three 
isoforms of TGF-β and many bone morphogenetic proteins (BMPs) or osteogenic proteins 
(OPs), are expressed in bone at different stages of development.89, 90 All of these factors are 
dimeric secreted proteins, synthesized as larger proproteins and cleaved at a consensus Arg-
X-X-Arg site to yield mature dimeric molecules.91 They all have a cluster of seven conserved 
cysteine residues, a cysteine knot, at the C-terminal region of the molecule.92, 93 They exert 
their biological function by binding to two types (I and II) of serine/threonine kinase 
receptors, of which type II transphosphorylates the type I receptor, and thus initiates the 
intracellular signaling by phosporylating transcription factors, Smads.93 According to current 
knowledge several BMPs (BMP-1, -2, -6, -7/OP-1) can induce the differentiation of 
mesenchymal cells to osteogenic cells, and also regulate osteoblasts in expression of bone 
matrix proteins.94, 95, 96 BMPs can also regulate osteoclastogenesis and bone resorption, either 
through osteoblasts or, according to recent evidence, directly via their receptors on 
osteoclasts.97, 98 TGF-βs have multifunctional effects on osteoblasts: they both promote and 
inhibit proliferation, and they stimulate growth factor and bone matrix component production 
under certain conditions whereas in other conditions they inhibit it.99 The activity of TGF-βs
is regulated to a great part by TSP1.84
Insulin-like growth factors (IGF) I and II are both produced by bone cells and found in the 
bone matrix,100 as are at least five of the seven known IGF binding proteins, IGFBPs,101, 102, 
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 and the binding protein proteases.104 Both IGFs stimulate osteoblastic cell proliferation 
and differentiation, and they are important mediators of the effects of several systemic 
hormones such as glucocorticoids, estrogen and growth hormone, as well as of mechanical 
load on bone remodeling, IGF-I mediating the effects of systemic hormones and IGF-II that 
of mechanical load.105, 106, 107 IGFs act through binding to either of the two types of receptors, 
IGF-1R or IGF-2R, and their activity is modulated by the binding proteins and the respective 
proteases. Most of the binding proteins inhibit the binding of the IGFs to their receptors, but 
IGFBP-3 and -5 enhance their activities.108 The regulation of bone remodeling by the IGF 
system may also vary depending on the skeletal site.109
Fibroblast growth factors are a family of polypeptides that have a crucial role in the 
regulation of cell proliferation, migration and differentiation in several tissues, including 
bone. To date twenty members of the family are known.110, 111, 112 FGFs act through high 
affinity cell surface receptors, which possess tyrosine kinase activity, FGFRs 1-4, and low 
affinity receptors, heparan sulfate proteoglycans.76, 110, 113 In bone osteoblast lineage cells both 
produce FGFs and respond to them. The effects of FGF-1 and 2 on osteoblasts have been 
shown to depend on the stage of the cells: in early maturation stage FGFs increase 
proliferation, in the later developmental stages they inhibit differentiation, as judged by 
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decreased expression of osteoblast markers such as type I collagen, alkaline phosphatase and 
osteocalcin.114, 115, 116
Platelet derived growth factor (PDGF) is a dimeric polypeptide. PDGF isoform AA has been 
shown to be expressed in bone, where it participates in the regulation of osteoblast 
proliferation and, probably through osteoblasts, of bone resorption.117 Vascular endothelial 
growth factor (VEGF) is a 44 kDa protein essential for angiogenesis. VEGF is expressed also 
in osteoblasts, and its receptors VEGFR-1/Flt-1 and VEGFR-2/KDR/Flk-1, which belong to 
the receptor tyrosine kinases of PDGFR family, are found in both osteoblasts and 
osteoclasts.118, 119 In bone VEGF has its common effect on angiogenesis, but it has also been 
shown to have a role in osteoclast recruitment and attachment as well as in osteoblast 
differentiation.
2.2.3.2 Cytokines 
Bone cells or cells in the bone marrow express several cytokines, which participate in the 
regulation of bone remodeling mostly as response to the effects of other remodeling 
regulating factors. 
Interleukin-1α and 1β are 17.5 kDa proteins, both potent activators of bone resorption.120
They exert their effect by binding to their 80 kDa or 60 kDa receptors, IL-1Rs.121 IL-1 
receptor antagonist (IL-1ra) binds to the same receptor, opposing the effects of IL-1.122 IL-1s 
stimulate osteoclast formation from their precursors as well as their differentiation. 
Interleukin-6 is a 26 kDa glycoprotein, which is produced by several cell types including 
osteoblasts.123 In bone it has been shown to stimulate bone resorption by mediating the effects 
of calciotropic hormones such as parathyroid hormone (PTH), of estrogen depletion or of 
other resorption stimulating factors.124, 125 It acts through binding to its receptor (IL-6R) to 
start a gp130 receptor subunit mediated signaling pathway.126 Both IL-1 and IL-6 have been 
shown to stimulate bone resorption by activating several bone degrading 
matrixmetalloproteinases.127 Interleukin-11 is also a multifunctional cytokine that stimulates 
bone resorption with a gp130 mediated pathway.128 It is activated by different stimulus than 
IL-1 and –6, and it has been shown to enhance cell adhesion via integrins.129 In addition to 
interleukins that stimulate bone resorption also those having an inhibitory effect on bone 
resorption such as interleukins - 4 and -18 are found in bone.130, 131
During recent years two members belonging to tumor necrosis factor alpha (TNFα) ligand 
and receptor families have been found to be expressed by osteoblastic cells. These factors 
have been shown to be crucial regulators of bone remodeling.  
Osteoprotegerin (OPG), also called osteoclastogenesis inhibitory factor (OCIF) and TNF 
receptor-like molecule 1 (TR1), was isolated and cloned by several groups, and has been 
found to be a molecule capable of inhibiting osteoclastogenesis.132, 133, 134, 135 OPG is a soluble 
secreted molecule with four cysteine rich domains, responsible for the molecule’s biological 
effect, and with two so called death domains. It can act as a 60 kDa monomer or as a 
homodimer formed by a disulfide linkage.136 It acts as a decoy receptor to a transmembrane 
TNF ligand family member, which was identified independently by several groups secondary 
to its receptor in T cells as well as in osteoblastic / stromal cells.137, 138, 139, 140 The molecule 
was named TNF-related activation-induced cytokine (TRANCE), osteoclastogenesis 
differentiation factor (ODF) or osteoprotegerin ligand (OPGL) and RANKL (receptor 
activator of NF-κB ligand) by different groups, and was proven to be an important factor for 
the development and function of T cells, dendritic cells and osteoclasts. It is a 316 amino acid 
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residue transmembrane protein with a TNF-family homologous domain in the extracellular 
part of the molecule. In bone it acts by activating its signaling receptor RANK (receptor 
activator of NF-kB), a member of the TNF receptor family, expressed on the membrane of 
osteoclasts and their precursor cells, which uses the c-Jun N-terminal kinase (JNK) signaling 
pathway.141 RANK is a 625 amino acid residue transmembrane receptor with four cysteine 
rich domains, typical to TNF receptor family, in the extracellular part of the domain. 
In addition to the cytokines mentioned above yet another secreted factor produced by the 
osteoblasts, the macrophage colony-stimulating factor (M-CSF or CSF-1), is essential for the 
proliferation of osteoclast progenitor cells, and for the differentiation of these cells into 
osteoclasts.142, 143
2.2.3.3 Arachidonic acid metabolites 
Prostaglandins, in bone especially those of E series (PGE2 and PGE1), are arachidonic acid 
metabolites which locally exert diverse effects on bone metabolism. They modulate osteoblast 
proliferation and function as response to systemic hormones and mechanical strain mainly by 
regulating the activity of cytokines and growth factors.144, 145, 146, 147 They are also powerful 
regulators of bone resorption, either stimulating or inhibiting osteoclast differentiation and 
function, mostly through factors produced by osteoblasts, but also through direct effect on 
osteoclastic receptors.148, 149, 150 Prostaglandins exert their effect in bone mainly through one 
of their four receptors, EP4, which is an adenylate cyclase activating receptor. In addition to 
prostaglandins, also several lipoxygenase metabolites of arachidonic acid, leukotrienes, have 
been shown to activate osteoclasts to resorb bone.151, 152
2.2.4 Bone proteolytic enzymes 
Bone matrix degradation is essential for normal bone remodeling. Two types of proteolytic 
enzymes are responsible for the matrix degradation in bone, lysosomal cathepsins and matrix 
metalloproteinases (MMPs), which seem to exert their effects in a manner depending on the 
stage of the remodeling cycle as well as on the type of the bone being remodeled.153, 154
According to recent evidence, cathepsin K is the enzyme mainly responsible for type I 
collagen degradation in acidic pH, an early event of the resorption process. Cathepsin K 
belongs to cysteine proteases, enzymes synthesized as proenzymes and activated at acidic 
environment.155 Active cathepsin K is a 27 kDa protein expressed in osteoclasts at high 
concentrations. It is capable of cleaving type I collagen at multiple sites, including several 
sites at the helical region.156 This leads to the unwinding of the triple helix which makes the 
molecule susceptible to further action of proteolytic enzymes, including matrix 
metalloproteinase action later in the resorption process at neutral pH.153 Other cathepsins e.g. 
B, H, L and S are also expressed in bone, but to a much lesser extent than cathepsin K.157 In 
addition to degrading type I collagen, cysteine proteases are capable of degrading non-
collagenous proteins of bone extra cellular matrix.153
Some twenty members of the matrix metalloproteinase family are known to date, some of 
them secreted proteins, and some membrane bound proteins, all capable of degrading extra 
cellular matrices at neutral pH.158 They have structural similarities, including a zinc-binding 
active site. They all are synthesized as proenzymes, which are activated by the cleavage of an 
80 amino acid residue amino-terminal peptide. Their activity is regulated by their specific 
tissue inhibitors, TIMPs (TIMP-1, -2 and –3) with which they form inactive complexes. They 
have different substrate specificities, and therefore their expression differs depending on the 
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tissue and its developmental stage. In bone the most important MMPs expressed in osteoclasts 
seem to be MMP-9, a 92 kDa protein which is also called gelatinase B because of its 
gelatinolytic activity, and MMP-14, a membrane-type I MMP, MTI-MMP.159, 160, 161 They are 
also expressed in osteoblasts and osteocytes, where in addition several other MMPs are 
detected. These MMPs act in the remodeling process prior to osteoclast attachment, in the 
early stage of the remodeling cycle, and among them are MMP-2 or gelatinase A, a 72 kDa 
protein with gelatinolytic activity, MMP-13, also called collagenase-3, and MMP-1 or 
interstitial collagenase, which are capable of degrading fibrillar collagens.162, 163 MMP-3 or 
stromelysin-1, capable of degrading non-collagenous proteins of bone matrix, is also 
expressed in osteoblasts early in the remodeling cycle.  
In addition to being able to degrade bone, matrix MMPs have an important role in effecting 
the recruitment of the osteoclast progenitor cells to the future resorption sites, and preparing 
the environment for osteoclast attachment.164, 165, 166 They have also been suggested to have a 
role in the coupling of resorption and formation together with bone lining cells.54, 167 The 
expression of the matrix metalloproteinases and their inhibitors in bone, as well as their 
activity, is regulated by factors that regulate bone remodeling.168, 169
2.3 Bone remodeling 
Bone remodeling takes place by teams of cells called basic multicellular units (BMUs) or 
bone remodeling units (BRUs) or osteons. The shapes of these units differ in the two different 
types of bone. In cancellous or trabecular bone, which comprises about 15 % of the skeleton, 
BRUs are saucer shaped so-called Howship’s lacunae. In compact or cortical bone, which 
forms the major part of the skeleton, the remodeling takes place in cylindrical structures 
called Haversian units. Although trabecular bone comprises the minor part of the skeleton, it 
is metabolically the more active type of bone, and about 25 % of trabecular bone is remodeled 
yearly, while about 3 % of cortical bone is renewed.1, 170
The cells are differently organized in the different types of bone, but the remodeling sequence 
is the same in both systems. The remodeling cycle starts with an activation phase, during 
which the lining cells are withdrawn from the bone surface, and the bone matrix is prepared 
for the attachment of osteoclast precursor cells. The precursor cells migrate to the resorption 
site where they are activated to form multinuclear bone resorbing cells. Activation phase is 
followed by a resorption phase during which the mineral component of bone is dissolved, and 
the organic matrix degraded. The resorption phase is followed by reversal phase during which 
apoptosis of osteoclasts and recruitment of preosteoblasts take place. In the following 
formation phase preosteoblasts differentiate to mature osteoblasts, which fill the resorption 
cavity with new unmineralized organic matrix, osteoid. Eventually the osteoid is mineralized, 
and the BMU goes to a quiescent phase. In trabecular bone the time from the activation to the 
completion of the resorption is normally about one month, and the remodeling cycle is 
completed in about three months. In cortical bone the remodeling cycle is somewhat longer, 
taking about four months. Figure 2 shows the bone remodeling cycle in trabecular bone. 
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Figure 2: Schematic presentation of bone remodelling cycle in trabecular bone. 
2.3.1 Regulation of bone remodeling 
Bone remodeling is regulated by both systemic hormones and local factors, which were 
discussed above. The most important systemic hormones, which regulate the remodeling 
process are calciotropic hormones, parathormone (PTH) and the hormonally active metabolite 
of vitamin D, 1,25-dihydroxyvitamin D or calcitriol (1,25-(OH)2D), and calcitonin (CT). 
These hormones are responsible for maintenance of the body calcium homeostasis, and they 
are under the negative feedback control of extracellular fluid calcium concentrations. PTH is 
the most important of them as a regulator of calcium homeostasis. Other systemic hormones 
having a great impact on bone metabolism are estrogens, glucocorticoids, thyroid hormones 
and growth hormone.1, 171 Most of these hormones affect bone metabolism through their 
receptors on the osteoblasts, and their effects are often mediated by locally produced 
cytokines, growth factors or prostaglandins. 
2.3.1.1 PTH 
Parathormone is an 84 amino acid residue peptide secreted from the parathyroid glands as a 
response to lowered extracellular calcium concentration, sensed by calcium sensing receptors 
on the parathyroid glands.172 PTH corrects calcium levels rapidly by increasing calcium 
reabsorption in the renal tubules, and more slowly by increasing the renal hydroxylation of 
25-OH-vitamin D to its active metabolite, which enhances the intestinal absorption of 
calcium, and by enhancing bone resorption, leading to the release of calcium from bone. 
PTH can have both catabolic and anabolic effects I bone, depending on the way of 
administration. Continuous effect leads to increased bone resorption, intermittent effect to 
increased bone formation. The increase in bone mass due to PTH action is seen in cancellous 
bone, perhaps at the expense of the cortical bone mass. PTH acts by binding to one of its two 
receptors, both transmembrane G-protein linked receptors (PTHR-1 and PTHR-2), and PTH 
effects in bone are mediated through several different signal transduction mechanisms.173, 174
As the receptors are found only in the osteoblasts, PTH effects bone resorption through 
osteoblasts, by upregulating the expression of several osteoblastic factors, crucial for bone 
resorption. Among these factors are IL-6, IL-11, M-CSF and RANKL, known to be essential 
for osteoclast proliferation, differentiation and activity.124, 128, 140, 175
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Parathyroid hormone related peptide (PTH-rP) is a peptide first discovered in association of 
humoral hypercalcemia of malignancy. Its amino-terminal end is 70 % homologous with 
PTH’s amino-terminus (13 amino acids), and it mimics PTH effects on calcium homeostasis 
and bone resorption, doing that through PTHR-1.171 It is essential for normal fetal skeletal 
development, and in adults it is expressed in the lactating breast and in the skin, in addition to 
being expressed by several malignant neoplasms. 
2.3.1.2 1,25-(OH)2D
1,25-dihydroxyvitamin D (I,25-(OH)2D) or calcitriol is the hormonally active metabolite of 
vitamin D. It is formed by 1-alphahydroxylation of 25-hydroxyvitamin D (25-OH-D) in the 
proximal renal tubules as response to lowered circulating phosphate concentration under the 
stimulation of PTH. 25-OH-D is formed in the liver by the hydroxylation of cholecalciferol 
(D3), obtained from the diet or formed in the skin from 7-hydroxycholesterol by ultraviolet 
irradiation, or of ergocalciferol (D2), found in small amounts in vegetables. 
1,25-(OH)2D has effects on calcium homeostasis, on bone resorption and on cell 
differentiation, also in other tissues than bone. One of its important effects in bone is its effect 
on the mineralization of the newly formed bone by supplying calcium and phosphate for it 
through stimulating their intestinal absorption. It also increases renal calcium reabsorption. 
1,25-(OH)2D is a potent bone resorbing agent. The way it acts on bone resorption has not 
been fully elucidated, but it acts through osteoblasts, on which it has two different kinds of 
effects. The rapid effect, mediated by a membrane bound receptor, causes a calcium influx 
into the osteoblast, and augments PTH action, leading to increased bone resorption and 
calcium release from bone.176 1,25-(OH)2D has been shown to upregulate the synthesis of 
RANKL and downregulate the expression of OPG, the decoy receptor of RANKL, leading to 
increased osteoclastogenesis.177 The slow effect of 1,25-(OH)2D on osteoblasts is an effect on 
osteoblast differentiation, mediated through binding to the nuclear vitamin D receptor (VDR). 
This causes heterodimerization of the receptor with retinoic acid receptor (RXR), and leads to 
initiation of gene transcription.178 One of its slow effects is to upregulate OPG mRNA 
expression.179 In the late phase of osteoblast differentiation calcitriol diminishes type I 
collagen synthesis, and enhances osteocalcin and osteopontin synthesis. It also upregulates 
VEGF expression in the osteoblasts, which in turn might stimulate the endothelial cells near 
by to produce osteoblasts differentiating growth factors.180, 181 A role in coupling bone 
resorption and formation for 1,25-(OH)2D has also been suggested.176
2.3.1.3 Calcitonin
Calcitonin (CT) is a peptide of 32 amino acid residues, secreted from the perifollicular C-cells 
of the thyroid gland as response to increased circulating calcium concentration. It has a short-
term lowering effect of the extracellular calcium concentration by decreasing bone resorption 
through a direct action on the osteoclastic CT receptors.171 It has been shown that CT effects 
osteoclast activity by causing loss of ruffled border, and changing the structure of the clear 
zone F-actin. 
2.3.1.4 Other than calciotrophic systemic hormones 
Several systemic hormones have an important impact on the regulation of bone remodeling. 
Among these hormones are sex steroids, especially estrogens, thyroid hormones and 
glucocorticoids, the effects of which on bone will be briefly referred. 
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Estrogens are important regulators of both skeletal growth and bone remodeling in both sexes. 
During skeletal growth estrogens mainly act by stimulating pituitary growth hormone 
secretion, whereas regulation of bone remodeling takes place via osteoblastic or, as recently 
shown, osteoclastic estrogen receptors, ERα or ERβ.182, 183, 184 In addition to the nuclear 
receptors, several co-regulators, transcription factors and response elements are involved in 
estrogen action, and they vary in different target tissues. Estrogens have been shown to have a 
rapid effect on target cells, similar to that of 1,25-(OH)2D, mediated through membrane 
bound receptor or binding protein and leading to calcium flux and activation of MAP 
(mitogen activated protein) kinase pathways. In bone estrogen inhibits bone resorption, to a 
great part through osteoblastic receptors by down-regulating the expression of bone resorbing 
cytokines IL-1β, IL-6 and TNF.185 Estrogen has also been shown to promote osteoclast 
apoptosis, mediated probably by TGF-β,186 and to suppress RANKL- and M-CSF-induced 
osteoclast differentiation from progenitor cells through a nuclear ER-dependent mechanism 
which does not require mediation by osteoblastic/stromal cells,184 or by inducing OPG 
synthesis in osteoblasts.187
Thyroid hormones, mainly the most potent one of them, triiodothyronine T3, are required for 
normal skeletal development. They effect cell proliferation and differentiation through 
nuclear thyroid hormone receptors, TRα1 and TRβ1, which are expressed in osteoblastic 
cells. Similarly to other nuclear receptors, they interact by heterodimerization with other 
nuclear receptors – retinoic acid receptor, vitamin D receptor - to regulate gene expression in 
these cells.188, 189 In proliferating preosteoblasts T3 has been shown to downregulate 
expression of genes typical for proliferating cells like c-fos/c-jun. Later it stimulates the 
expression of mRNA for markers reflecting osteoblast differentiation such as osteocalcin and 
alkaline phosphatase.190 There is also evidence that T3 might be involved in the 
mineralization process of osteoid by stimulating membrane bound alkaline phosphatase 
release from osteoblasts.191
Glukocorticoids have diverse effects on bone remodeling. In physiological concentrations 
they stimulate osteoblast progenitors to proliferate, they effect the differentiation of 
osteoblasts by stimulating the synthesis of osteoblastic proteins, e.g. alkaline phosphatase, 
osteopontin and bone sialoprotein. Depending on the developmental stage of the osteoblast 
glucocorticoids either stimulate or inhibit type I collagen synthesis, and they inhibit 1,25-
(OH)2D induced osteocalcin synthesis. They have also been shown to have a role in the 
mineralization of bone extra cellular matrix.192, 193, 194, 195 They exert their effects through 
specific receptors (GR) that belong to the same nuclear receptor superfamily as other steroid 
hormone receptors, vitamin D and thyroid hormone receptors, and the effector molecules 
needed for nuclear receptor function. Some of their effects in bone are mediated by 
modulating the activity of paracrine factors, growth factors and cytokines.196, 197
2.3.2 Proposed model for the regulation of bone remodeling 
The factors initiating bone resorption are not fully elucidated, but it is known that lining cells, 
some growth factors such as VEGF, and matrix metalloproteinases have important roles in 
preparing the bone surface, about to be resorbed, for osteoclast attachment, and in the 
recruitment of osteoclast progenitor cells to the future resorption site. According to the 
current knowledge, crucial factors for osteoclast proliferation and differentiation are the 
recently found membrane bound member of tumor necrosis factor (TNF) ligand family, the 
receptor activator of NF-κB ligand (RANKL) produced by the osteoblasts, and the secreted 
macrophage-colony stimulating factor (M-CSF), also produced by the osteoblasts.198 Cell-cell 
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contact between the osteoblast and the hematopoietic osteoclast precursor cell is needed for 
RANKL to activate its receptor NF-κB (RANK) on the osteoclast precursor cell / osteoclast 
membrane. The activation of RANK leads to several signaling pathways leading to 
differentiation and maturation of multinuclear, TRACP and CT receptor positive 
osteoclasts.42 Osteoclastogenesis is regulated by systemic hormones and local factors, which 
to a great extent regulate the expression of RANKL, M-CSF and RANK.131, 199 RANKL is 
also regulated by osteoprotegerin (OPG), its decoy receptor produced by osteoblasts, which 
binds RANKL and thus inhibits its binding to RANK. RANKL is also needed for the 
activation of osteoclasts and for maintaining their activity. Downregulation of RANKL and 
upregulation of OPG leads to osteoclast apoptosis. 
Figure 3: Formation of actively resorbing osteoclast according to the ref. 198, with permission. 
In the reversal phase of bone remodeling osteoblast precursor cells are recruited to the 
resorption cavity, and osteoblastogenesis proceeds under the control of systemic hormones 
and local factors. Osteoblasts synthesize the components of bone organic matrix, and the 
formed osteoid is then mineralized. The mechanism of coupling bone resorption to bone 
formation has not been elucidated, and several possible factors have been proposed, including 
growth factors TGF-β and BMPs, 1,25-(OH)2D, MMPs and bone lining cells. 
After bone organic matrix has been laid down by the osteoblasts, mineralization of the osteoid 
takes place. In the mineralization process collagen molecules probably form the structural 
background for the deposition of mineral. Matrix vesicles, formed from chondroblasts and 
osteoblasts, contain high amounts of alkaline phosphatase and other enzymes needed for 
initiation of mineralization process, and they act as nucleation sites for crystal formation. The 
process is regulated by extra cellular matrix macromolecules such as proteoglycans. 
As discussed above, several systemic hormones and locally produced growth factors, 
cytokines and arachidonic acid metabolites regulate bone remodeling in a phase dependent 
manner; some factors have diverse, even opposite effects on bone cell differentiation 
depending on the phase of the remodeling cycle. Most of the regulating factors, also those 
stimulating resorption, act through their receptors on the osteoblasts, by regulating the 
expression of RANKL and OPG. In addition to systemic hormones and local factors, 
mechanical strain is an important regulator of bone remodeling. Mechanical strain is sensed 
by the osteocytes, which signal its effect to the other cells of bone through cap junction net 
work by producing mediator molecules such as PGE2 and nitric oxide, and which finally 
leads to increased bone formation. Table 1 summarizes some important factors that regulate 
bone remodeling, and the expression of RANKL and OPG. 
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Table 1: Some systemic and local factors, which regulate bone remodeling and the expression of RANKL 
and OPG. 
Factor Effect on 
resorption
Effect on 
formation 
Effect on 
RANKL Effect on OPG 
PTH, continuous ? ? ? ?
PTH, intermittent ? ? NK NK
1,25-(OH)2D, rapid ? ? ? ?
1,25-(OH)2D, slow ? ? ? ?
Systemic 
hormones
E2 ? ? ? ?
IL-1 ? ? ? ?
IL-6 ? ? ? ?
IL-11 ? ? ? ?
TNFα ? ? ? ?
PGE2 ? ? ? ? ? ?
TGF-β ? ? ? ? ? ?
BMPs ? ? ? ?
Local 
factors 
IGFs ? ? NK NK
NK = not known 
2.3.3 Disorders of bone remodeling 
2.3.3.1 Osteoporosis and other benign bone disorders  
Osteoporosis is the most common of metabolic bone disorders. It is a state, where bone 
resorption eventually exceeds bone formation, leading to reduced bone mass and detoriated 
bone microarchitecture, and making bone susceptible to fractures. Definition of osteoporosis 
at present is based on bone mineral density (BMD), most often measured by dual-energy X-
ray absorptiometry (DXA) at the lumbar spine or proximal femur. By definition, osteoporosis 
in a Caucasian female is a state were BMD is more than 2.5SD (standard deviations) below 
the young adult average BMD value. Osteopenia (low bone mass) is defined as a state where 
BMD is under 1SD but not more than 2.5SD below the young adult average BMD.200
Postmenopausal osteoporosis (type I osteoporosis) is one type of primary osteoporosis, and 
by far the most common form of osteoporosis. It is caused by estrogen depletion at 
menopause, which causes activation of osteoclasts and increased bone resorption, and leads to 
a deep reduction of BMD during the first menopausal years, and which goes on but lessens 
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during later years. Postmenopausal osteoporosis effects mainly trabecular bone, and the most 
common type of fracture is vertebral. Type I osteoporosis can present also in males, but is 
much more rare than in females. In age-related or senile osteoporosis (type II osteoporosis) 
bone turnover is decreased, and bone formation impaired, and the effect is seen both in 
cortical and trabecular bone. Senile osteoporosis presents normally in population over 75 
years of age, and presents only somewhat more often in females than in males. Juvenile and 
idiopathic osteoporosis are rare types of primary osteoporosis.201
Secondary osteoporosis can be caused by several disease states as well as by medications, and 
also by some life style factors, such as alcohol abuse, tobacco smoking and low physical 
activity, which all are risk factors for osteoporosis. Hormones that in physiological 
concentrations are essential for normal bone remodeling can in non-physiological amounts 
lead to osteoporosis. Glucocorticoids in excess, as in Cushing’s syndrome or on 
glucocorticoid treatment, accelerate osteoclastic bone resorption, at least partly through 
decreasing intestinal calcium absorption and causing secondary hyperparathyroidism. They 
also reduce osteoblast function and thus bone matrix formation, leading to imbalanced 
remodeling with excessive bone resorption, and they can cause osteocytes apoptosis. Some of 
their effects are probably mediated by rapid non-genomic interaction with bone cells.202
Thyroid hormone excess – hyperthyroidism or high dose thyroxine substitution - causes 
greatly increased bone turnover, which eventually leads to imbalance between resorption and 
formation and bone loss.203 In both primary and secondary hyperparathyroidism, excess of 
parathyroid hormone, bone turnover is increased. In primary disease resorption depths are 
reduced and bone architecture is therefore preserved, while in secondary disease large 
resorption depths cause detoriated bone structure.203
Osteogenesis imperfecta is an inherited disorder, caused by one of several known point 
mutations in either of the two genes coding for alpha 1 and alpha 2 peptide chains of type I 
collagen. These mutations lead either to decreased collagen synthesis or impaired collagen 
function and consequently poor bone quality.204
Chronic liver disease is often associated with osteopenia or osteoporosis, partly due to 
reduced osteoblast function, partly because of impaired vitamin D metabolism.203 Other 
conditions involving malabsorption are often associated with osteopenia or osteoporosis. 
Rickets in children and osteomalacia in adults are caused by vitamin D deficiency or by 
deficient vitamin D effect. These disorders are characterized by impaired mineralization of 
bone organic matrix and reduced strength of bone.201
Increased number and greatly increased activity of osteoclasts, often with tens of nuclei, are 
characteristic to Paget’s disease of bone. Not only bone resorption but also bone formation is 
greatly enhanced, but the bone formation is irregular and results in a mixture of woven and 
lamellar bone.205
Smoking is one of the lifestyle factors, known to be risk factors for osteoporosis and fracture 
by influencing calcium and bone metabolism in several ways. Smoking may be antiestrogenic 
decreasing calcium absorption from the gut, it reduces the hepatic metabolism of estrogens, it 
might modulate the activity of cytokines and their receptors, and it can also directly effect the 
osteoblasts.206, 207, 208
Table 2 summarizes benign disorders of bone remodeling. 
24
Table 2: Different types of osteoporosis / benign disorders of bone remodeling. 
Postmenopausal
Senile
Idiopathic
Primary 
osteoporosis
Juvenile
Cushing’s syndrome 
Hypogonadism 
Hyperthyroidism 
Diabetes mellitus 
Acromegaly 
Endocrine
etiology
Hyperprolactinemia 
Osteogenesis imperfecta Genetic
diseases Hypophosphatemia 
Glucocorticoid therapy 
Heparin therapy 
Cancer chemotherapy 
Thyroxin therapy 
Iatrogenic
Gonadotropin releasing hormone agonists 
Chronic obstructive pulmonary disease 
Rheumatoid arthritis 
Chronic liver disease 
Malabsorption syndromes 
Pregnancy related 
Lactation
Malnutrition
Immobilization 
Smoking 
Secondary
osteoporosis
Miscellaneous
etiology
Alcohol abuse 
Paget’s disease of bone 
Rickets / osteomalacia 
2.3.3.2 Malignant bone disorders 
Several cancers are associated with metastatic bone disease. Bone metastases from breast 
cancer, the most common female malignancy in the western world, are mostly of lytic nature. 
Cancer cells that metastasize to bone produce PTHrP and cytokines (IL-1, IL-6, TNFα, PGE2 
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etc.), which interact with osteoblasts to stimulate RANKL production, and decrease OPG 
production, and thus induce osteoclastic bone resorption. Bone cells on the other hand 
produce cytokines and growth factors that stimulate cancer cell growth. This vicious cycle 
leads to greatly accelerated bone resorption, often with only some concomitant increase in 
bone formation, and to lytic bone lesions, which in advanced disease can cause 
hypercalcemia.209, 210
In prostate cancer, which is most common male malignancy in the western world, the 
metastases are mainly of sclerotic nature. Cancer cells in bone secrete growth factors (FGFs, 
BMPs, endothelin-1, TGF-β), which accelerate bone formation around the tumor cell 
deposits, without prior bone resorption.209 The accelerated bone formation is accompanied 
with increased bone resorption, but to a lesser extent.211, 212 Calcium is deposited in sclerotic 
metastases, and hypocalcemia is frequently seen in this type of metastatic bone disease with 
resulting secondary hyperthyroidism, which further causes increased bone resorption. 
Multiple myeloma is a plasma cell malignancy, which is frequently associated with 
destructive bone lesions, caused by diffuse osteopenia or localized osteolysis. Myeloma cells 
produce several factors such as IL-1 and IL-6, which are known to stimulate osteoclastic bone 
resorption by stimulating RANKL production, and a similar vicious cycle as seen in lytic 
metastases of solid tumors, is involved also in multiple myeloma. In multiple myeloma there 
is usually no concomitant increase in bone formation, and hypercalcemia is often a 
complication in advanced disease.209
2.3.3.3 Treatment of bone remodeling disorders 
The ultimate aim of the treatment of bone remodeling disorders is to prevent fractures and 
other skeletal complications. Bone related disorders are currently treated with agents which 
reduce bone resorption.213, 214 Most commonly used treatment of postmenopausal osteoporosis 
is estrogen replacement therapy (ERT), combined with progestin (HRT) treatment to prevent 
unwanted side-effects on endometrium, and treatment with bisphosphonates and calcitonin. 
These compounds are also used for prevention of postmenopausal osteoporosis. More 
recently selective estrogen receptor modulators (SERMs) have been introduced to be used 
both in prevention and treatment of postmenopausal osteoporosis. Calcium supplementation, 
together with vitamin D treatment, has also been used especially in the elderly. Only very 
recently treatment with intermittent parathyroid hormone has been approved to be used in the 
treatment of severe osteoporosis. To date this is the only treatment to stimulate bone 
formation. HRT and bisphosphonates have been shown to increase BMD, and to reduce 
vertebral fracture risk to about half of the risk in untreated population. Raloxifene, the only 
SERM so far approved for the prevention and treatment of osteoporosis, increases BMD less 
than do estrogens or bisphosphonates, but its influence on fracture risk is similar. With 
calcitonin BMD increments are smaller. The increase in BMD as response to PTH therapy is 
more pronounced than with antiresorptive therapies. 
Bisphosphonates are the most commonly used agents in the treatment of secondary 
osteoporosis, as well as bone related disorders due to malignancy.215 Both non-
aminobisphosphonates such as clodronate, and aminobisphosphonates, e.g. pamidronate and 
zoledronate, have been shown to be effective in reducing skeletal complications due to lytic 
bone metastases from breast cancer or bone lesions due to multiple myeloma. In addition, 
clodronate has been shown to prevent the development of bone metastases in primary breast 
cancer.216 In sclerotic bone metastases from prostate cancer bisphosphonates have been used 
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mostly in advanced disease for bone pain palliation, believed to be due to increased bone 
resorption.
2.4 Markers of bone turnover 
2.4.1 Markers reflecting bone formation 
Markers, which reflect bone formation are proteins produced by the osteoblast, and liberated 
into the circulation where their concentrations can be measured. To date total activity of 
alkaline phosphatase or, more specifically, the activity or concentration of the bone-specific 
isoform of the enzyme, the concentration of different immunoreactive forms of osteocalcin, 
and the circulating concentrations of type I procollagen amino- and carboxy-terminal 
propeptides have been used as reflectors of bone formation rate. 
Table 3 summarizes the markers reflecting bone formation rate and the methods available to 
measure them. In the following chapters some methods are referred in more detail. 
Table 3: Biochemical markers reflecting bone formation. 
Marker Method 
HPLC
electrophoresis, all isoforms semiquantitavely determined after pretreatment  
lectin precipitation and calculation, activity measured 
IRMA or ELISA, mass concentration measured 
Bone-specific alkaline 
phosphatase (Bone ALP) 
immunoextraction with a monoclonal antibody, activity measurement 
several RIAs, bovine OC as immunogen, intact OC and several fragments 
measured
Osteocalcin (OC) 
several RIAs and IRMAs, or methods with other than radioactive label, with 
human OC as immunogen, measuring intact OC, its N-Mid-fragment or both or in 
addition smaller fragments 
Procollagen I carboxy-terminal 
propeptide (PICP) RIA or ELISA 
Procollagen I amino-terminal 
propeptide (PINP)  
RIA measuring intact PINP 
ELISA and automated ECIA measuring intact PINP and Col 1 fragment of PINP 
2.4.1.1 Bone alkaline phosphatase
Bone alkaline phosphatase is coded by the tissue non-specific ALP gene, which is expressed 
in bone, liver and kidney.38 The products of the tissue non-specific gene are 
posttranslationally differently glycosylated in different tissues, or even in one tissue, leading 
to several tissue specific isoforms of ALP. In bone two differently glycosylated isoforms are 
found, and the proportion of these isoforms might change in different pathological 
conditions.78 Mainly bone and liver isoforms are found in the circulation, in some persons 
also small amounts of intestinal isoenzyme circulate. In childhood the bone isoform 
predominates whereas in adults about half of the ALP activity comes from the bone, the other 
half from the liver. During pregnancy heat stabile placental isoenzyme contributes part of the 
ALP activity in the circulation. Certain tumors produce placental-like isoenzyme of ALP. 
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Several methods for determining the different circulating forms of ALP have been described. 
Electrophoresis has been the most widely used method in clinical chemistry. Irrespective of 
the medium used, electrophoresis has to be run for native sample and for differently 
pretreated sample in order to get the different isoforms and isoenzymes separated and 
quantitated. Heat denaturation in 56 oC for ten minutes inactivates almost all bone isoforms, 
neuraminidase handling of the sample modifies the mobility of the other isoenzymes but the 
intestinal one.217, 218, 219 A wheat germ lectin precipitation method was introduced in mid 
80’s.220 In this method almost all bone isoform is precipitated with lectin. The activity of 
Bone ALP is calculated from the total and the residual activity using a formula, which takes 
into account that not all Bone ALP is precipitated. Two immunoassays have also been 
developed for measuring Bone ALP. The immunometric assay uses two monoclonal 
antibodies directed against different epitopes of the isoform, measures the mass concentration 
of Bone ALP, and is available in two formats, either as an immunoradiometric (IRMA) or an 
immunoenzymometric assay (IEMA).17, 221 In the ELISA assay Bone ALP is 
immunoextracted from the sample using a specific monoclonal antibody coated on a 
microtiter well.18 After washing the well the activity of Bone ALP is measured. Because the 
specificity of the antibodies used in the immunoassays is based on the differential 
glycosylation of the enzyme protein, both methods have some cross reactivity with the liver 
isoform, and they do not necessarily recognize all bone isoforms formed in pathological 
conditions.222
2.4.1.2 Osteocalcin
Osteocalcin is one of the two proteins known to date as being specific for bone and dentin,37 
and the only one of these two whose concentration in circulation has been used as a reflector 
of bone formation. In the circulation osteocalcin exists in several immunoreactive forms.9
About 30 % of immunoreactive osteocalcin is intact molecule, one third is the so called N-
mid fragment. The N-Mid fragment forms via proteolytic cleavage of the intact molecule 
between two Arg residues at positions 43 and 44.223 The rest of the circulating osteocalcin 
consists of several smaller breakdown products. Degradation of OC takes place both in vivo
and in vitro.
The early immunoassays for osteocalcin in the 80’s used bovine osteocalcin as the antigen for 
raising the assay antibodies and to be used as labeled competing antibody and standards.8, 224,
225
 Bovine osteocalcin shows great homology with human osteocalcin, was not so prone to 
degradation during the purification process, and the antibodies against bovine OC had a 100 
% cross reactivity with the human OC. These early assays recognized different circulating 
immunoreactive forms of OC to varying extents, and different assays gave greatly differing 
results. The knowledge of the different immunoreactive forms of OC, introduction of 
monoclonal antibodies against human OC, and immunometric techniques have made it 
possible to measure certain molecular forms of OC, and methods for undercarboxylated OC 
have also been described.226, 227, 228, 229, 230
Some of the newly formed OC is liberated directly into the circulation, where it can be 
measured. The immunoreactive OC has been shown to correlate with histomorphometrical 
measures of bone formation rate.231 However, as OC is incorporated into the bone 
extracellular matrix, some of the circulating OC might originate from degrading bone, and the 
circulating immunoreactive OC thus rather reflects bone turnover, not just bone formation.232,
233
 Even to date, no standard preparation of OC exists, and the results obtained with tens of 
commercially available or in-house OC assays are not comparable.10, 11, 12, 234, 
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Currently it is recommended that when possible, methods recognizing the N-Mid fragment 
are used. Intact OC degrades rapidly in vitro, and therefore the serum must be quickly 
separated from the red blood cells. Even in serum the intact OC loses its immunoreactivity in 
hours, if not stored in low temperature (minus 70 oC or lower). 
2.4.1.3 Type I procollagen propeptides 
Type I collagen is synthesized by the osteoblasts, starting at an early phase of osteoblast 
differentiation, as a large procollagen molecule consisting of two procollagen I alpha 1 and 
one procollagen alpha 2 chains.57 The chains are post-translationally modified and assembled 
to a trimeric procollagen molecule, which is secreted into the extracellular space, where large 
extension peptides from each end of the molecule are cleaved off by specific 
endopeptidases.59 The carboxy-terminal extension peptide (PICP) is cleaved off first, the 
amino-terminal peptide (PINP) after some delay. The propeptides are liberated into the 
circulation in an equimolar ratio, and their concentrations can be measured by specific 
immunoassays. Although type I collagen is not specific to bone it is believed that the 
circulating type I procollagen propeptides are derived mainly from bone due to higher 
osseous turnover as compared to other tissues. 
2.4.1.3.1 Carboxy-terminal propeptide of type I procollagen PICP 
The carboxy-terminal propeptide of type I procollagen is composed of three equal size 
peptide chains (MW approximately 33 kDa each), held together by disulphide bridges. It is 
globular in shape, and it has been post-translationally glycosylated containing high-mannose 
type oligosaccharides. In the circulation only one form of PICP exists, and it is cleared from 
the circulation via liver endothelial cell mannose receptors.235
PICP can be measured with a radioimmunoassay (RIA)13 or an enzyme immunoassay 
(ELISA). Serum PICP concentrations measured with the commercially available RIA have 
been shown to correlate with bone formation rate as determined by histomorphometry and 
calcium kinetics.236, 237, 238
2.4.1.3.2 Amino-terminal propeptide of type I procollagen PINP 
The amino-terminal propeptide of type I procollagen is a partly helical, partly globular protein 
with two equal size alpha 1(I) chains and one shorter part of alpha 2(I) chain, and a molecular 
weight of approximately 35 kDa. The molecule is phosphorylated, and it is cleared from the 
circulation via liver endothelial cell scavenger receptors.239 In the circulation at least two 
molecular forms of PINP are found, the intact trimeric form and a smaller monomeric peptide 
from the Col 1 part of the proalpha 1(I) chain of the procollagen molecule. 
Several immunoassays have been developed for measuring the circulating PINP 
concentration. In these assays polyclonal antibodies have been raised against synthetic 
sequences of proalpha 1(I) chain,14, 240 against a proalpha 1(I) chain purified from human 
amniotic fluid,16 or an antigen purified from cultured human osteosarcoma cells.15 Of these 
assays the RIA with a synthetic peptide containing amino acids 1-12 from the amino-terminus 
of human proalpha 1(I) chain as the antigen showed good correlation with other indices of 
bone formation (OC, Bone ALP, PICP), whereas no correlation was found with the synthetic 
peptide-based ELISA, and the values in healthy adults were 100-fold higher than those of 
PICP. The ELISA method using the antigen purified from human amniotic fluid recognized 
two circulating forms of PINP, the intact PINP and the small Col 1 fragment. The latter is 
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cleared from the circulation via kidneys, and thus its concentration might be elevated in renal 
insufficiency. The RIA using the antigen purified from human osteosarcoma cells measures 
only the circulating intact trimeric PINP. 
2.4.2 Markers reflecting bone resorption 
Markers of bone resorption are almost solely type I collagen degradation products, amino 
acids, free or peptide-bound crosslinks  formed during collagen degradation and liberated into 
the circulation, from where they are cleared via kidneys.19 - 26 In addition to type I collagen-
derived markers, methods for measuring tartrate-resistant acid phosphatase activity or 
concentration, or specifically the osteoclast specific isoenzyme 5b, have been described and 
suggested to be used as reflectors of osteoclast activity.27 Also methods for bone sialoprotein, 
BSP, have been described.241 Although an osteoblast product, BSP is incorporated into the 
bone matrix, from where it is liberated during extra cellular matrix degradation, and thus its 
circulating concentration is believed to reflect bone resorption. 
Table 4 summarizes the markers and methods that can be used for measuring bone resorption, 
which are referred in more detail in the following chapters. 
Table 4: Biochemical markers reflecting bone resorption. 
Marker  Method 
Type I collagen-derived markers 
Total Pyr, total DPD HPLC after hydrolysis 
Free Pyr, free DPD HPLC without preceding hydrolysis  
Free Pyr and DPD ELISA 
Urinary excretion 
of pyridinoline 
and
deoxypyridinoline 
(crosslinks) 
Free DPD ELISA, automated methods (CIA) 
Crosslinked amino-terminal 
telopeptides, NTX ELISA, automated CIA 
Peptide-bound 
crosslink 
excretion
Crosslinked carboxy-
terminal telopeptides, CTX ELISA for CTX-beta, RIA for CTX-alpha 
Crosslinked amino-terminal 
telopeptides, NTX ELISA
Crosslinked carboxy-
terminal telopeptides, CTX ELISA or automated ECIA for the beta-isomer 
Serum 
crosslinked 
telopeptides of 
type I collagen 
Carboxy-terminal 
crosslinked telopeptide ICTP 
or CTX-MMP  
RIA
Tartrate-resistant acid phosphatase TRACP in 
serum 
Several assays, which measure either activity or concentration 
Osteoclastic tartrate-resistant acid phosphatase 
TRACP 5b in serum Immunoextraction and measurement of activity 
Bone sialoprotein BSP in serum RIA (not commercially available) 
30
2.4.2.1 Type I collagen degradation products 
Urinary excretion of hydroxyproline (HOP), an iminoacid formed from proline and a 
prerequisite for the triple-helical conformation of collagen, has been used as an estimate of 
bone resorption rate.5, 6 However, HOP is partly metabolized in the liver, and the excreted 
HOP can originate from various sources: from diet as well as from bone or from other 
proteins like the C1q component of the complement,242 or from newly formed collagen. Thus 
only about 10% of the excreted HOP originates from degrading bone, making it an unspecific 
marker of bone resorption. Therefore, during the last decade HOP measurement has been 
replaced by more specific assays, measuring either urinary excretion or serum concentrations 
of the type I collagen breakdown products, free crosslinks deoxypyridinoline (DPD, lysyl 
pyridinoline) or pyridinoline (Pyr, hydroxylysyl pyridinoline) or crosslink peptides from the 
amino- or carboxy-terminal telopeptide areas of type I collagen (ICTP=CTX-MMP, CTX, 
NTX).19-26 These degradation products can originate only from mature collagen, and they are 
not further metabolized. Hydroxypyridinium crosslinks of collagen form during the 
extracellular maturation of fibrillar collagens like type I collagen.62-72 Both deoxypyridinoline 
(DPD) and pyridinoline (Pyr) are trivalent crosslinks that form between two adjacent collagen 
molecules, and are crucial for the mechanical properties and strength of collagen. DPD is 
almost exclusively found in bone and dentin whereas Pyr is found also in cartilage, ligaments 
and vessels. In addition to mature cross-links, immature divalent crosslinks are found in bone, 
and their proportion might increase with aging as well as in some pathological processes such 
as malignancies.243, 244 Figure 4 shows the origin of the different breakdown products of type I 
collagen, measurable currently with immmunoassays or with chromatography.245
Figure 4:The origin of type I collagen breakdown products, used as markers of bone resorption. From ref. 
245 by courtesy of Dr Simon Robins. 
Originally pyridinoline excretion was measured using reverse phase HPLC with fluorescent 
detection, either after acid hydrolysis (total crosslinks) or without hydrolysis (free crosslink 
fraction),19 but less cumbersome immunoassays have largely replaced the chromatographic 
method, at least in clinical routine. The most commonly used sample is a two-hour sample 
after voiding the first morning urine, and the crosslink excretion is proportioned to creatinine 
excretion.246 In addition to measuring crosslink excretion, methods for assessing serum 
concentrations of the crosslink peptides have been developed. 
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2.4.2.1.1 Methods for urinary free crosslink compounds 
An enzyme immunoassay (ELISA) for measuring pyridinoline excretion to urine was 
introduced and became commercially available in early 90’s.21 Both Pyr and DPD, either free 
or peptide-bound with a molecular weight less than 1000 Daltons, were measured with the 
assay. Somewhat later a monoclonal antibody-based assay measuring only free DPD became 
available in an ELISA format,22  and somewhat later as an automated chemiluminescent 
immunoassay (CIA).247 In healthy adults a constant proportion of 40 – 50 % of the pyridinium 
crosslinks was shown to be excreted in free, non-peptide-bound form, and therefore 
measuring only free crosslinks  was considered an adequate reflector of bone resorption 
rate.248 However, the ratio of free to peptide-bound crosslinks might change in states of 
altered rate of bone turnover,249 the proportion of excreted peptide-bound crosslinks 
increasing with increasing turnover. 
2.4.2.1.2 Methods for urinary peptide-bound crosslink compounds 
2.4.2.1.2.1 Type I collagen cross-linked amino-terminal telopeptides (NTX) 
Type I collagen amino-terminal telopeptides (NTX) are collagen breakdown products 
containing trivalent pyridinoline or deoxypyridinoline crosslink structure and two peptide 
chains from the amino-terminal telopeptide region of one collagen molecule connected to the 
helical region of an adjacent collagen molecule.23 The crosslink at the N-terminal telopeptide 
region forms predominantly between alpha 1(I) and alpha 2(I) or alpha 2(I) and alpha 2(I) 
chains of collagen, a feature that is found only in type I collagen in bone. The antigen was 
originally isolated from adolescent human urine, and monoclonal antibodies were raised 
against it. An ELISA method was developed using an antibody that recognizes the amino-
terminal region of the alpha 2-chain of type I collagen.23 The antibody did not react with the 
linear peptide sequence, but needed to have the conformation of the crosslink peptide, and the 
binding was not dependent on the nature of the cross-link. Later an automated 
chemiluminescent immunoassay (CIA) was introduced. The automated assay uses the same 
antibody as the original ELISA, but the antigen used as standard and competing antigen is a 
synthetic crosslink peptide. The structure of the NTX antigen is shown in Figure 5. 
Figure 5. The structure of the NTX antigen. 
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2.4.2.1.2.2 Crosslink peptide from the carboxy-terminal telopeptide region of type I 
collagen (CTX) 
The CTX antigen is an octapeptide (Glu-Lys-Ala-His-Asp-Gly-Gly-Arg) from the 
crosslinking site of the alpha 1(I) chain of the type I collagen carboxy-terminal telopeptide 
region. The aspartyl residue of the peptide can exist in two isomeric forms, the beta-form 
resulting from aging of type I collagen.250, 251 The non-isomerized alpha-form predominates in 
states of high turnover. A polyclonal antibody base enzyme immunoassay (ELISA) was 
developed for measuring the urinary excretion of the beta-isomerized form of CTX 
(CrossLaps). Only the linear peptide sequence is required for the immunoreactivity in this 
assay. A monoclonal antibody-based radioimmunoassay (RIA) was later developed for 
measuring the urinary excretion of the non-isomerized alpha-isomer of the peptide.252 An 
increased alpha-CTX to beta-CTX ratio was shown in untreated Paget’s disease of bone with 
accelerated bone turnover.253 The origin and structure of the CTX antigen is shown in
Figure 6. 
Figure 6. The origin and structure of the 8 amino acid sequence of the CTX antigen from ref 251, with 
permission.
2.4.2.1.3 Methods for serum type I collagen crosslinked compounds 
2.4.2.1.3.1 Assay for the crosslinked carboxy-terminal telopeptide of type I collagen 
(ICTP, CTX-MMP) 
The first immunoassay for measuring type I collagen degradation product in serum was a 
polyclonal antibody-based radioimmunoassay measuring a trivalent crosslink-containing 
carboxy-terminal telopeptide of type I collagen (ICTP).20 The antibody binding requires the 
trivalent crosslink, either DPD or Pyr, and the phenylalanine-rich domains of telopeptide 
region of the two alpha 1 chains to be present. The antibody does not recognize divalently or 
non-crosslinked peptides. Recently it has been shown that the antigen is destroyed by 
cathepsin K, the cysteine proteinase mainly responsible for collagen degradation in acidic pH 
during normal conditions.254 Cathepsin K degrades the bond between the phenylalanine-rich 
domain and the cross-link, resulting in the loss of immunoreactivity. The action of matrix 
metalloproteinases on bone collagen leads to the formation of ICTP antigen, which therefore 
has been proposed to be called CTX-MMP.255
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Figure 7: The structure of the ICTP or CTX-MMP antigen, from ref 254, with permission. 
2.4.2.1.3.2 Serum assays for NTX and CTX-β
Recently serum assays for the carboxy- and amino-terminal telopeptides of type I collagen 
have become available. The assay for serum NTX utilizes the same antibody as the assay for 
urinary NTX, and the same assay design as the manual ELISA assay for U-NTX.25 Serum 
CTX-β concentration is measured with a sandwich method where the same monoclonal 
antibody is used as capturing and as detecting antibody.26 The antibody recognizes the same 
peptide sequence as the antibody in the urinary CTX-β-assay, but a crosslink and two alpha 1 
chains are needed for antibody binding. The assay is available in manual ELISA format and 
as an automated electrochemiluminescent immunoassay (ECIA).256 The latter one uses a 
synthetic antigen as the standard. 
2.4.2.2 Tartrate resistant acid phosphatase
Human serum contains two isoforms of tartrate-resistant acid phosphatase (TRACP), 5a and 
5b, which are products of the same gene and differ from each other in glycosylation, 5a 
containing sialic acid, 5b not.27, 257 The isoform 5b has been shown to originate from 
osteoclasts, and isoform 5a from other sources, most probably from macrophages. Several 
assays have been developed for measuring either TRACP activity or its mass concentration, 
but thus far they have been disappointing as reflectors of bone resorption. A novel 
immunoassay measuring specifically TRACP 5b activity has recently been developed.27 In 
this assay TRACP isoforms 5a and 5b are both first captured to the solid phase by a TRACP-
specific monoclonal antibody, after which the bound TRACP activity is measured at pH 6.1, 
at which 5b is highly active and 5a almost completely inactive. 
2.4.3 Markers of bone turnover in different clinical situations 
The value of markers of bone turnover has been evaluated in a large number of clinical 
studies. Serum concentrations of the markers of bone formation S-OC, S-Bone ALP and S-
PICP have been shown to vary with age, being at their highest during puberty. 258, 259, 260  They 
also have been shown to correlate with growth velocity in healthy children and in children 
treated for growth hormone deficiency or for short stature without hormone deficiency.259, 261
The marker values before treatment did not correlate with the response to treatment, but the 
height gain and the increase in markers showed good correlations, and early marker change 
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predicted later height gain. Urinary and serum type I collagen-derived resorption markers 
show a similar age dependent pattern as do the formation markers.262, 263 Serum ICTP was 
shown to be very high in neonates, increasing further somewhat up to one month of age, and 
then declining from values close to 100 µg/l to values around 30 µg/l at one year of age.264
Markers have been evaluated in several disease states and during treatments, which are 
known to effect bone metabolism. Glucocorticoids (GC) are frequently used to treat 
inflammatory diseases such as rheumatoid arthritis (RA) and asthma. They are known to 
cause osteoporosis which is characterized by decreased bone formation and unchanged or 
increased bone resorption.202, 265 In RA itself there is evidence of unbalanced bone formation 
and resorption, in favor of resorption: the type I collagen-derived resorption markers are 
elevated in active disease and their levels correlate with the disease activity,266, 267 whereas the 
formation markers have been reported to be either normal or lowered.268, 269 In newly 
diagnosed asthmatic patients type I collagen-derived marker values have been similar to 
values in control subjects, but serum osteocalcin has been shown to be lowered in pediatric 
patients with asthma.270 Oral use of GCs as well as inhaled GCs, depending on the dose, 
further decrease bone formation, shown by decreasing levels of osteocalcin and PICP both in 
adults and children.271, 272, 273, 274 On the markers of bone resorption the effect of GCs is less 
clear, and they have been shown either to increase, decrease or remain unchanged. On the 
other hand, some studies have shown no changes in any markers of bone turnover during 
treatment with inhaled GCs.275, 276 In one study an age-dependent response in S-ICTP was 
shown, increasing in young patients but decreasing in older patients.274 The changes in bone 
turnover markers are seen while on treatment, and the values return to baseline levels after 
withdrawal of GCs. 
Hyperthyroidism is characterized by accelerated bone turnover, due to a direct effect of 
triiodothyronine on hormone receptors in the osteoblasts.188, 189 The accelerated turnover is 
reflected as increased levels of markers of bone formation osteocalcin and Bone ALP, and as 
increased excretion of type I collagen-derived resorption markers.277 In some studies, 
increased levels of markers of bone formation and resorption have also been measured during 
thyroxine treatment, indicative of increased bone turnover.278, 279  Whether this increased bone 
turnover leads to increased bone loss is still controversary. In some studies significantly 
reduced BMDs have been reported, 280, 281, 282  in some studies the detrimental effect has been 
seen only in postmenopausal women,280 whereas in some studies the effect has been the same, 
irrespective of menopausal status.281, 282
Bone metastases are frequently seen in context of solid tumors such as breast cancer and 
prostate cancer, and lytic bone lesions are characteristic to multiple myeloma.209 Several 
markers of bone resorption have been shown to be elevated in patients with bone metastases, 
whether lytic or sclerotic.283, 284 The diagnostic value of especially the urinary markers of 
bone resorption is, however, lessened due to their poor clinical specificity: they are often 
elevated also in patients without bone involvement. Nevertheless, some bone markers are of 
value as prognostic tools as well as in the follow-up of disease outcome. The prognostic value 
of serum ICTP has been shown in several different solid tumors and in multiple myeloma,32, 
285, 286, 287
 and its concentration correlates with both the tumor burden in bone and bone 
pain.288, 289 The value of ICTP in the follow-up of disease outcome has also been shown.290, 291
The clinical sensitivity of elevated values of bone formation markers Bone ALP and PICP, 
and thus their value in diagnosis of metastatic bone disease, increases from lytic to mixed to 
sclerotic metastases, with low sensitivities when the bone disease is of lytic nature, but with 
sensitivities approaching 100% in prostate cancer patients with bone involvement.32, 283, 288, 289, 
292
 Osteocalcin is only seldom elevated, even in patients with blastic bone disease, and 
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lowered results have also been reported, irrespective of the type of metastases.288, 293  Some 
studies have shown low osteocalcin values to correlate with worse outcome of patients with 
multiple myeloma or with lytic lesions from solid tumors.286, 294, 295
Smoking is one of the lifestyle factors known to be a risk factor for osteoporosis. Its effect on 
the markers of bone turnover have been studied in a few studies 296, 297, 298, 299  In these studies 
osteocalcin or Bone ALP were measured as reflectors of bone formation, type I collagen 
breakdown products were measured for bone resorption. These studies showed unbalanced 
bone formation and resorption in smokers, either due to decreased bone formation297, 298or due 
to increased bone resorption.296, 299 Osteocalcin was shown to be lowered in current smokers, 
whereas Bone ALP was similar in smokers and non-smokers. Bone resorption was increased 
or unchanged in smokers as compared with non-smokers. In two of the above mentioned 
studies smoking was shown to significantly decrease circulating concentration of 25(OH) 
metabolite of vitamin D.296, 297
The mean values of most markers of bone turnover in postmenopausal osteoporosis have been 
shown to be higher in osteoporotic subjects in comparison to healthy subjects.29, 300 However, 
they cannot be used in the diagnosis of osteoporosis due to the overlap of the values between 
the two groups of subjects. Marker values before intervention have been correlated with bone 
mineral density (BMD), and they have been evaluated as predictors of future bone loss and 
fracture.301, 302,  303, 304 Several population based studies have also shown bone resorption 
markers and BMD to be independent factors for prediction of bone loss and subsequently of 
fractures, bone resorption being increased and BMD lowered in subjects who will sustain 
fractures.305, 306  The predictive value of bone formation markers is less well established, and 
contradictory results have been published.305, 307, 308 Of greatest value for the clinician, bone 
markers serve to monitor the efficacy of antiresorptive therapy. Significant decreases in 
resorption markers can be seen as soon as one month after the start of an efficient treatment 
whereas formation markers decrease significantly after three months on treatment, with 
significant increases in BMD being observed in 1 to 2 years.300, 309, 310, 311 Also, marker 
changes after 3 months on antiresorptive treatment have been shown to predict later BMD 
changes, at least at sites where trabecular bone predominates.300
3 Aim of the study 
The aim of the present study is to evaluate commercially available immunoassays for type I 
collagen-derived markers as to their performance. In addition, preanalytical factors like 
sample handling and storage, effect of hemolysis on serum markers, and diurnal variation of 
the markers are studied. The methods evaluated are radioimmunoassays for the amino- and 
carboxy-terminal propeptides of type I procollagen (S-PINP, S-PICP) and for the cross-linked 
carboxy-terminal telopeptide of type I collagen (S-ICTP), enzyme immunoassays for 
measuring the urinary excretion of pyridinolines (Pyr), free deoxypyridinoline (DPD) and 
amino-terminal telopeptides of type I collagen (NTX), and the automated chemiluminescent 
immunoassays for DPD and NTX. In addition, in one study S-PINP and U-NTX are 
compared with the serum activity of tartrate-resistant acid phosphatase 5b (TRACP 5b), 
measured with the novel immunoextraction method. In two studies osteocalcin (OC) and in 
one study bone specific alkaline phosphatase (Bone ALP) are measured. The clinical value of 
the type I collagen-derived markers is assessed in different situations: in healthy persons, in 
children with asthma and on corticosteroid treatment, in patients with prior differentiated 
thyroid carcinoma on and off thyroxine treatment, in metastatic bone disease, and in 
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postmenopausal osteoporosis before and after treatment with estrogen or bisphosphonate. 
Also the effect of smoking on two markers is evaluated. 
4 Materials and methods 
4.1 Subjects and study designs 
4.1.1 Study I 
In study I serum concentrations of amino- and carboxy-terminal propeptides of type I 
procollagen (S-PINP, S-PICP) were measured in healthy volunteers, control persons from 
several studies, three of which are included here as original publications (studies II, III and 
IV). The age range of the healthy females (n = 158) was 3.8 – 80.5 years, and of the healthy 
males (n = 95) 0.9 – 70.9 years. The same subjects have been used for establishing reference 
ranges for other markers referred here. Study I was designed to assess the performance of 
intact PINP radioimmunoassay, to measure S-PINP in healthy persons, and to compare S-
PINP values to S-PICP values in healthy population. 
4.1.2 Study II 
The subjects in study II were prepubertal children (6 boys and 8 girls) with median age of 9.1 
years (range 7-11). They all had newly diagnosed perennial asthma, and they had not been on 
previous anti-inflammatory treatment. The study was designed to measure bone turnover in 
these children before treatment, after they had been one month on high dose (800 µg/m2/day)
inhaled budesonide (Turbuhaler, Draco AB, Lund, Sweden), after 5 months on lower dose of 
budesonine (400 µg/m2/day), and after 6 months on inhaled nedocromil (Tilade, Fisons, UK). 
As markers of bone formation serum concentrations of amino- and carboxy-terminal 
propeptides of type I procollagen (S-PINP, S-PICP) and osteocalcin (S-OC) were measured. 
Bone resorption was assessed by measuring serum concentration of type I collagen carboxy-
terminal cross-linked telopeptide (S-ICTP), and urinary excretion of pyridinolines (U-Pyr), 
free deoxypyridinolines (U-DPD), and amino-terminal cross-linked telopeptides of type I 
collagen (U-NTX). The baseline values were compared to values of age and gender matched 
controls (n=21). 
4.1.3 Study III 
The subjects in study III were 29 patients (25 women, 4 men, median age 45 years) with prior 
differentiated thyroid cancer. The patients had been treated with near total thyroidectomy 
followed by radioiodine ablation, in most patients 9 to 11 years before the study, and since 
then they had been on thyroxine therapy. The dose of levothyroxine was sufficient to render 
serum thyroid stimulating hormone (S-TSH) level undetectable as assessed with a second 
generation TSH method (detection limit 0.05 mU/l). Bone turnover was assessed with several 
markers of bone turnover: serum concentrations of amino- and carboxy-terminal propeptides 
of type I procollagen (S-PINP, S-PICP) and of osteocalcin (S-OC), and serum activity of bone 
specific alkaline phosphatase (S-Bone ALP) were measured as reflectors of bone formation, 
and serum concentration of type I collagen cross-linked carboxy-terminal telopeptide (S-
ICTP) and urinary excretion of hydroxyproline (U-HOP) were used as reflectors of bone 
resorption. The marker values were compared to the values of age and gender matched 
controls (n=38). In a subgroup of 14 patients the T4 treatment was stopped after baseline 
evaluation for 5 weeks, and the marker measurements were repeated after 5 weeks. 
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4.1.4 Study IV 
Study IV included 25 patients with breast cancer and confirmed bone metastases (mean age 
56 years, range 33-79 years), and 12 breast cancer patients with no bone metastases (mean 
age 56 years, range 38-76 years), and their age matched healthy controls. The patients had 
normal renal function, they had no metabolic bone disease, and they were normocalcemic. 
The study was designed to assess the value of three type I collagen-derived markers, serum 
concentrations of amino- and carboxy-terminal propeptides of type I procollagen (S-PINP, S-
PICP) and type I collagen cross-linked carboxy-terminal telopeptide (S-ICTP), in diagnosis of 
skeletal disease due to breast cancer. In addition, their value in the follow-up of treatment 
response, either chemotherapy or bisphosphonate treatment, was assessed for 13 patients with 
skeletal disease. 
4.1.5 Study V 
Study V included 89 breast cancer patients, who were divided in two groups. A group of 49 
patients were patients with stable disease (SD), and these patients had no or minor metastases 
and stable clinical outcome of the disease. The other group of 40 patients consisted of patients 
with progressive disease (PD), and these patients had bone, liver or other metastases, and 
clinically evaluated aggressive type of disease. The study was designed to assess the value of 
the serum concentrations of amino- and carboxy-terminal propeptides of type I procollagen 
(S-PINP, S-PICP), and the ratio of the propeptides (PICP/PINP) as indicators of aggressivity 
of breast cancer. The patients in study IV were included in the patient population of study V. 
4.1.6 Study VI 
The subjects in study VI were healthy smoking (n = 63) and non-smoking (n = 67) women, 6 
months to 5 years postmenopausal. The median age of smokers was 51.8 years (range 46 - 55 
years), and of non-smokers 52.9 years (range 47 – 59 years). The subjects could be 
osteoporotic, but no other systemic illnesses were allowed, and they were not to be on 
medication known to effect bone and calcium metabolism. The study was designed to assess 
the effect of smoking on the efficacy of transdermal estrogen replacement therapy on bone. 
The efficacy was assessed by measuring bone mineral density (BMD) at several skeletal sites, 
and by measuring bone turnover with one marker of bone formation, serum concentration of 
amino-terminal propeptide of type I procollagen (S-PINP), and one marker of bone 
resorption, urinary excretion of amino-terminal cross-linked telopeptides of type I collagen 
(U-NTX), before ERT and after 1 and 2 years on treatment. Vitamin D (25-OH-D) was also 
measured at each time point. In addition, the marker values at baseline were compared to 
those of healthy premenopausal non-smoking women with a median age of 36.8 years (range 
20 – 51 years). 
Smokers were randomized to receive either 1.0 mg (n=32, group 1) or 1.5 mg (n=31, group 2) 
of transdermal estradiol daily, and non-smokers 1.0 mg (n=46, group 3) for 2 years. Estrogen-
treated women with intact uterus received medroxyprogesterone acetate or dydrogesterone 10 
mg daily for 12 days of each cycle (=month). Non-smokers without estrogen treatment (n=22) 
served as a control group. 
4.1.7 Study VII 
Nine healthy postmenopausal women, all 68 years of age, participated in study VII. The study 
was designed to assess the effect of treatment with oral clodronate for one month on markers 
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of bone turnover and their diurnal variation. The subjects received a daily dose of 800 mg of 
clodronate for the first two weeks on treatment and 1600 mg of clodronate for the last two 
weeks. Serum concentration of carboxy-terminal propeptide of type I procollagen (S-PICP) 
was measured to assess bone formation, serum concentration of type I collagen carboxy-
terminal cross-linked telopeptide (S-ICTP), and urinary excretion of pyridinolines (U-Pyr) 
and amino-terminal cross-linked telopeptides of type I collagen (U-NTX) were measured for 
assessing bone resorption. To assess the diurnal variation of the markers, serum samples were 
drawn at 2-hour intervals for 24 hours. The diurnal variation of the urinary markers was 
assessed from 4-hour urine samples. In addition, serum concentrations of calcium (S-Ca) and 
parathormone (S-PTH) and urinary excretion of Ca (U-Ca) were assessed. Diurnal variation 
of the amino-terminal propeptide of type I procollagen (S-PINP) was established later for 
samples taken before clodronate treatment.  
4.1.8 Study VIII 
The subjects in study VIII were women of over 45 years of age, and 1 to 3 years 
postmenopausal from an oral clodronate dose-ranging study (Probone study).312 They all had 
vertebral osteopenia, a lumbar spine bone mineral density (BMD) at least one standard 
deviation below the mean for premenopausal women (T-score <-1). Subjects with diseases or 
medications known to affect bone or calcium metabolism were excluded from the study. The 
study consisted of a primary 3-year dose-finding study of oral clodronate (BONEFOS?,
Leiras Oy, Finland) and a 2-year extension study. Study VIII was designed to compare a 
novel method for measuring the activity of tartrate resistant acid phosphatase from osteoclasts 
(S-TRACP 5b) to two type I collagen-derived markers, serum concentration of amino-
terminal propeptide of type I procollagen (S-PINP) and urinary excretion of amino-terminal 
cross-linked telopeptides of type I collagen (U-NTX) as reflectors of the efficacy of oral 
clodronate treatment. The study population consisted of 59 subjects who had been on placebo
in the primary study and were then switched to 800 mg clodronate for 2 years in the extension 
study. The marker values in the placebo group of the primary study (n=28) were used to 
calculate the intraindividual variation (CVi) of the markers from samples taken at entry and at 3, 
12 and 24 months. With respect to each marker, the percentage of responders was determined 
according to the least significant change (LSC) in the marker, calculated from these CVis. In 
the extension study, samples were taken yearly (baseline, 1 year and 2 years). BMD of the 
lumbar spine and at the upper femur was measured at baseline and yearly thereafter. 
Studies I and II were approved by the Ethical Committee of the Department of Allergic 
Diseases, Helsinki University Central Hospital. Studies III, VI, VII and VIII were approved 
by the Ethical Committee of the Third Department of Medicine, Helsinki University Central 
Hospital, and study VIII additionally by local Ethical Committees of five Medical Centers in 
Helsinki, Turku, Tampere, Hämeenlinna, Seinäjoki and Joensuu. Study IV was approved by 
the Ethical Committee of Vaasa Central Hospital, and study V by the Ethical Committees of 
the Medical faculty of the University of Oulu and Vaasa Central Hospital. 
Table 5 summarizes the study populations and the markers and methods used in each original 
study.
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Table 5: The study populations and markers used in each original study. 
Original publication Subjects Marker Method 
S-PINP RIA 
I Healthy volunteers, n=253 
S-PICP RIA 
S-PINP RIA 
S-PICP RIA 
S-OC RIA 
S-ICTP RIA 
U-Pyr ELISA 
U-DPD ELISA 
II Asthmatic children, n=14, and 
control children, n=21 
U-NTX ELISA 
S-PINP RIA 
S-PICP RIA 
S-OC RIA 
S-Bone ALP Lectin precipitation 
S-ICTP RIA 
III
Patients with prior differentiated 
thyroid carcinoma on, n=29, and 
off, n=14, thyroxine treatment, 
and healthy controls, n=38 
U-HOP Prockop and Udenfriend 
S-PINP RIA 
S-PICP RIA IV
Patients with breast cancer with, 
n=25, and without, n=12, bone 
metastases, and healthy controls, 
n=37 S-ICTP RIA 
S-PINP RIA 
V
Patients with breast cancer, 
either stable (n=49) or recurrent 
disease (n=40). S-PICP RIA 
S-PINP RIA 
VI
Postmenopausal smoking (n=63) 
and non-smoking (n=67) women, 
and premenopausal non-smoking 
women (n=38) U-NTX CIA, ELISA 
S-PICP RIA 
S-ICTP RIA 
U-Pyr ELISA 
U-NTX ELISA 
VII Healthy postmenopausal women (n=9) 
S-PINP RIA 
S-PINP RIA 
S-TRACP 5b ELISA VIII
Postmenopausal women with 
vertebral osteopenia, n=59 (and 
n=29) 
U-NTX ELISA 
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4.2 Methods
4.2.1 Assay for carboxy-terminal propeptide of type I procollagen (PICP) 
A competitive radioimmunoassay with PICP RIA kit from Orion Diagnostica, Oulunsalo, 
Finland, was used. In this assay PICP was produced by collegenase digestion of type I 
procollagen from culture medium of human skin fibroblasts, and it was purified by lectin-
affinity chromatography. This PICP was used as immunogen to produce PICP specific 
polyclonal antibody in rabbits, as competing antigen labeled with 125-iodine (125I), and as 
assay standards. A known amount of labeled PICP and PICP in the sample competed for the 
restricted amount of binding sites of the antibody. The labeled antigen-antibody complex was 
separated from free labeled antigen by second antibody conjugated to solid phase, kaolin. 
The assay standard range was 0 – 500 µg/l, and the kit contained 5 standards (0, 50, 100, 200 
and 500 µg). The assay was performed according to kit instructions with some minor 
modifications: The sample was incubated simultaneously with the competing antigen and the 
PICP-specific antibody in 37 oC for two hours. The reaction mixture was then cooled to room 
temperature (5 minutes in a waterbath), and a second antibody-kaolin was then added. After a 
30 minutes' incubation time the solid phase was separated by centrifuging the tubes (+5 oC,
30 minutes at speed 1500g). The liquid was removed with suction, and the radioactivity of the 
pellet was counted with a 10-channel gammacounter (Gammamaster™, Wallac, Turku, 
Finland). A standard curve was run simultaneously with the samples, and the curve was fitted 
and the results calculated with a program connected to the counter (MultiCalc™, Wallac, 
Turku, Finland). The assay required 100 µl of sample for each determination, and samples 
were assayed in duplicates. Childrens’ samples were analyzed using a sample volume of 50 
µl, and the needed reagent volumes were also halved. One reagent kit was designed for 100 
determinations. Samples with high PICP concentrations were diluted with physiological 
saline. Standards, samples, competing antigen and antibody solutions were pipeted either 
manually or by using an automated pipeting device (Tecan, USA). 
4.2.2 Assay for amino-terminal propeptide of type I procollagen (PINP) 
A competitive radioimmunoassay with intact PINP RIA kit from Orion Diagnostica, 
Oulunsalo, Finland, was used. The assay principle was similar to that of PICP assay. Intact 
PINP used as immunogen, competing antigen and standards, was isolated from pleural fluids 
of cancer patients using ion-exchange, gel-filtration and reversed-phase chromatography. The 
polyclonal PINP specific antibody recognized the circulating intact PINP, the cross-reaction 
with the small monomeric Col1 domain being only 1%. 
The assay standard range was 0 – 250 µg/l, and the kit contained 5 standards (0, 25, 50, 100 
and 250 µg). In studies I, II and III a protokit was used. The assay design was similar to that 
of PICP assay except for the sample volume requirement, which was 50 µl in PINP assay. 
One reagent kit was designed for 100 determinations. 
4.2.3 Assay for carboxy-terminal telopeptide of type I collagen 
A competitive radioimmunoassay with ICTP RIA kit from Orion Diagnostica, Oulunsalo, 
Finland, was used. The assay principle was similar to that of the propeptide assays. The ICTP 
antigen was produced by digesting type I collagen from human femoral bone with trypsin or 
bacterial collagenase. The digestion resulted in formation of a degradation product with 
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molecular weight of about 10000 Da, corresponding the circulating C-terminal telopeptide of 
type I collagen. In the ICTP assay the free and antibody-bound labeled antigen were separated 
by a second antibody and polyethylene glycol. 
The assay standard range was 0 – 50 µg/l, and the kit contained 5 standards (0, 5, 10, 25 and 
50 µg). The assay design was similar to that of propeptide assays with same incubation times. 
Sample volume needed for one determination was 100 µl, and the samples were run as 
duplicates. Similarly to PICP assay, hhildrens’ samples were analyzed using a sample volume 
of 50 µl, and the needed reagent volumes were also halved. One reagent kit was designed for 
100 determinations. 
4.2.4 Assays for urinary pyridinolines 
4.2.4.1 Pyridinoline (Pyr) enzyme immunoassay 
Urinary excretion of free and small peptide-bound cross-links, either pyridinoline or 
deoxypyridinoline, was determined using Pyriliks® kit from Metra Biosystems, Palo Alto, 
CA, USA. The assay standard range was 0 – 3000 nmol/l, and the kit included 6 standards. 
The assay was a competitive enzyme immunoassay using microtiter well as the solid phase 
(ELISA). The competing antigen, pyridinoline, purified from human urine, was labeled with 
biotin and bound to avidin coated wells. The polyclonal antibody produced in rabbits was 
recognized by both pyridinoline and deoxypyridinoline, and the Pyr in the solid phase and in 
the sample competed for the restricted amount of binding sites of the antibody. The amount of 
Pyr-specific antibody bound to the competing antigen was assessed with a second antibody 
(goat antibody against rabbit IgG) conjugated to the assay label enzyme, alkaline phosphatase 
(ALP). The amount of ALP in the solid phase was quantitated by using para-nitrophenyl 
phosphate as the substrate.
The samples (100 µl) for this assay were pretreated by centrifuging them through a filter 
(Spinfuge filter), which retained peptides larger than 1000 Da. Pretreated sample (10 µl) was 
incubated in the coated microtiter well with the antibody in an overnight (18-24 h) incubation 
at +5 +3 oC. After the incubation the wells were washed, and a second antibody-alkaline 
phosphatase conjugate was added. In an one-hour incubation at room temperature the enzyme 
conjugate was bound to the Pyr-specific antibody on the solid phase. The unbound conjugate 
was washed away, and the amount of label enzyme bound to the well was then measured by 
adding the substrate. The enzyme reaction was stopped after 60 minutes with a base (sodium 
hydroxide), and the intensity of color formed was measured within 30 minutes in a plate 
reader at wavelength 405 nm (Multiscan, Labsystems, Helsinki, Finland). Standards were 
assayed at each run. MultiCalc program was used for curve fitting and calculation of the 
results, which were then corrected for creatinine excretion. Creatinine was measured with a 
modified Jaffe reaction with reagents included in the reagent kit. The samples were analyzed 
as duplicates, and the samples and reagents were manually pipeted. The reagent kit was 
designed for 96 determinations. 
4.2.4.2 Free deoxypyridinoline (DPD) enzyme immunoassay
Urinary excretion of DPD was determined using Pyriliks-D® kit from Metra Biosystems, Palo 
Alto, CA, USA. A monoclonal antibody specific for free DPD crosslink was used in this 
assay. The assay solid phase, microtiter well, was coated with the monoclonal antibody, and 
the competing antigen, deoxypyridinoline, was conjugated to the label enzyme, alkaline 
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phosphatase (ALP). The amount of enzyme bound to the solid phase was assessed by using 
para-nitrophenyl phosphate as the substrate.
Turbid samples were centrifuged for 5 minutes at 1500g, and the supernatant was used for the 
assay. Samples were prediluted 1:10 with the assay buffer. The assay standard range was 0-
300 nmol/l, and the kit included 6 standards. Diluted sample (50 µl) was incubated in the 
coated well with the competing antigen for 2 hours at +5+3 oC in the dark. The amount of 
enzyme label bound to the well was detected as in Pyrilinks® assay. The pipeting of the 
sample and the liquid reagent was done either manually or by using an automated pipeting 
device (Tecan). MultiCalc program was used for curve fitting and calculation of the results, 
which were corrected for creatinine excretion. Creatinine was measured either with the 
modified Jaffe method in a microtiter well format or with a kinetic Jaffe method on a clinical 
chemistry analyzer (Hitachi 911, Boehringer-Mannheim, Germany). 
4.2.4.3 Free deoxypyridinoline (DPD) automated chemiluminescent 
immunoassay 
The assay was an automated assay on ACS:180 immunoanalyzer (Chiron, USA). In this assay 
the same monoclonal antibody as in the enzyme immunoassay was used. The competing 
antigen was covalently coupled to the assay solid phase, paramagnetic particles. The 
monoclonal DPD-specific antibody was coupled to a polyclonal anti-mouse antibody, which 
was labeled with acridinium ester. The amount of label in the solid phase was detected as 
light intensity released after the acridinium ester was triggered to a higher energy state by 
adding NaOH and nitrite. The manufacturer calibrated the assay with a full standard curve. 
For each reagent lot the standard curve was fed to the analyzer, and the standard curve was 
fitted for the analyzer by assaying two calibrators at weekly intervals. The overall incubation 
time for all methods on the analyzer was 7.5 minutes, and the time from pipeting the sample 
to getting the result was approximately 15 minutes. The analyzer was used as a patch analyzer 
for DPD measurements, and 60 samples or controls could be assayed in one run. The samples 
were assayed as single determinations, and the results were proportioned to creatinine 
excretion, measured with a kinetic Jaffe method. 
4.2.5 Assays for urinary amino-terminal telopeptides of type I collagen (NTX) 
4.2.5.1 NTX enzyme immunoassay 
Urinary excretion of NTX was determined by using a kit (Osteomark™) from Ostex 
International, Seattle, USA. In this assay the solid phase, microtiter well, was coated with the 
competing antigen, crosslinked N-terminal telopeptide from human urine. The monoclonal 
antibody, specific for a peptide sequence in the alpha 2 chain telopeptide region when 
attached to a crosslink, was conjugated to the assay label enzyme, horseradish peroxidase 
(HRP). The amount of HRP in the solid phase was quantitated by using tetramethylbenzidine 
in dimethylsulfoxide as the substrate.  
The assay standard range was 1-3000 nmol bone collagen equivalents (BCE)/l, and the kit 
included 6 standards. Sample (25 µl) was incubated for 90 minutes at room temperature. 
After washing the wells the amount of label in the solid phase was determined with a color 
reaction and the color intensity was measured at 630 nm and using a reference wavelength of 
430 nm using a plate reader. The pipeting of the sample and the liquid reagent was done 
either manually or by using an automated pipeting device (Tecan). MultiCalc program was 
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used for curve fitting and calculation of the results, which were proportioned to creatinine 
excretion, measured with a kinetic Jaffe method. 
4.2.5.2 NTX automated chemiluminescent immunoassay 
The assay was an automated assay on Vitros ECi immunoanalyzer (Ortho Clinical 
Diagnostics, USA). The analyzer used an individual streptavidin coated well as the solid 
phase, and HRP as the label. The amount of label enzyme in the solid phase was detected by 
using a chemiluminescent substrate. The automated NTX assay utilizes the same monoclonal 
antibody as in the manual assay, but the competing antigen is a synthetic cross-linked 
telopeptide. The antibody is labeled with HRP, and the competing antigen with biotin. For 
each reagent lot a standard curve made by the manufacturer was read to the analyzer from a 
magnetic card. The standard curve place was fitted for each analyzer by assaying two 
calibrators at weekly intervals. The overall incubation time of the assay was 30 minutes, and 
the analyzer was a random access analyzer. The samples were assayed as single 
determinations, and the results were proportioned to creatinine excretion, measured with a 
kinetic Jaffe method. 
4.2.6 Other bone marker measurements 
Osteocalcin (OC) was measured with a competitive radioimmunoassay (RIA) from Nichols 
Institute, San Juan Capistrano, USA. The method utilized a polyclonal antibody against 
human OC, and the competing antigen was human OC labeled with 125-iodine. The 
immunocomplex was precipitated with a second antibody conjugated to cellulose particles. 
The assay standard range was 0-50 µg/l, the assay sensitivity was 0.3 µg/l, and the intra- and 
interassay coefficients of variation (CV) were 4.5-6.2% and 4.1-8.9%. The antibody 
recognized mainly the intact OC and the N-Mid-fragment (1-43), but with a lesser avidity 
also smaller fragments of OC. 
Bone-specific alkaline phosphatase (Bone ALP) was measured with lectin-precipitation 
method using a kit from Boehringer-Mannheim, Mannheim, Germany.220 In this method bone 
isoform of ALP was precipitated with lectin, and the activity of Bone ALP was calculated 
from the total and residual activity of the supernatant using a formula, which takes into 
account the fact that not all Bone ALP is precipitated. The activities were measured according 
to the Scandinavian recommendation on a clinical chemistry analyzer (para-nitrophenyl 
phosphate as the substrate, pH 10.1, reaction temperature 37 oC).313 The intra- and interassay 
coefficients of variation were 4% and 5%, respectively. 
Urinary hydroxyproline (HOP) was determined by the method of Prockop and Udenfriend.5
Tartrate resistant acid phospatase isoform 5b (TRACP 5b) was measured with BONE 
TRAP™ kit from Suomen Bioanalytiikka Oy, Oulu, Finland. This method was a novel 
immuno extraction method, where both TRACP 5b and 5a were first extracted to the assay 
solid phase with a monoclonal TRACP specific antibody. After that the enzyme activity in the 
solid phase was measured in conditions (pH 6.1), where 5b isoform was fully active and 
isoform 5a almost completely inactive. The intra- and interassay coefficients of variation 
were <6%. 
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4.2.7 Other laboratory methods 
Vitamin D metabolites 25-OH-D and 1,25-(OH)2-D in study III were extracted with 
acetonitrile, and the metabolites were purified using SepPak C18 cartridges and acetonitrile as 
the eluant. The metabolites were separated in SepPak Silica cartridges with hexane-
isopropanol elution. Both metabolites were quantitated using saturation analysis with reagents 
from Amersham International plc, Amersham, UK. The intra- and interassay imprecision for 
25-OH-D were < 12% (CV), and for 1,25-(OH)2-D <15% (CV). 
25-OH-D in study VI was measured by a competitive radioimmunoassay (RIA) after 
acetonitrile extraction of the sample using reagents from DiaSorin, Stillwater, MN, US. The 
assay sensitivity was 5 nmol/l, and the intra- and interassay precision as CVs was 5.9 – 8.9% 
and 6.0 – 9.0%, respectively.
Intact parathyroid hormone PTH in studies III and VI was measured by an 
immunoradiometric method (IRMA) with reagents from Nichols Institute, San Juan 
Capistrano, US. The method uses two affinity-purified polyclonal antibodies against two 
different epitopes of iPTH. The analytical sensitivity was 1 ng/l, and the intra- and interassay 
CVs were <6% and <8%, respectively. 
Serum and urinary calcium Ca (studies III, IV, V, VI) were measured with a colorimetric 
method (ortho-cresolftalein complex) on a clinical chemistry analyzer. The intra- and 
interassay CVs were <4%. Serum calcium was corrected for albumin concentration using the 
equation: S-Cacor = S-Catot – 0.2 x (S-Alb g/l – 40). Albumin was measured with a 
colorimetric method (bromcresolgreen). 
Total activity of alkaline phosphatase ALP (studies III, V) was measured according to the 
Scandinavian recommendation using para-nitrophenyl phosphate in diethylamine buffer, pH 
10.1, as substrate and a reaction temperature of 37 oC. The intra- and interassay CVs were 
<5%.
Serum magnesium Mg and inorganic phosphate Pi (study III) were measured by routine 
methods on a clinical chemistry analyzer; the CVs of the assays were <5%. 
Serum and urinary creatinine (study III) were measured by a kinetic Jaffe method on a 
clinical chemistry analyzer. The CVs of the assay were <4%. 
Serum free thyroid hormones FT4 and FT3 in study III were measured by 
radioimmunoassays after equilibrium dialysis.314
Serum thyrotropin TSH in study III was measured by a second generation 
immunoradiometric method (IRMA) with analytical sensitivity of 0.05 mU/l using reagents 
from Behringswerke, Marburg, Germany. 
Serum estradiol E2 in study VI was measured by a direct radioimmunoassay (RIA) with 
reagents from Sorin Biomedica Diagnostics, Italy. The analytical sensitivity of the assay was 
0.04 nmol/l, and the intra- and interassay CVs ranged from 3 to 12%. 
4.2.8 BMD measurements 
In study VI BMD was measured with Hologic densitometer (Hologic QDR-1000, Waltham, 
MA). In study VIII three different brands of bone densitometers were used; Lunar (Lunar 
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DPX, Madison, WI), Hologic and Norland (Norland XR 26, Medical System Inc., Fort 
Atkins, WI). 
4.2.9 Assessment of assay performance 
The method performance was tested by assessing its analytical sensitivity, intra- and 
interassay precisions (repeatability, reproducibility), accuracy and linearity: 
? The analytical sensitivity was calculated from the response of at least ten zero standard 
measurements. The analytical sensitivity of a competitive assay was the concentration 
corresponding the mean response minus three standard deviations of the measurements. 
? The functional sensitivity of the automated NTX assay was assessed during 3 months by 
serial analyses of a pooled sample with concentration close to the analytical sensitivity of 
the assay. 
? The intra-assay imprecision was calculated by assaying pooled samples with varying 
concentrations as ten replicates in one run. PINP assay precision was also tested by using 
a sample volume of 10 µl instead of 50 µl (1 to 5 dilution). The 40 µls were not 
compensated for. 
? The inter-assay imprecision was calculated from the values of control samples or pooled 
samples measured in several runs (8 – 10) using one reagent lot and several lots. 
? The accuracy was tested by adding known amounts of the marker to samples of varying 
marker concentrations; the accuracy was expressed as spiking recovery. Also deviations 
of target values of commercial controls were used for assessing accuracy. 
? The linearity was assessed from serial dilutions of samples with marker concentrations 
that fell within the standard curve range of the assay, and was expressed as dilution 
recovery.
? The dilution point for the samples was determined for each assay based on the linearity 
and accuracy of the assay. The patient samples exceeding this concentration were diluted 
with physiological saline. 
? Correlations of the two formation markers and several resorption marker assays were 
established; also correlation between S-PINP and U-NTX was assessed. 
4.2.10 Assessment of factors effecting results 
A number of samples were stored at room temperature up to 4 days, at +5 +3 oC up to one 
week, and at –20 oC for longer periods to test the effect of different ways of storing the 
sample on the results. The effect of 3-5 freeze-thaw cycles on the results was also tested. 
Adding grossly hemolyzed serum to unhemolyzed sera from five healthy volunteers tested the 
effect of hemolysis on the results. The marker concentrations were measured for the 
unhemolyzed samples and samples with increasing degree of hemolysis (0.25 – 5.0 g Hb/l). 
Diurnal variation of several markers was assessed in postmenopausal healthy women to 
assess the effect of timing the sample. 
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The short-term intra individual variation (CVi) of U-NTX and U-DPD was established in five 
premenopausal women from samples taken four times during one month. The long-term intra 
individual variation of S-PINP, U-NTX and S-TRACP 5b was calculated from the samples of 
the placebo group subjects in study VIII. The samples were taken at baseline, 3 months, 12 
months and 24 months. The CVis were used to calculate the least significant changes (LSC) 
of the markers with 95% confidence intervals. The LSC takes into account the CVi and the 
inter assay precision of the method, and it was calculated using the formula LSC = 1.96 x 
sqr(2 x ΣCVi2/n). Changes larger than the LSC are considered clinically significant. 
4.3 Samples
Blood for serum marker measurements was drawn in the morning between the hours 7:30 and 
9:30. In the study VII samples were drawn every two hours for 24 hours. Venous blood was 
collected either into normal vacum tubes or into gel tubes, the blood was allowed to clot for 
30 to 90 minutes, serum was separated by centrifugation for 10 minutes at 1500 x g, aliquoted 
and stored at -20 oC or -70 oC until analysis.  
Two hour morning urine after voiding the first urine was used for urinary marker 
measurements in adults. In the study VII 4-hour samples were used for establishing diurnal 
variation of the markers. In children the first morning urine was used. The difference of the 
results between these two types of urinary samples was tested with samples of 5 healthy 
premenopausal females, the difference being non-significant. The samples were aliquoted and 
stored at –20 oC until analysis. As pyridinoline crosslinks  in urine are known to degrade in 
ultraviolet light, exposure to UV-light was avoided by using colored tubes. 
Commercially available control samples were used when possible, and if necessary, pooled 
and aliquoted patient samples were used to control the precision of the assays. 
4.4 Statistics
StatView program (studies I, IV, partly VI), SAS System (studies VII, VIII), and SigmaStat 
for Windows (study II, III, V, VI) were used for statistics.  
StatView program was used when factors affecting the results - sample storage, freezing-
thawing, and hemolysis - were tested; the comparisons were made using paired t-test and the 
correlations were calculated either as linear regression or using Spearman’s rank correlation 
test.
In study I and II correlations were calculated using Spearman’s rank correlation test. Marker 
values in different groups were expressed as means or medians, standard deviations (SD) and 
ranges. Comparisons were made by using Mann-Whitney test (between groups), Wilcoxon 
signed rank test (within group), or Student’s two-sided two-group t-test (between groups) and 
paired t-test (within group) where the distribution was normal. In study II the marker values 
were also expressed as standard deviation scores (SDS), calculated from the distribution of 
values in healthy children. 
In study III data with normal distribution was presented as means + SD, medians with ranges 
were used for skewed distributions. Comparisons were made by Student’s two-sided two-
group t-test (between groups) and paired t-test (within group) when data was normally 
distributed, otherwise Mann-Whitney rank sum test and Wilcoxon signed rank test were used. 
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In study IV nonparametric tests were used for comparisons and correlations (Mann-Whitney, 
Spearman). The marker data were presented as medians and ranges. 
In study V both linear and nonlinear regressions were used. Student’s t-test or Mann-Whitney 
rank sum test was used for comparisons. Receiver operator characteristics curves (ROC) were 
used to assess the accuracy of the markers and their ratio in discriminating between stable and 
progressive disease. 
In study VI linear regression with StatView program was used to establish the correlation of 
the markers in different groups according to postmenopausal status and smoking habits. In the 
comparisons between the study groups, normally distributed variables were studied using 
one-way ANOVA or two group t-tests, and those non-normally distributed were tested with 
Kruskal-Wallis one-way ANOVA or the Mann-Whitney rank sum test, as appropriate. Paired 
data were compared using paired t-test (normally distributed data) or Wilcoxon signed-rank 
test (nonnormal data). 
In study VII areas under curve (AUC) for the 24-hour study periods were calculated for each 
parameter, and the AUCs were compared with paired t-test or Wilcoxon matched-pair test. 
The repeated measures analysis of variance was used to study the difference of diurnal 
variation between the study days; the analysis included time-effect. Day and measurements 
done within the day were included as factors in the analyses. Huynh-Feldt adjusted p-values 
were used for within factors, and the tests were performed two-sided. 
In study VIII the markers were analyzed with analysis of variance for repeated measures with 
mixed modeling, including treatment group, time-point and their interaction as factors in the 
model. The percentage changes from baseline were assessed with one-way analysis of 
variance. Pearson correlation coefficients were calculated to measure the strength of the linear 
relationship between different marker changes and also between the marker and BMD 
changes.
In all studies a p-value of equal to or less than 0.05 was considered significant. 
5 Results
5.1 Performance of the assays 
5.1.1 Performance characteristics 
The performance characteristics of each assay are tabulated in Table 6. The control samples 
were chosen to cover the concentration range of the standard curve, the concentration of the 
lowest control being close to the concentration of the lowest standard containing the analyte, 
and the concentration of the highest control being slightly higher than the second highest 
standard. In each assay 3 or 4 control samples were analyzed, and at least one of them was 
always analyzed twice, before and after the patient samples. In the automated assay for U-
DPD two of the three available control samples were run before the patient samples and one 
after them. In the automated NTX assay the three control samples from the manufacturer 
were analyzed once daily. In addition a pooled sample with concentration close to the 
analytical sensitivity of the assay was analyzed daily. 
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Table 6: Performance characteristics of the assays. 
Assay imprecision as coefficients 
of variation, % Accuracy Linearity 
 Interassay CV Method 
Unit of 
the
marker
Analytical 
sensitivity 
Intra-
assay CV 
Within 
one lot 
Between 
several lots 
Value from 
target, % 
Spiking
recovery, 
%
Dilution
recovery, 
%
Intact PINP 
RIA µg/l 2.3 2.4 –3.5* 2.5 - 5.2 2.7 – 6.7 96 – 105 96 – 100 79 – 103 
PICP RIA µg/l 1.2 2.1 – 3.7 3.5 – 6.6 2.8 – 6.9 96 – 103 ND 85 - 101 
ICTP RIA µg/l 0.4 3.8 – 7.3 4.7 – 6.9 2.5 – 8.0 98 - 100 ND 86 - 105 
Pyr ELISA nmol/l 25 2.7 – 7.0 5.7 – 8.5 ND 101- 110 ND 98 - 112 
DPD ELISA nmol/l 3 1.4 – 5.3 2.8 – 6.2 7.3 – 14.2 97 - 108 ND 96 - 106 
DPD CIA nmol/l 5 0.5-3.0 3.3 - 6.0 0.9 – 8.5 97 - 103 96 - 111 84 - 100 
NTX ELISA nmol/l 30 3.0 – 7.0 4.5 – 6.8 6.1 – 10.5 99 - 107 90 - 102 91 - 105 
NTX CIA nmol/l 5** 2.0 – 8.0 5.1 – 9.8 4.8 – 10.8 107 - 110 94 -108 85 - 113 
ND = not done 
*The intra-assay CV in intact PINP assay when 10 µl of sample was used was 3.8 %.  
**The functional sensitivity of NTX CIA was 8 nmol/l. 
An extra standard was used in the serum assays, all of them conventional competitive radio 
immunoassays, in order to improve the precision in the low response area of the standard 
curves (high concentrations). This standard was prepared from the highest and second highest 
standard provided by the manufacturer, and its concentration in intact PINP assay was 175 
µg/l, in PICP assay 350 µg/l, and in ICTP assay 37.5 µg/l. This standard enabled the dilution 
point of the samples to be extended in these assays. In addition, the standard curve was 
slightly modified in PINP assay; standards 0, 5, 17.5, 50, 100, 175, 250 µg/l were used. In 
intact PINP assay samples with concentrations higher than 200 µg/l were diluted, in PICP 
assay the dilution point was 400 µg/l, and in ICTP assay it was 38 µg/l.
In the urinary resorption marker assays the dilution points were following: U-Pyr 2000 
nmol/l, U-DPD ELISA 220 nmol/l, U-DPD CIA 300 nmol/l, U-NTX ELISA 2000 nmol 
BCE/l, and U-NTX CIA 2500 nmol BCE/l 
The use of 10 µl of the sample for intact PINP assay without adding the 40 µl of diluent to the 
reaction mixture did not have an effect on the results as tested with Student's t-test for 5 adult 
samples (p=0.80). This decreased the needed sample volume for childrens’ samples, and also 
the dilution step of the samples was omitted. 
5.1.2 Correlation of the assays 
The correlation of the two propeptide assays was good. When the correlation was assessed 
with samples of concentration range from 10 to 1400 µg/l for S-PINP and from 50 to 1300 
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µg/l for S-PICP, the Spearman rank correlation coefficient r was 0.82 (p<0.0001), and the 
linear regression equation was y(S-PINP) = 1.63(S-PICP) – 137 for the whole population (n = 
253). When the correlation was studied in different age groups, it was better in young adults 
and children (females under 20 years, males under 25 years) than in adults. In the original 
publication I the correlation was studied by gender in different age groups, in figure A 
(adults) and B (females <20 years, males < 25 years) the correlation is shown in the two age 
groups with the genders combined.  
A    B
Figure 8: Correlation of S-PINP and S-PICP assays in adults (females >20 years, males > 25 years) in A 
and in young adults and children in B. 
Table 7 summarizes the correlations of different resorption marker assays; correlation 
coefficient, and the slope and intercept of the linear regression equation are shown. Samples 
from studies I, II, VI and VII as well as of healthy controls from other studies were used to 
assess the correlations. 
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Table 7: Correlation of type I collagen-derived resorption markers and different methods for U-DPD and 
U-NTX. 
x y n r p Slope Intercept 
ICTP RIA DPD ELISA 74 0.954 <0.0001 1.22 1.35 
ICTP RIA NTX ELISA 74 0.957 <0.0001 50.7 -88.7 
Pyr ELISA DPD ELISA 74 0.980 <0.0001 0.16 -0.52 
DPD ELISA NTX ELISA 152* 0.975 <0.0001 35.0 -107 
DPD ELISA NTX ELISA 93** 0.769 <0.0001 10.0 1.30 
DPD ELISA DPD CIA 161** 0.965 <0.0001 1.11 -1.13 
NTX ELISA NTX CIA 176** 0.992 <0.0001 1.13 20.0 
* childrens’ samples included, ** childrens’ samples excluded 
Although the correlation between the methods for the same analyte was good, individual 
values could be quite different when different methods were used. The mean ratio of DPD 
CIA value to DPD ELISA value was 1.056, SEM 0.023, and the mean ratio of NTX CIA 
value to NTX ELISA value was 1.167, SEM 0.017, indicating that both automated methods 
yielded somewhat higher results than the ELISA methods. 
5.2 Factors effecting the assay results 
5.2.1 Effect of hemolysis 
Hemolysis did not have any effect on the results obtained in PICP and ICTP assays. In PINP 
assay strong hemolysis, 2.5 and 5 gHb/l, lowered the measured PINP concentration by 12% 
and 20%, shown in Figure 9. The effect was significant as assessed by t-test, p=0.01 for both. 
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Figure 9: Effect of hemolysis on S-PINP values. 
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5.2.2 Effect of sample storage 
All type I collagen-derived markers showed good stability both in serum and in urine. 
Samples for serum markers PICP, PINP and ICTP could be kept in room temperature for four 
days, in +5 +3 oC for one week and in –20 +3 oC for years. Three freeze-thaw cycles did not 
have any effect on the results. Urinary markers showed similar stability, but the room 
temperature, which was not tested. Ultraviolet light degrades pyridinoline ring structure, seen 
as decreased U-Pyr and U-DPD values if kept in daylight. On the contrary, the peptide bound 
marker U-NTX increased if kept in daylight. Therefore the urinary samples were stored in 
colored tubes. 
5.2.3 Timing of the sample 
The timing of the sample was deducted from the diurnal variation of the markers, assessed 
from samples of nine healthy postmenopausal volunteers. For S-PINP samples of two 
volunteers were excluded due to several grossly hemolyzed samples. Figure 10 A shows the 
diurnal variation of serum formation markers PINP and PICP and the resorption marker ICTP 
as percentages from the lowest value, and the diurnal variation of urinary excretion of Pyr and 
NTX is similarly displayed in Figure 10 B. 
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Figure 10: Diurnal variation of serum (A) and urinary (B) type I collagen-derived markers; the values at 
each time point are expressed as percentage from the lowest value. 
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Type I procollagen propeptides showed their peak values at midnight, approximately 20% 
higher than the lowest values at 10 am. The serum resorption marker ICTP was at its highest 
in early morning hours, and fairly stable in the afternoon. The urinary excretion of Pyr and 
NTX were at their highest in samples collected from 4 to 8 and 8 to 12, the highest excretion 
being 40 – 50 % higher than the excretion in the afternoon. 
The reference ranges of the serum markers were established in samples taken in the morning 
between the hours 7:30 and 9:30. Urinary markers were assessed from second voided 
morning samples in adults and first morning samples in children. 
5.2.4 The least significant change of the markers 
The short-term (one month) intra individual variation (CVi) of urinary resorption markers 
NTX and DPD in five healthy premenopausal volunteers varied from 6% to 11%. Depending 
on the method and its precision, the LSC for DPD varied from 28% to 49% and for NTX 
from 34% to 46%. 
Long-term (2 years) intra individual variation was calculated from the samples of the placebo 
group patients in study VIII for S-PINP, U-NTX (ELISA method) and S-TRACP 5b. The 
calculated LSCs were 32% for S-PINP, 55% for U-NTX and 27% for S-TRACP 5b. 
5.3 Type I collagen markers in healthy subjects, study I 
5.3.1 S-PINP and S-PICP 
The marker values were very high in young children up to 1 year of age; they declined 
somewhat during the following years, and then increased again during the pubertal growth 
spurt. After the puberty the marker values declined eventually to the adult levels, in girls 
somewhat earlier than in boys. In females the adult marker levels were reached between the 
ages 18 to 22, in males between the ages 22 to 27. Table 8 displays the marker values in 
groups according to age and gender.  
The ratio of PICP-to-PINP mass concentrations should be approximately 3, as the propeptides 
are liberated into the circulation in equimolar concentration. This was the case in adults, but 
in children and adolescents the ratio was lowered. In Table 8 the PICP-to-PINP ratio is shown 
by age gender, Figure 11 shows the ratio in the whole population. 
Table 8: Type I procollagen propeptides and their ratio in healthy population according to age group and 
gender. 
S-PICP, µg/l S-PINP, µg/l PICP/PINP ratio 
Gender Age group n 
Median Range Median Range Median Range 
< 20 yr 37 260 93 – 480 405 52.2 – 820 0.80 0.44 – 2.36 
20-50 yr 93 110 60 – 239 37.1 18.5 – 80.6 3.32 1.53 – 4.83 female 
> 50 yr 28 125 66 – 187 43.8 23.5 – 89.8 2.81 1.38 – 4.46 
< 25 yr 30 317 117 – 1380 589 35.5 - 1404 0.64 0.38 – 3.30 
male
> 25 yr 65 130 64 - 253 47.4 21.8 – 89.0 2.94 1.64 – 4.94 
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In the groups of young adults and children, a significant negative correlation between S-PINP 
and age (r = -0.70, p < 0.001 for females, r = -0.52, p = 0.004 for males), and a significant 
positive correlation between the PICP-to-PINP ratio and age (r = 0.83, p <0.001 for females, r 
= 0.51, p = 0.005 for males) was found. 
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Figure 11: The ratio of PICP-to-PINP in healthy population as the function of age. 
Based on the results on healthy subjects, the reference interval for premenopausal women 
above the age of 20 years was set from 15 to 80 µg/l for S-PINP and from 50 to 170 µg/l for 
S-PICP. The reference intervals for adult men above the age of 25 years were from 20 to 100 
µg/l for S-PINP and from 50 to 230 µg/l for S-PICP. 
5.3.2 Type I collagen-derived resorption markers 
Type I collagen resorption marker values were also established using a part of the same 
healthy population as was used for formation markers. Table 9 shows the values of the 
urinary excretion of Pyr, DPD and NTX values by age and gender. For DPD and NTX the 
values obtained with the original ELISAs are shown. Total pyridinolines was the first urinary 
resorption marker assay evaluated, and the number of female subjects under the age of 20 and 
over the age of 50 was so small that the values are not shown in the Table 9. 
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Table 9: Urinary resorption markers in healthy subjects. 
U-Pyr, nmol/mmol Crea U-DPD, nmol/mmol Crea
U-NTX, nmol/mmol 
CreaGender Age group n 
Median Range Median Range Median Range 
< 20 yr 44   21.1 5.8 – 112 490 53 - 3410 
20-50 yr 40 34 17 – 49 5.2 2.6 – 9.3 34 14 – 122 female 
> 50 yr 16   5.8 3.9 – 11.1 43 17 - 86 
< 25 yr 25 101 26 - 181 18.6 2.4 – 81.1 643 32 – 3472 
male
> 25 yr 20 23 17 – 35 3.0 2.3 – 4.9 38 17 - 89 
The ratio of NTX value to DPD value (peptide-bound to free cross-links) varied with age, the 
relative proportion of excreted peptide-bound crosslinks being higher in children than in 
adults, shown in Figure 12. A significant negative correlation was also found between the 
NTX-to-DPD ratio and age in females < 20 years of age (r = -0.74, p<0.001), and in males < 
25 years of age (r = -0.60, p < 0.001). After menopause a positive correlation between the 
ratio and age was found (r = 0.40, p<0.001). 
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Figure 12: The dependence of the ratio of NTX-to-DPD (peptide bound to free crosslinks) on age. 
Table 10 displays S-ICTP values in healthy population. Also S-ICTP was high in children, 
but no difference was found in the values of adult females and males. The reference ranges 
for various resorption markers in adults are shown in Table 11. 
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Table 10: S-ICTP in healthy population. 
S-ICTP, µg/l 
Gender Age group n 
Median Range 
< 20 yr 22 14.6 4.0 – 24.5 
20-50 yr 77 2.6 1.6 – 4.9 female 
> 50 yr 22 3.1 2.0 – 4.5 
< 25 yr 18 12.5 2.9 – 20.0 
male
> 25 yr 46 2.8 1.1 – 4.6 
Table 11: Adult reference ranges of type I collagen-derived resorption markers 
 Premenopausal women > 20 years Men > 25 years 
S-ICTP, µg/l 1.5 – 4.5 1.5 – 4.5 
U-Pyr, nmol/mmol Cr 15 – 50 15 – 45 
U-DPD, nmol/mmol Cr* 1.0 – 8.0 2.0 – 9.0 
U-NTX, nmol/mmol Cr, ELISA 5 – 65 5 – 85 
U-NTX, nmol/mmol Cr, CIA 15 – 80 20 – 100 
* A correction factor was used in the automated DPD assay to have the same the reference range in both DPD assays 
5.4 Type I collagen markers during inhaled corticosteroid treatment in 
children with asthma, study II 
In children with newly diagnosed asthma (n=14, age 7-11 years), the type I collagen-derived 
markers of bone formation and degradation did not deviate from marker values in age and 
gender matched control children before the treatment with inhaled budesonide was started. 
Serum osteocalcin was, however, significantly lower in asthmatic children than in controls 
(p<0.001, -3.4 SDs from the control mean). All the markers of bone formation decreased 
significantly after one-month treatment with high-dose budesonide (800 µg m-2 day-1), and 
similar significant decrements were seen in all markers of bone resorption but U-NTX. After 
5-month treatment with lower dose of budesonide (400 µg m-2 day-1) all markers of bone 
turnover were lower than at baseline. However, only U-NTX significantly changed from 1-
month time point. After half-a-year treatment with nedocromil all the type I collagen-derived 
markers significantly increased from the values after inhaled corticosteroid treatment, 
reaching the baseline values at 12 months. S-OC also increased during the treatment with 
nedocromil, and reached above baseline values at 12 months. 
Marker values of patients and controls at baseline as medians and ranges are displayed in 
Table 12, and marker values of the patients before and after the treatments are displayed in 
Table 13. Figure 13 A shows the changes in formation markers as standard deviation scores 
(SDS), and Figure 13 B shows similarly the changes in resorption markers. 
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Table 12: Marker values in control children and in children with newly diagnosed asthma. 
Controls, n = 21 Patients, n = 14 
Marker 
Median Range Median Range 
S-PICP, µg/l 320 190 – 460 320 240 – 570 
S-PINP, µg/l 522 392 – 798 483 343 – 963 
S-OC, µg/l 31.0 22.0 – 55.0 11.5*** 4.7 – 33.5 
S-ICTP, µg/l 14.9 10.1 – 21.2 14.6 11.4 – 21.4 
U-Pyr, nmol/mmol Crea 128 93 – 181 150 96 -216 
U-DPD, nmol/mmol Crea 18.4 12.1 – 31.8 18.4 13.6 – 24.4 
U-NTX, nmol/mmol Crea 659 353 – 894 532 85.9 – 894 
*** significantly lower than in controls, p < 0.001 
Table 13: Marker values in asthmatic children before treatment, after treatment with high-dose 
budesonide (1 month), low-dose budesonide (1 to 6 months), and nedocromil (6 to 12 months). 
Baseline 1 month, n= 14 6 months, n = 14 12 months, n = 12 
Marker 
Median Range Median Range Median Range Median Range 
S-PICP, µg/l 320 240 – 570 250*** 180 – 300 270** 190 – 420 290 190 – 510 
S-PINP, µg/l 483 343 – 963 350** 210 – 557 322** 207 – 567 462## 315 – 753 
S-OC, µg/l 11.5 4.7 – 33.5 9.0* 1.8 – 42.2 7.0** 2.3 – 11.4 21**## 10.1 – 38.5 
S-ICTP, µg/l 14.6 11.4 – 21.4 10.2** 5.5 – 15.4 10.4** 6.6 – 14.8 15.1## 8.2 – 20.0 
U-Pyr, nmol/mmol Cr 150 96 -216 111** 67 – 169 106** 60 – 161 132# 82 – 172 
U-DPD, nmol/mmol Cr 18.4 13.6 – 24.4 14.2* 7.7 – 20.0 14.3* 7.8 – 19.4 19.3## 12-0 – 30.1 
U-NTX, nmol/mmol Cr 532 86 – 894 473 69 – 1056 366** 74 – 756 578# 209 – 783 
* p < 0.05, ** p < 0.01, *** p < 0.001 as compared to baseline, # p < 0.05, ##  p < 0.01 as compared to 6 months 
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A    B 
Figure 13: Markers of bone formation (A) and resorption (B) in asthmatic children before and after 
treatment, expressed as standard deviation scores from the values of healthy control children. The 
children were treated with budesonide up to six months and with nedocromil from 6 months to 1 year. 
The changes in S-PINP and S-PICP during both treatments (budesonide, nedocromil) 
correlated positively (r = 0.73 and 0.70, p <0.01 and < 0.05) as did S-PINP changes with 
changes in S-ICTP (r = 0.63 and 0.68, p < 0.05). In addition, S-PICP correlated positively 
with S-ICTP during the treatment with budesonide (r = 0.66, p < 0.05). Positive correlation 
was also found between changes in U-Pyr and U-DPD during both treatments (r = 0.70 and 
0.83, p < 0.05 and < 0.01). Other significant correlations were not found between the marker 
changes. 
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5.5 Thyroid hormone effects on the type I collagen markers, study III 
The patients (n = 29) and their age and gender matched controls (n = 38) were well balanced 
as to the baseline characteristics age, weight, height and BMI. Thyroid hormones free 
thyroxine (FT4) and free tri-iodothyronine (FT3) concentrations were higher and thyroid 
stimulating hormone (TSH) activity lower in patients than in controls, as could be expected. 
Patients and controls were also well balanced as to the markers reflecting bone and calcium 
metabolism, except for urinary excretion of phosphate (Pi) and magnesium (Mg) which were 
higher in patients (Table 14). Also creatinine excretion was higher in patients. 
Table 14: Markers reflecting bone and calcium metabolism in patients and controls; mean + SD or 
median with ranges are shown. 
Marker, unit Patients Controls 
S-Ca_cor, mmol/l 2.45 + 0.10 2.46 + 0.08 
S-Pi, mmol/l 1.05 + 0.17 1.08 + 0.13 
S-Mg, mmol/l 0.87 + 0.08 0.90 + 0.07 
S-25-OH-D, nmol/l 64 + 22 62 + 21 
S-1,25(OH)2-D, pmol/l 106 (55 – 218) 111 (72 – 204) 
S-PTHi, ng/l 39 (16 –77) 30 (13 –56) 
U-Ca, mmol/24 h 3.6 + 1.7 3.4 + 1.8 
U-Pi, mmol/24 h 32 + 10* 26 + 8 
U-Mg, mmol/24 h 5.0 + 1.8* 3.9 + 1.4 
* p < 0.05 for the difference between patients and controls 
Markers of bone turnover during LT4 treatment 
In the total population markers of bone formation, total ALP, OC, PICP and PINP were 
significantly higher in patients than in controls, total ALP being 21% higher, p < 0.05, OC 
35% higher, p < 0.001, PICP 10% higher, p < 0.05, and PINP 46% higher, p < 0.001. Bone 
ALP was also higher in patients than in controls, but the difference was not significant 
(Figure 14 A). Markers of bone resorption were also significantly higher in patients than 
controls, ICTP by 21%, p < 0.05, and U-HOP by 37%, p < 0.001 (Figure 14 B). Table 15 
shows the markers of bone turnover in female patients and their controls by menopausal 
status. In premenopausal patients S-OC, S-PINP and both resorption markers were 
significantly higher than in controls, whereas only S-PINP and U-HOP were higher in 
postmenopausal patients than in their controls. On the whole, markers of bone turnover 
indicated increased bone turnover in patients with prior differentiated thyroid carcinoma and 
on thyroxine treatment. 
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Figure 14: Markers of bone formation (A) and resorption (B) in patients and controls; medians and 
interquartile ranges are shown (from the original publication with permission). 
Table 15: The markers of bone turnover in female patients and their controls by menopausal status; mean 
+ SD or median with range are shown. 
Premenopausal Postmenopausal 
Marker, unit 
Patients (n = 15) Controls (n = 22) Patients (n = 10) Controls (n = 13) 
S-Bone ALP, U/l 56 + 36 46 + 23 81 + 18 74 + 28 
S-OC, µg/l 7.7 + 3.3* 4.6 + 3.0 8.8 + 3.7 8.5 + 4.3 
S-PICP, µg/l 159 (27 – 236) 103 (66 – 164) 127 + 37 115 + 35 
S-PINP, µg/l 56 (13 – 105)* 34 (22 – 52) 62 + 16* 44 + 16 
S-ICTP, µg/l 3.6 + 0.9* 2.8 + 0.8 3.5 + 1.2 3.1 + 0.7 
U-HOP, µmol/24 h/m2 0.088 (0.049-0.137)* 0.062 (0.042-0.101) 0.089 + 0.028* 0.067 + 0.017 
*p < 0.05 for the difference between patients and controls 
Bone mineral density at each measured site did not differ between patients and controls. 
Markers of bone turnover after 5 weeks of iatrogenic hypothyroidism 
In 14 patients the treatment with LT4 was stopped for 5 weeks, and the markers of bone 
turnover were measured after this period of hypothyroidism. The withdrawal of LT4 caused a 
significant decrease in S-OC (54%, p < 0.001), S-PINP (7%, p < 0.05) and S-ICTP (54%, p < 
0.001), whereas S-PICP increased by 24% (p < 0.001) and S-1,25(OH)2-D by 29% (p < 
0.01). The changes in bone turnover markers are shown in Figure 15. 
A
B
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Figure 15: Markers of bone turnover before and after interruption of LT4 therapy for 5 weeks (from the 
original publication with permission). 
5.6 Type I collagen markers in metastatic bone disease 
5.6.1 S-ICTP, S-PICP and S-PINP as markers of metastatic bone disease in 
breast cancer, study IV 
In patients with breast cancer, metastatic to bone (BM+), serum concentrations of ICTP and 
PINP were significantly higher than in healthy controls (p < 0.0001 and p = 0.046) whereas 
S-PICP did not significantly differ in patients as compared to controls. The ratio of PICP-to-
PINP was significantly lower in BM+ breast cancer patients than in controls (p = 0.002), 
shown in Table 16. Also in patients with breast cancer but without bone metastases (BM-) S-
ICTP was significantly higher than in healthy controls (p=0.001), but the propeptides or their 
ratio did not significantly differ between BM- patients and controls. ICTP was marginally 
significantly higher in BM+ patients as compared to BM- patients (p=0.06), and the ratio of 
the propeptides was significantly lower in BM+ patients (p=0.047). PICP and PINP did not 
differ in the two groups of patients. In the BM+ patient group a significant positive 
correlation was found between ICTP and PICP, r = 0.58 and p = 0.005, and for ICTP and 
PINP, r = 0.60 and p = 0.005, and a negative correlation between ICTP and the PICP-to-PINP 
ratio, r = -0.61, p = 0.004. In patients without bone metastases no correlations were found 
between the markers. 
Neither of these markers nor the ratio of the propeptides was clinically sensitive enough to be 
used in diagnosing bone metastases, the clinical sensitivities being 56%, 24%, 30% and 52% 
for ICTP, PICP, PINP and the ratio PICP-to-PINP. Also some patients without bone 
metastases had S-ICTP and S-PINP exceeding the upper reference limit of the markers, and 
the ratio of the propeptides was lowered in some patients, and the clinical specificities were 
thus 93% for ICTP, 98% for PINP and 91% for the PICP-to-PINP ratio. 
61
Table 16: Serum concentrations of ICTP, PICP, PINP and the ratio of the propeptides in breast cancer 
patients with (BM+) and without (BM-) bone metastases and healthy controls.  
BM+ patients, n = 25 BM- patients, n = 12 Controls, n=37 Marker 
Median Range Median Range Median Range 
S-ICTP, µg/l 5.1** 2.2 – 90.6 4.0* 3.1 – 5.2 2.8 1.9 – 4.5 
S-PICP, µg/l 116 61 – 343 110 77 – 177 117 82 – 178 
S-PINP, µg/l 49* 18 – 1006 45 19 – 86 36 25 – 61 
PICP/PINP ratio 1.98* 0.31 – 3.93 2.93# 1.31 – 3.99 2.98 2.33 – 4.30 
** difference between patients and controls, p<0.0001, * difference between patients and controls, p<0.05, # difference between BM+ and 
BM-, p<0.05 
In 13 BM+ patients follow-up samples after chemotherapy or treatment with bisphosphonate 
were also available. Due to small patient number, no statistics were calculated for changes, 
but S-ICTP, S-PINP and the PICP-to-PINP ratio and to a lesser extent S-PICP changed in 
parallel with the course of the disease. 
5.6.2 PINP and PICP in aggressive breast cancer, study V 
Table 17 shows the metastatic status of the patients who were divided into two groups 
according to their clinical status, to groups with stable disease (SD) or with progressive 
disease (PD). 
Table 17: The percentage of patients with different types of metastases. 
 Bone only, % of n Visceral and soft tissue only, % of n 
Bone, visceral and 
soft tissue, % of n None, % of n 
SD group, n = 49 38 15 23 24 
PD group, n = 40 60 5 35 0 
The mean of S-PINP was 7.2 times higher in PD group patients than in SD group patients 
whereas the mean of S-PICP was only 1.7 times higher in the PD group. Also, the ratio of 
propeptides was significantly lower in patients with progressive disease, as shown in Table 
18. Figure 16 displays the box-and -whiskers plots of the propeptides and their ratio in the 
two patient groups. In the PD group 2 of the 3 patients with no bone metastases had elevated 
S-PINP, and they all had a PICP-to-PINP ratio 1.4 or lower. In the SD group one patient 
without bone metastases had a low PICP-to-PINP ratio (1.3), but her S-PINP was normal. 
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Table 18: S-PINP and S-PICP concentrations and the PICP-to-PINP ratio in breast cancer patients with 
stable or progressive disease. 
SD group PD group Difference 
Mean + SD 95% Cls p 
S-PINP, µg/l 38.1 + 2.9 276.1 + 79.1 77.9, 398.3 0.005 
S-PICP, µg/l 100.2 + 5.0 174.3 + 19.7 33.1, 115.1 0.001 
PICP/PINP ratio 3.07 + 0.18 1.02 + 0.07 1.66, 2.44 < 0.001 
Figure 16: Box plots of S-PINP, S-PICP and their ratio in breast cancer patients with stable or with 
progressive disease. O = 5 and 95 percentiles, horizontal bars = 10 and 90 percentiles, lower and upper 
limits of the boxes = 25 and 75 percentiles. The solid line inside the box marks the median and the dotted 
line the mean (from the original publication with permission). 
The receiver operator characteristic (ROC) curves, shown in Figure 17, were calculated for 
the propeptides, their ratio, and also for total alkaline phosphatase activity (ALP), which is 
routinely measured in these patients to monitor bone and liver status. The optimal sensitivity 
(0.90) and specificity (0.90) of S-PINP would be attained by using a cut-off value of 70 µg/l,
and those of PICP-to-PINP ratio (0.98 and 0.90) by using a cut-off value of 1.74. 
Figure 17: ROC curves over a range of cut-off points for S-PINP, S-PICP, PICP-to-PINP ratio and S-ALP 
(from the original publication with permission). 
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5.7 Type I collagen markers in postmenopausal osteoporosis 
5.7.1 Effect of smoking on transdermal estrogen replacement therapy in 
postmenopausal women, study VI 
At baseline the formation marker S-PINP was similar in both non-smoking and smoking 
postmenopausal women, and it did not differ from S-PINP of premenopausal women. U-NTX 
was significantly higher in postmenopausal women as compared to premenopausal women (p 
< 0.001), but it was similar in smokers and non-smokers. The correlation of the two markers 
was poorer in postmenopausal smokers as compared to postmenopausal or premenopausal 
non-smokers. 25-OH-D was 20% lower in postmenopausal smokers than in postmenopausal 
non-smokers (p = 0.05). The baseline results in smokers and non-smokers are shown in Table 
19, the correlation of S-PINP and U-NTX in different populations is shown in Table 20.
Table 19: S-PINP and U-NTX in postmenopausal smokers and non-smokers before ERT, and in 
premenopausal non-smokers, and S-25-OH-D in postmenopausal women at baseline. 
S-PINP, µg/l U-NTX, nmol/mmol Cr 25-OH-D, nmol/l 
Median Range Median Range Median Range 
Postmenopausal smokers 43.2 14.3 – 134.9 60.5* 24.4 – 171.4 36** 15 - 86 
Postmenopausal non-smokers 38.4 8.7 – 92.7 59.4* 18.0 – 178.1 52 17 - 74 
Premenopausal non-smokers 38.3 20.3 – 80.6 42.8 20.7 – 90.3 - - 
* significantly different from premenopausal non-smokers, p < 0.001, ** significantly different from non-smokers, p < 0.05 
Table 20: Correlation of S-PINP and U-NTX in postmenopausal smokers and non-smokers at baseline, 
and in premenopausal non-smokers. 
r, p Slope Intercept 
Postmenopausal smokers 0.34, <0.001 0.50 44 
Postmenopausal non-smokers 0.62, <0.001 0.92 28 
Premenopausal women 0.71, <0.001 0.95 10 
The two groups of non-smokers, those allocated to receive estrogen and those who did not 
want to start ERT, had significantly different S-PINP at baseline, being higher in control 
group (median 59 µg/l vs. 35 µg/l, p < 0.05). The marker values in different study groups are 
shown in Table 21. Other baseline characteristics, including BMD at lumbar spine and three 
femoral sites, were well balanced between the study groups, the two groups of smokers, 
randomized to receive either 1 mg or 1.5 mg of E2, and the two groups of non-smokers.  
Table 21: Marker values in the study groups at baseline. 
Smokers, 1 mg 
E2
Smokers, 1.5 mg 
E2
Non-smokers on 
E2
Non-smokers 
without E2 
S-PINP, µg/l median (range) 43 (14-135) 43 (18-85) 35 (9-93) 59 (24-119)* 
U-NTX, 
nmol/mmol Cr median (range) 58 (27-151) 67 (24-171) 59 (18-178) 74 (34-141) 
* p<0.05 as compared to other groups 
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The two doses of E2 resulted in a similar marker and BMD response in smokers, and 
therefore the groups were combined for further analyses.  
At 1-year time point the marker of bone formation, S-PINP, decreased significantly more in 
smokers on E2 (-36%) than in non-smokers on E2 (-24%, p = 0.038). Also a significant 
difference between smokers on E2 and non-smokers without treatment was seen (p < 0.0001), 
S-PINP decreasing in the latter group non-significantly (-7%). Non-smokers on E2 and 
without treatment did not significantly differ in response. At 2-year time point S-PINP did not 
further change in smokers on E2, but increased in non-smokers on E2, the difference between 
the groups being significant (p = 0.006). In non-smokers without treatment S-PINP was stable 
from 1 to 2 years. Percentage changes of S-PINP are shown in Figure 18A. 
U-NTX changed to a similar extent in smokers (-35%) and non-smokers (-33%) on E2 at 1-
year time point, whereas in non-smokers without treatment U-NTX slightly increased (+6%). 
From 1 to 2 years U-NTX increased somewhat in smokers on E2, and it further decreased in 
non-smokers on E2, leading to a marginally significant difference between the treated groups 
at 2-year time point (p = 0.07). In non-smokers without E2 U-NTX returned to baseline at 2 
years. Percentage changes of U-NTX are shown in Figure 18B. 
A    B 
     
A    B 
Figure 18: Percentage changes of S-PINP (A) and U-NTX (B) in postmenopausal smokers on E2, non-
smokers on E2 and non-smokers without ERT. 
ERT for 2 years improved the correlation of the markers in smokers, whereas the correlation 
worsened in non-smokers without ERT during the 2-year follow-up, shown in Table 22.  
Estrogen treatment did not have any effect on the vitamin D status of the smokers (data not 
shown).
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Table 22: Correlation of S-PINP and U-NTX in postmenopausal smokers and non-smokers on E2 before 
the treatment was started and during the ERT, and in postmenopausal non-smokers without ERT during 
the 2-year follow-up. 
Smokers on E2 Non-smokers on E2 Non-smokers without E2 
r slope interc. r slope interc. r slope interc. 
Baseline 0.34 0.50 44 0.63 1.35 18 0.66 0.65 28 
1 year 0.63 1.14 12 0.58 1.01 14 0.39 0.49 33 
2 years 0.64 0.87 20 0.62 0.86 13 0.17 0.21 54 
The BMD changes were similar in all treated groups, ERT causing an increase of BMD at all 
measured sites, whereas women without treatment lost bone during the 2-year follow-up. 
BMD changes at the lumbar spine and femoral neck are shown in Table 23, at the trochanter 
and Ward’s triangle the changes were similar. 
Table 23: The percentage change of BMD at the lumbar spine and femoral neck in smoking and non-
smoking postmenopausal women on ERT, and in postmenopausal women without treatment. 
Lumbar spine Femoral neck 
1 yr, % change 2 yr, % change 1 yr, % change 2 yr, % change 
Smokers on E2 2.1 3.6 1.4 2.2 
Non-smokers on E2 1.7 2.6 0.9 2.4 
Non-smokers without E2 -2.1 -2.4 -0.7 -0.2 
In the estrogen-users the changes in bone markers correlated better to changes in the lumbar 
spine BMD than to those in the femoral neck BMD. As related to the changes in the lumbar 
spine BMD, the r values for the simultaneous changes in urinary NTX were –0.44 (p<0.0001) 
at 1 year and –0.52 (p<0.0001) at 2 years, and for serum PINP –0.46 (p<0.0001) and –0.41 
(p<0.0001), respectively. As to the femoral neck BMD, the respective coefficients ranged 
from –0.20 (p=0.016) to –0.25 (p=0.003) for urinary NTX and from –0.16 (p=0.0049) to         
–0.25 (p=0.003) for serum PINP. 
Estradiol concentrations of the whole study population were measured at baseline and at 1- 
and 2-year time points. On the daily dose of 1mg estradiol serum concentrations were non-
significantly 10-20% lower in smoking vs. nonsmoking women, ranging from 0.25 nmol/l to 
0.30 nmol/l in smokers. In smokers using the daily dose of 1.5 mg estradiol the concentrations 
were 16-20% higher than in those on the lower dose, but the difference did not reach 
significance. 
5.7.2 Effect of short-term clodronate treatment on bone turnover, study VII 
As already shown in 5.2.3, all measured markers had a clear circardian variation with a 
significant time effect (p<0.0001 for all measured markers). S-ICTP had its peak value at 4 
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am, whereas the urinary excretion of the resorption markers was as their highest somewhat 
later, at early morning hours. The peak values of formation markers were reached earlier, for 
PINP at midnight and for PICP at 2 am. 
Treatment with clodronate tended to attenuate the diurnal variation of U-NTX (p=0.07 for day 
x time), but it did not have a significant effect on the diurnal variation of U-Pyr (p=0.13), S-
ICTP (p=0.65) or S-PICP (p=0.99).  
The area under curve (AUC) for each marker and for variables reflecting calcium metabolism 
before and after the treatment is shown in Table 24. The significance of the change in AUC is 
expressed as p-values. Four-week treatment with oral clodronate significantly decreased 
urinary excretion of type I collagen-derived resorption markers, pyridinolines and NTX, but it 
had no effect on serum resorption marker ICTP, nor on the formation marker PICP. 
Treatment also significantly decreased serum calcium and urinary excretion of calcium, 
whereas serum concentration of intact PTH increased. 
Table 24: AUCs for markers of bone turnover and calcium metabolism before and after 4-week treatment 
with oral clodronate. 
AUC, mean + SE 
Analyte 
Before After 
Change in AUC 
p
S-ICTP 69.4 + 6.2 72.8 + 4.2 0.41 
U-Pyr 803 + 28 765 +  25 0.016 
U-NTX 872 + 74 513 + 53 0.0002 
S-PICP 2988 + 100 2987 + 105 0.99 
S-Ca 55.9 + 0.4 55.1 + 0.3 0.030 
U-Ca 11.2 + 2.7 7.5 + 1.6 0.021 
S-PTHi 1028 + 71 1223 + 115 0.004 
The effect of clodronate on osteoclastic bone resorption not only decreased urinary excretion 
of NTX, but also attenuated its circardian variation, shown in Figure 19 A. The treatment did 
not change the circardian pattern of the other measured markers of bone turnover, although 
the AUC of Pyr significantly decreased after treatment, shown in Figure 19 B. The effect of 
clodronate on osteoclastic activity was also seen as significantly decreased serum calcium 
concentration as well as decreased urinary excretion of calcium. These changes were 
compensated for by hyperparathyroidism, seen as a significant increase in circulating intact 
PTH concentrations, shown in Figure 20. 
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A
Figure 19: Diurnal variation of urinary excretion of NTX (A) and Pyr (B) before and after treatment with 
oral clodronate; mean + SE at each completed urine collection time point is shown (from the original 
publication with permission). 
A
Figure 20: Serum intact PTH (A) and urinary calcium excretion (B) before and after 4-week treatment 
with oral clodronate in nine healthy postmenopausal women; mean + SE are shown (from the original 
publication with permission). 
5.7.3 Comparison of S-TRACP 5b with S-PINP and U-NTX as the reflector of 
the efficacy of oral clodronate treatment in postmenopausal women with 
vertebral osteopenia, study VIII 
Marker values over time and changes in markers 
At baseline of the extension study, the median value for S-TRACP 5b and S-PINP fell within 
reference ranges for premenopausal women whereas the median U-NTX was above the 
reference range. S-TRACP 5b was above the reference range for premenopausal women for 
42% (25) of the subjects, who had been on placebo for the preceding 3 years, U-NTX was 
elevated in 70% (41) of the subjects, whereas S-PINP was elevated in only 6.9% (4) of these 
subjects. All the marker values decreased significantly during the first year of clodronate, 
stabilizing thereafter. At the end of the study 8 (14%), 7 (13%) and 0 subjects had values 
exceeding the upper reference range for premenopausal women for S-TRACP 5b, U-NTX, 
and S-PINP. Marker values at baseline and after one and two years clodronate treatment 
together with the reference values for premenopausal women are shown in Table 25.  
B
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Table 25: Reference values of the markers for premenopausal women and over time marker values in 
subjects on clodronate for two years.  
Clodronate group, median (range) Reference range 
of premenopausal 
women baseline 1 year 2 years 
S-TRACP 5b U/l 2.40 – 4.00 3.77 (2.32 – 5.55) 3.06 (0.90 – 5.12) 3.06 (1.00 – 4.81) 
U-NTX/Crea 
nmol/mmol 5.0 – 65.0 74.7 (32.5 – 149.0) 31.5 (11.7 – 128.0) 36.3 (13.5 – 96.9) 
S-PINP µg/l 15.0 – 80.0 53.1 (16.7 – 91.6) 26.0 (9.8 – 75.9) 24.5 (10.7 – 75.2) 
The percentage changes in all measured markers from baseline to 1- and 2-year time-points 
were significant (p<0.0001). The mean decrease in S-TRACP 5b was 21% (95% CI -25.5 to   
-15.5) at the 1-year time-point and 18% (95% CI -23.3 to -11.7) at the 2-year time-point, the 
mean decrements in U-NTX being 51% (95% CI -60.8 to -36.5) and 47% (95% CI -65.5 to
-28.7), and in S-PINP 46% (95% CI -54.8 to -37.3) and 42% (95% CI -52.5 to -30.9) at the 
two time-points (Figure 21). 
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Figure 21: Mean percentage changes in the markers at 1- and 2-year time-points. 
BMD changes 
Clodronate treatment for two years resulted in a mean change in the lumbar spine BMD of 
+2.1% (95% confidence interval +1.1 to +3.1, p=0.0002), and a mean change in the 
trochanter BMD of +2.6% (95% confidence interval +1.3 to +3.8, p=0.0001). 
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Correlations
Between marker percentage changes 
Significant correlations existed between all the marker changes from baseline to the two other 
time points (1 and 2 years), with correlation coefficients ranging from 0.34 (p=0.009) 
between S-TRACP 5b and S-PINP at 2 years to 0.48 (p=0.0002) between TRACP 5b and U-
NTX at 2 years.
Between marker and BMD percentage changes 
The correlations between the percent changes in markers and in BMD are shown in Table 26. 
The percentage change in S-TRACP 5b from baseline to 1 year correlated with the percentage 
change in lumbar spine and trochanter BMD at the 1- and 2-year time-points. The percentage 
change in U-NTX from baseline to 1 year correlated with the percentage change in trochanter 
and lumbar spine BMD at the 2-year time-point. The percentage change in S-PINP from 
baseline to 1 year correlated with the percentage changes in lumbar spine BMD at the 1- and 
2-year time-points, and also with the percentage changes in trochanter BMD at the 2-year 
time-point. 
Table 26: Correlation between marker percentage changes 1 year after start of the treatment with 
clodronate and percentage changes in BMD at measured sites at 1 and 2 years. Correlation coefficient (r) 
and significance (p) are presented where the correlation was significant or marginally significant. 
BMD % change at lumbar 
spine
BMD % change at 
femoral neck 
BMD % change at 
trochanter 
1 year 2 years 1 year 2 years 1 year 2 years 
S-TRACP 5b -0.35, 0.0066 -0.36, 0.0068 NS NS -0.37, 0.0041 -0.45, 0.0006
U-NTX NS -0.33, 0.014 NS NS -0.23, 0.087 -0.37, 0.0058% change at 1 year 
S-PINP -0.28, 0.037 -0.39, 0.0032 NS NS NS -0.36, 0.0081
NS = non-significant. 
Responders
The calculated least significant changes for the markers were 26.6% for S-TRACP 5b, 55.1% 
for U-NTX, and 32.4% for S-PINP. 
The S-TRACP 5b change showed 39.7% of the subjects (23/58) at the 1-year time-point and 
34.4% of them (20/58) at the 2-year time-point to be responders. The respective percentages 
for U-NTX were 55.2 (32/58) at 1 year and 40.0 (22/55) at 2 years. In terms of the S-PINP 
change, the majority of the subjects were responders, 72.4% (42/58) at the 1-year time-point, 
and 79.3% (46/58) at the 2-year time-point. The mean percentage change of the whole study 
group exceeded the LSC only for S-PINP. The percentage of responders to clodronate 
treatment at the two time points by each marker is shown in Figure 22. 
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Figure 22: The percentage of responders to clodronate treatment by S-TRACP 5b, U-NTX and S-PINP. 
Responders were those exhibiting a change larger than the LSC of the marker (26.6%, 55.1% and 
32.4%). 
6 Discussion
6.1 Assay performance and factors effecting the results 
Based on the evaluation of the assays they all performed adequately well to be used in 
assessing bone turnover. However, the first Pyr assay was cumbersome with the pretreatment 
of samples and overnight incubation. With more specific antibody the pretreatment step was 
eased. The precision of the assays over the concentration range used was acceptable in all 
assays even when performed manually, it improved when automated pipeting device was 
used for sample and reagent pipeting, and was clearly best in the automated assays for DPD 
and NTX. Our results on the assay performance were in agreement with the results reported 
by the groups who developed the assays, and also by others.13, 15, 21, 23, 24, 247, 315, 316, 317 In 
addition, in the NTX CIA assay the analytical sensitivity was greatly improved as compared 
to the NTX ELISA. The better assay performance of the two chemiluminescent assays was 
not only due to the automation of the reaction steps but also to the more sensitive assay label 
in the automated DPD assay and to the more sensitive detection technique of the enzyme 
lable in the automated NTX assay.318
In the conventional RIAs for PICP and PINP the standard curve range was limited. By using 
the extra standard between the second highest and highest standards included in the reagent 
kit, the measuring range was extended to cover the adult reference range, but childrens’ 
samples were prediluted in PICP assay, and smaller sample volume was used in PINP assay. 
Also in S-ICTP assay an extra standard was used, although the reference range fell to the low 
concentration area of the standard curve. This standard improved the precision in the 
concentration range above 20 µg/l, and enabled most childrens’ and pathological samples to 
be assayed without predilution. 
The correlation of the propeptide assays as well as all resorption marker assays was highly 
significant. The correlation coefficients, the slopes and the intercepts of the linear regression 
lines were dependent on whether childrens’ samples were included or not. When the ELISA 
and CIA methods for U-DPD and U-NTX were compared, a good correlation between the 
methods was found. However, both automated methods produced somewhat higher results as 
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compared to ELISAs. Moreover, we observed that individual results could be quite different 
with different methods. The two DPD methods as well as the two NTX methods utilized the 
same antibody, but it would be reasonable to assume that slightly individually differing 
antigens in the different reaction mixtures could cause different results with different 
methods. Also other study groups have reported good correlations between several type I 
derived resorption markers, and also between different methods for the same analyte.317 In 
that study no differences in individual results by different methods for the same analyte were 
reported, in contrast to our results. 
We have shown that hemolysis decreases the osteocalcin results in a dose-dependent manner, 
independent of the method used. Therefore we undertook to study the effect of hemolysis on 
the results of S-PINP, S-PICP and S-ICTP. The results of PICP and ICTP were unaffected by 
hemolysis, but gross hemolysis (> 2.5 gHb/l) caused a significant decrease in S-PINP results. 
Therefore, S-PINP results from grossly hemolyzed samples were not included in the data 
presented here.
Type I collagen-derived markers were shown to be stable in both serum and urine. Serum 
markers could be stored in room temperature for 4 days, refrigerated for one week, and deep 
frozen in –20 oC for years. The stability of urinary markers NTX and DPD was not tested in 
room temperature, but they were stable in freezer for 4 days, and for years in –20 oC. Both 
serum and urine samples could be thawed and frozen several times having no effect on the 
results. The stability results are in line with the results by others.245, 317 The robustness of 
these markers makes it possible to assay the samples after storage periods of years in -20 oC,
and in this respect make these markers superior to labile markers such as intact osteocalcin 
and TRACP activity.245
Ultraviolet light degrades free (deoxy)pyridinoline ring structure and thus decreases U-DPD 
results.319 On the contrary, we observed that N-telopeptide results increase when samples 
were kept in daylight. The reason for this could be that part of the N-telopeptides reside in 
large aggregates and are not within reach of the antibody; the aggregates are degraded by the 
UV light, causing an increase in measured U-NTX result. For these reasons urine samples 
were stored in colored tubes. 
All the type I collagen-derived markers have short half lives in the circulation and therefore a 
clear diurnal variation, shown in study II in postmenopausal healthy women, but also by 
others in premenopausal women.320 The peak values of formation markers were seen at 
midnight, those of resorption markers later, in early morning hours. Thus after midnight the 
formation marker values declined whereas the resorption marker values increased. 
Glucocorticoids are known to cause uncoupling of bone formation and resorption. Serum 
cortisol levels show their nadir at midnight, and rising cortisol could explain the uncoupling 
of bone formation and resorption after midnight, although results against this theory have 
been published.321, 322 In children, significant circardian rhythm for S-PICP, S-ICTP, U-DPD 
and U-NTX but not for S-PINP was shown.323 As regards to serum concentration of CTX-β,
the diurnal variation is aggravated by meals, whereas diurnal variation of osteocalcin was not 
affected by eating.324, 325 Furthermore, fasting did decrease several marker values in morning 
samples of healthy premenopausal women, the effect being more pronounced in resorption 
markers than in formation markers.326 Molecules with longer half lives, such as Bone ALP 
and TRACP, show only non-significant circardian variations.327, 328
The circardian variation is an important contributor to the intra individual variation of the 
markers, and thus to the least significant change (LSC) of the marker.329 The intra individual 
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variation (CVi) is largest for the urinary excretion of type I collagen degradation products, 
especially for the peptide-bound crosslink compounds. The timing of the sample is therefore 
of utmost importance, and the sample should preferably be taken in a fasting state.246, 326 In
healthy premenopausal women we calculated CVis of 6 to 11% for U-DPD and U-NTX in 
samples taken during one month, in agreement with short-term CVis obtained for 
postmenopausal women with a mean menopausal age of 17 years.330 The long-term CVis
calculated in study VIII were up to 68% for U-NTX and up to 44% for serum markers, 
reflecting the population in early menopause when bone loss is at its fastest, and changes in 
bone turnover accordingly at their highest. The LSCs calculated in study VIII were, however, 
in accordance with LSCs reported in other studies.329, 331, 332, 333 The LSC for S-TRACP 5b, 
27%, was smaller than LSC for S-PINP (32%), and similar to the reported LSC for S-Bone 
ALP.329
6.2 Markers in healthy subjects 
In healthy adults the marker concentrations were slightly higher in men than in women, 
reflecting the fact that men achieve higher peak bone mass than women do,334, 335 S-ICTP 
making an exception. In children and young adults all markers were high, declining to adult 
levels between the ages 18 to 22 in females and between the ages 23 to 27 in males.  
The ratio of type I procollagen propeptide mass concentrations in circulation is expected to be 
close to 3, on a molar basis close to one. This was the case in adults, the mean ratio of PICP-
to-PINP being 3.2 in women and 2.9 in men. In children, S-PINP was much higher than S-
PICP, and thus PICP-to-PINP ratio was low. Even in young adults between the ages of 20 and 
30 the ratio of propeptides was often under 2.0. An explanation to proportionally high S-PINP 
as compared to S-PICP could be their different clearance from the circulation. They both are 
cleared via liver endothelial cell receptors, PICP via mannose and PINP via scavenger 
receptors.235, 239 Mannose receptors have been shown to be regulated by some hormones and 
growth factors,336, 337, 338 resulting perhaps in higher clearance of PICP from the circulation 
during growth and even in early adulthood. We found significant correlations between S-
PINP and age, and PICP-to-PINP ratio and age, in the groups of children and young adults. In 
pubertal girls significant negative correlation has been reported between several markers of 
bone turnover and estrogen.339 The estrogen effect could be the reason for the significant age 
dependence of S-PINP and PICP-to-PINP ratio in our study in females under 20 years of age. 
In males a similar correlation between S-PINP and age and PICP-to-PINP ratio and age was 
found when the age range was extended to 25 years. It is well known that pubertal growth 
spurt starts later in boys than in girls, due to androgen effect,334 and men gain bone mass for a 
longer period of time, leading to a higher peak bone mass in men than in women.335 Some 
very high S-PINP values and low PICP-to-PINP ratios were seen in pubertal boys indicating 
growth spurt, as does serum concentration of the amino-terminal propeptide of type III 
collagen.340 The growth spurt is not seen as elevations in S-PICP,259 leading to low PICP-to-
PINP ratio. In pubertal boys during the growth spurt the PICP-to-PINP ratio varied from 0.38 
to 0.50. S-PINP value as high as in pubertal boys was also seen in the youngest child of study 
I (under 1 year of age); however, the PICP-to-PINP ratio in this child was close to1.0. Data on 
S-PINP in healthy children is scanty, but in one recent study it was measured in healthy 
pubertal boys (n=155) and girls (n=151), among other markers of bone formation.341 In that 
study S-PINP increased from prepuberty until the pubertal stage B3 in girls and G4 in boys; 
in both sexes S-PINP correlated with height velocity which peaked at same stage where S-
PINP was as its highest. Similarly to our study, the highest values were seen in boys. 
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The type I collagen-derived markers of bone resorption were also high in childhood, and like 
S-PINP and S-PICP, declined to adult levels somewhat earlier in females than in males. In 
several studies involving larger number of healthy children and adolescents it has been shown 
that the markers of bone resorption increase up to 2 months of age, then decrease reaching a 
stable level at about the age of three years.262, 342 Depending on the marker, the levels in 
children are even more than ten times higher than in adults. During puberty the resorption 
markers increase, earlier in girls than in boys, and similarly to our study decline to adult 
levels earlier in girls than in boys.343 The results obtained in different studies are, however, 
somewhat contradictory, in one study the highest values during puberty were seen in girls,343
in another study, consistent with our results, in boys.341 We found a relationship between the 
ratio of peptide bound crosslink (NTX) to free crosslink (DPD) excretion and age, the relative 
proportion of NTX declining with age. This probably reflects the fact that during high 
turnover relatively more of peptide bound crosslinks are excreted.249 Probably due to the same 
reason, in studies by others, urinary excretion of DPD increased less than other resorption 
markers in pubertal girls.341, 343  Our results on the values of the serum marker of bone 
resorption, ICTP, are consistent with the results of others, values declining gradually to adult 
levels after puberty. In one study S-ICTP was shown to have the best correlation to bone mass 
of the markers measured, and it also correlated well with the height velocity.341 We found the 
highest ICTP-values in pubertal girls, contrasting the results of urinary resorption markers. 
No difference according to gender was seen in adults.  
6.3 Markers in different disease states 
6.3.1 In children with asthma, on and off inhaled corticosteroid treatment 
Several markers of bone formation, S-PINP, S-PICP and S-OC, and of bone resorption, S-
ICTP, U-Pyr, U-fDPD and U-NTX, were measured in study II to assess the effect of inhaled 
budesonide (BUD) treatment on bone metabolism of asthmatic children. Before the treatment 
was started type I collagen-derived markers were similar in asthmatic and healthy children, 
but S-OC was significantly lower in asthmatic children, consistent with results reported by 
others.270 Lowered OC could reflect impaired mineralization, caused by changes in cytokine 
production due to the asthmatic inflammation.344 One-month treatment with high-dose 
budesonide caused a decrease in all markers. The type I collagen-derived markers did not 
markedly change during the 5 months of lower dose budesonide treatment, and they returned 
to baseline levels after 6-month treatment with nedocromil. Also OC was stable during the 
lower dose of budesonide, and increased above the baseline level, almost reaching the level of 
healthy children during nedocromil treatment. Moreover, the good correlation of type I 
collagen-derived markers of bone formation (PINP, PICP) and resorption (ICTP) during 
budesonide treatment indicated that the balance between the two processes was maintained, 
though the turnover was lowered. Slightly different results have been obtained in one 
comparative study of the effect of inhaled BUD, fluticasone propionate (FP) or cromone on 
bone turnover in 75 school-aged asthmatic children.345 In that study high-dose medication 
was given for two months after which the dose was reduced to half. Four months’ treatment 
with BUD reduced formation markers (PICP and OC) whereas ICTP-level did not change, 
suggesting imbalance between bone formation and resorption. Moreover, in children with 
growth or adrenocortical suppression the marker changes were more pronounced. In another 
study with prepubertal asthmatic children inhaled corticosteroids (BUD or beclomethasone) 
for one year reduced PINP, OC and ICTP whereas PICP slightly increased and Bone ALP did 
not change.346 In the former study, the imbalance between bone formation and resorption 
could have been caused by the longer treatment period with high-dose BUD, whereas the 
results of the latter study are in line with our results, suggesting that the coupling between 
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bone formation and resorption is maintained during the inhaled budesonide, but bone turnover 
is lowered. The small increase in PICP could be due to its changed clearance by the liver. 
Out of the formation markers, the largest change was seen in S-PINP. Of the resorption 
markers, S-ICTP (CTX-MMP) showed the most marked decrease, whereas the decrease in U-
NTX during high-dose budesonide was non-significant. This difference in response of the two 
markers is different from the response seen in postmenopausal osteoporosis.300 The reason for 
this difference might be the different mechanisms of bone modeling in children and 
remodeling in postmenopausal women. The good sensitivity of S-ICTP is supported by its 
good correlation with growth velocity, shown also by others.346 
The results obtained in some studies of adults on inhaled corticosteroid treatment have shown 
no changes in markers of bone formation (S-Bone ALP, S-OC, S-PICP) or resorption (U-Ca, 
U-DPD), neither did the treatment have any effect on BMD.275, 276 In our study, BMD of the 
children was not measured, but their height gain during the study year was similar to the 
height gain of healthy children, supporting the marker data and the fact that inhaled 
corticosteroids do not have deleterious effect on bone or growth as do oral formulations.273, 274
6.3.2 Markers in patients with prior thyroid cancer, on and off thyroxine 
treatment
In study III bone turnover and bone mineral density were assessed in patients with prior 
thyroid carcinoma and on thyroxine suppressive therapy. All the measured type I collagen-
derived markers of bone formation and resorption and OC were elevated in the patient 
population of 15 premenopausal, 10 postmenopausal women and four men, who had been on 
thyroxine therapy for 9 to 11 years, in comparison to age and gender matched controls. Bone 
ALP was also higher in patients, but the difference did not reach significance. In several other 
studies high bone turnover has been shown in hyperthyroidism and during thyroxine 
treatment.277, 278, 347, 348 In one study PICP in patients did not differ from that of controls,348
and indeed, also in our study the median PICP was only 10% higher in patients than in 
controls whereas median PINP was 46% and OC 35% higher. Bone ALP in our study was not 
significantly higher in patients as compared to controls, a result not in agreement with the 
results of several other reported results. The reason for this discrepancy could be the method 
used in our study, lectin precipitation of bone isoform combined with electrophoretic 
separation of the isoforms in polyacrylamide gel. The method might underestimate the second 
bone isoform, which normally is found in minor amounts in the circulation, but can be greatly 
elevated in situations characterized by high bone turnover.4, 78, 245, 349 Of the formation 
markers measured in our study, PINP seemed the most sensitive one to reflect increased bone 
turnover, but unfortunately, it has not been measured in other studies. For bone resorption we 
measured only the excretion of HOP, quite an unspecific maker, and serum ICTP, known to 
be produced by matrix metalloproteinases. Nevertheless, both of these markers indicated 
increased bone resorption to about same extent as markers of bone formation reflected 
increased bone formation.  
In our study bone formation and resorption were in balance as judged by the measured 
markers, and also by the bone mineral densities, which were not reduced in patients as 
compared to controls. In some studies significantly reduced BMDs have been reported,348 and 
in some studies the detrimental effect has been seen only in postmenopausal women,280
whereas in some studies the effect has been the same, irrespective of menopausal status.281, 282 
No changes in bone turnover or bone mass have been observed in some studies when the 
smallest possible dose to keep serum TSH suppressed has been used.350, 351 In our study 
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population, no reduction in BMD could be shown, despite of increased bone turnover and 
standard doses of LT4 used. The reason for this could be high intake of calcium in the Finnish 
population,352 which might counteract the high bone turnover, and keep the formation and the 
resorption in balance, resulting in no bone loss. 
After the withdrawal of LT4 therapy, the markers decreased significantly reflecting lowered 
bone turnover, in agreement with results by others.277 PICP, however, made an exception. 
Iatrogenic hypothyroidism caused a significant increase in PICP whereas PINP significantly 
decreased. The increase in PICP after stopping the treatment, as well as it being less, although 
significantly, increased during therapy in comparison to PINP, results most probably from the 
action of thyroxine on mannose receptors. As discussed above, mannose receptors are 
sensitive to growth factors and hormones, and they are responsible for the clearance of PICP 
whereas PINP is cleared via scavenger receptors, which are insensitive to hormones. The 
same phenomenon was also seen in growing children, who had lower than expected PICP 
concentrations and therefore a lowered PICP-to-PINP ratio. 
Serum OC decreased by 42% after five weeks of hypothyroidism whereas PINP decreased 
only by 7%. The decrease in OC was almost of same magnitude as the decrease in ICTP, 
54%. The method with which OC was measured was a competitive radioimmunoassay 
against human OC, and the antibody recognized intact OC, N-Mid-OC and also smaller 
breakdown products of the protein. OC is imbedded to bone organic matrix, and therefore OC 
and its breakdown products are freed to the circulation during bone resorption. Moreover, our 
study showed that during hypothyroidism the active metabolite of vitamin D increased. 
Vitamin D stimulates OC synthesis which would increase de novo liberated circulating OC. 
Therefore, with the method in our study, OC reflected both bone resorption and formation. 
Bone formation was reflected by PINP, which in five weeks decreased much less than OC, 
consistent with the fact that changes in markers of bone formation are seen later than changes 
in markers of bone resorption, due to the bone remodeling cycle which starts with resorption, 
followed by reversal phase and finally formation. Even in these patients with high bone 
turnover, five weeks was too short a time for PINP to decrease as much as marker of bone 
resorption, ICTP, or turnover, OC, decreased. 
6.3.3 Markers in bone disease due to malignancy 
In the study of type I collagen-derived serum markers in patients with breast cancer and bone 
metastases, serum ICTP was significantly higher in patients than in healthy, age-matched 
controls, the median and mean value being above the upper reference range of the marker. 
Also its specificity in diagnosis, 93%, was better than that of urinary excretion of several type 
I collagen breakdown products, urinary deoxypyridinolines or N-telopeptides.283, 284 In our 
study it was, however, elevated only in 56% of the patients, and therefore was not sensitive 
enough to be used for diagnosis of the bone disease. In later studies ICTP has been shown to 
be a sensitive marker of bone metastases, whether lytic or sclerotic, and higher clinical 
sensitivities than we obtained have been reported.284, 353, 354, 355 Some studies have shown the 
value of ICTP in the follow-up of disease outcome.290, 291 In our study 13 patients with bone 
metastases were followed up, and indeed, ICTP changes reflected the disease outcome. 
Significance of the changes was not calculated due to the small number of patients. Several 
recent studies have, however, shown that ICTP does not respond to the treatment with 
bisphosphonates, the most common therapy for bone metastases, as sensitively as do the 
excretion of peptide-bound type I collagen breakdown products, especially NTX.284, 356 The
reason for this different response lies most probably in the mechanism of action of 
bisphosphonates. It has been clearly demonstrated that all bisphosphonates decrease 
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osteoclastic bone resorption by several mechanisms, one of them being the inhibition of the 
activity of bone resorbing enzymes, both cathepsins and matrix metalloproteinases.357, 358
Nevertheless, in an in vitro model of multiple myeloma bisphosphonates have been shown to 
have an opposite effect on one of the MMPs, the MMP2: the aminobisphosphonates 
pamidronate and zoledronate upregulated MMP2 expression, and the upregulation was more 
prominent with the more potent bisphosphonate zoledronate.359 NTX and CTX are produced 
by cathepsin K and MMP9, whereas MMP2 and MMP13 are responsible for the formation of 
ICTP.360 MMP2 is frequently expressed in tumors, and its increased expression during 
bisphosphonate therapy could explain the unchanged levels of ICTP.
The markers of bone formation, PICP and PINP were elevated in only 24% and 30% of the 
patients, respectively, reflecting the fact that most patients had osteolytic bone lesions, some 
having mixed lytic and sclerotic lesions. The results of several studies support our data, 
formation markers being elevated only seldom when the bone disease is lytic.288, 292 Although 
the sensitivity of PINP was low in detecting bone metastases from breast cancer, we were the 
first to show that the ratio of the two propeptides changes in these patients: the PICP-to-PINP 
ratio was lowered from about 3 to less than 2 in more than 50% of the patients with bone 
involvement, and only a few patients without bone lesions had a lower than normal ratio, the 
specificity of the ratio being 91% when the cut-off value of 2 was used. The propeptides and 
their ratio were then analyzed in a larger population of breast cancer patients, divided into two 
groups according to the aggressiveness of the disease, into patients with progressive or stable 
disease. The optimal sensitivity and specificity of 90% of S-PINP for aggressive disease were 
attained, when a cut-off value of 70 µg/l was used. Similarly the optimal sensitivity and 
specificity of 98% and 90% of the PICP-to-PINP ratio was attained using a cut-off value of 
1.74. As the PICP-to-PINP ratio is lowered during growth and when bone mass is gained, as 
well as during thyroxine treatment and in active Paget’s disease of bone,361 a reasonable 
explanation to the altered ratio in advanced neoplastic disease would be that the cytokines and 
growth factors secreted by the tumor enhance the clearance of PICP by the liver endothelial 
cell mannose receptors. Another explanation to the discrepant propeptide levels could be the 
formation of α1-trimeric variant form of type I collagen in malignancy,362, 363 the variant 
PINP being measured in the assay used whereas homotrimeric PICP would not be recognized 
by the assay antibody.  
The prognostic value of S-PINP has been later shown in a study involving 300 node-positive 
breast cancer patients. 364 Postoperative intact PINP was shown to be higher in patients who 
developed metastatic disease, either to bone, visceral or soft tissues, and patients with high 
PINP value had poorer survival as compared to patients with low PINP. Similar results of the 
value of S-PINP were obtained in a study where the ELISA method that recognizes the intact 
PINP and the Col1 fragment was used to measure S-PINP in 100 patients with recurrent 
breast cancer.16, 365 In that study S-PINP was measured after the first recurrence, before 
systemic treatment was started. S-PINP was shown to correlate positively with the tumor 
burden, and patients with high PINP had shorter time to disease progression, shorter overall 
survival and their response to systemic treatment was poorer than patients with low PINP 
level. In line with our study, the highest PINP concentrations were seen in patients with bone 
involvement, but also in patients with only soft tissue metastases the median PINP was higher 
than in healthy controls.
6.3.4 Effect of smoking on markers 
Study VI was undertaken to investigate the effect of smoking on the marker of bone 
formation, S-PINP, and resorption, U-NTX, and on the response of transdermal estrogen 
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replacement therapy in early postmenopausal women. Also vitamin D status of smoking and 
non smoking postmenopausal women was assessed.  
At baseline smokers did not differ from non-smokers as to their marker values, in line with 
the similar BMD values in the two groups. The BMD finding is confirmed by a recent meta-
analysis on on the risk factors for fractures.366 However, in smokers the correlation of the two 
markers was worse than in postmenopausal and premenopausal non-smokers, perhaps 
indicating worse balance between bone formation and resorption in smokers. Unbalance 
between bone formation and resorption has been reported in a few recent studies, either due to 
decreased bone formation or increased bone resorption or both.296 - 299 In these studies serum 
OC was shown to be lowered in smokers whereas Bone ALP was similar in smokers and in 
non-smokers. In two of the studies bone resorption was shown to be increased in smokers as 
compared in non-smokers.296, 299 In one of the studies this was shown especially in heavy 
smokers with over 20 years since menopause, in non-heavy smokers markers did not differ 
from those of non-smokers.296 In the other two studies no difference in bone resorption, 
measured as urinary NTX or hydroxyproline, was seen.297, 298
Our finding of lowered serum 25(OH)D levels in smoking women is in agreement with 
previous studies,296, 297, 367 hypovitaminosis D perhaps being a major contributor to reduced 
calcium absorption in smokers.367 Furthermore, hypovitamonis D could at least in part explain 
lowered OC levels in smokers, reported by others, as vitamin D stimulates the synthesis of 
OC.
6.4 Markers in the follow-up of antiresorptive treatment of 
postmenopausal osteoporosis 
6.4.1 Estrogen replacement therapy 
Study VI showed no difference in response to estrogen treatment between smokers and non-
smokers, shown by both BMD changes and changes in markers. Also, increasing the E2 dose 
in smokers from the standard dose of 1 mg daily to 1.5 mg daily did not change the response. 
Some studies have exhibited a lessened response of BMD to oral estrogen treatment in 
smokers vs. non-smokers, supporting the suggestion that smoking may negate the protective 
effect of oral ERT on BMD and hip fracture. 368 In one study, it was shown that the effect of 
smoking on BMD was dose dependent, reducing the BMD increase in women using 1 mg oral 
estradiol daily but not at all in those using 2 mg.369 With both estradiol doses, the serum 
estradiol levels in smokers were half of that in non-smokers, but the level of 0.15 nmol/l in 
smokers on 2 mg daily estradiol was adequate to keep the response similar as in non-smokers. 
The reason for lessened BMD response to oral treatment resides in an increased hepatic 
metabolism of estrogens resulting in lower estrogen levels among postmenopausal smokers. 
In our study serum estradiol levels were non-significantly lower in smokers than in non-
smokers, ranging from 0.25 nmol/l to 0.30 nmol/l in women receiving 1 mg estradiol daily, 
and being well above the critical level of 0.15 nmol/l in the above mentioned study. Our study 
demonstrated that smoking does not diminish the response of the lumbar spine and femoral 
neck BMD to transdermal estrogen treatment even when used in standard doses, transdermal 
route of administration circumventing smoking-induced increase in hepatic metabolism of 
estrogens.
Bone marker measurements confirmed that the bone-sparing effects of treatment with 
transdermal estrogen were not negated by smoking. Urinary excretion of NTX was reduced to 
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a similar extent in both smoking and non-smoking women during the treatment. The 
reduction was somewhat less than a 52% decrease during one year of oral estrogen treatment 
in a study in which increases in BMD corresponded those obtained in our study.370 The 
formation marker serum PINP diminished to a similar extent as urinary NTX, but seemed to 
do so more in smokers than in non-smokers. Also, S-PINP increased in non-smokers during 
the second treatment year whereas in smokers it remained stable. In two studies of 
postmenopausal women, the circulating concentration of PINP decreased to about half of the 
pre-treatment level during 1 year of transdermal ERT, consistent with our results.371, 372 In these 
studies the subjects were a combined group of smokers and non-smokers, and the follow-up 
periods were 1 and 2 years. The study with a 2-year follow-up did not show any increase in S-
PINP during the second year in subjects less than 67 years of age. The difference in the results of 
our study could perhaps be explained by somewhat, though not significantly, higher circulating 
E2 concentrations in non-smokers, which could stimulate osteoblast activity as well as suppress 
osteoclast activity, leading to more positive balance in non-smokers during extended 
treatment.373 Another explanation could lie in the metabolism of PINP. The formation of PINP 
and its release to circulation is decreased by estrogen treatment through slowing bone turnover, 
which decrease can be anticipated to be similar in smoking and non-smoking women. PINP is 
eliminated from the circulation mainly via scavenger receptors on liver endothelial cells.239 It can 
be hypothesized that smoking increases the removal of serum PINP through hepatic induction. 
Subsequently, in the face of a similar reduction in input, the ongoing increase in removal might 
result in a more pronounced drop in S-PINP level in smoking vs. non-smoking women during 
ERT.  
Our marker data also showed that ERT reverses the poor balance between bone resorption 
and formation in smokers, the correlation of the two markers, S-PINP and U-NTX, reaching 
similar level as in non-smokers after one year on ERT. On the other hand, the marker data 
also showed worsening of the balance in non-smokers with advancing menopausal age and 
without estrogen replacement. 
6.4.2 Short-term clodronate treatment 
In the study of the effects of short-term treatment with oral clodronate on markers of bone 
turn-over and their diurnal variation, the response was seen only in the urinary excretion of 
NTX. The AUC for NTX decreased by 41% whereas that of free Pyr decreased only by 4.7%, 
and no change was seen in the AUC of S-ICTP or in the AUC of the marker of bone 
formation, S-PICP. Further, treatment with clodronate lessened diurnal variation of NTX 
only. Several studies have shown the different response to treatment of various markers. Six 
weeks’ treatment with estrogen decreased urinary excretion of NTX and total 
deoxypyridinoline, measured by HPLC, by 38% and 40%, but free pyridinoline excretion, 
measured by ELISA, and S-ICTP decreased only by 16%.374 In one study the response to 
alendronate treatment for one year in late postmenopausal osteoporotic women was assessed 
with several markers of bone turnover.300 Of the resorption markers, the best response was 
seen in urinary NTX, in S-ICTP and urinary free pyridinolines the response was poorest. Yet 
another study showed that free deoxypyridinoline excretion responded to estrogen treatment 
but not at all to treatment with bisphosphonate.375 A doubt was thrown as to the bone 
specificity and origin of U-Pyr and S-ICTP, due to their unresponsiveness to bisphosphonate 
treatment. It is known that pyridinoline crosslinks originate from cartilage as well as from 
bone, whereas deoxypyridinoline is more specific to bone. The ELISA for free pyridinoline 
excretion was the first available immunoassay for assessing urinary excretion of type I 
collagen degradation product, and it measured both pyridinolines and deoxypyridinolines, 
free and bound to peptides less than 1000 Daltons. Pyr assay has been greatly replaced by 
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more bone specific markers since the introduction of the ELISA measuring specifically free 
DPD excretion, and especially the assays measuring peptide-bound crosslink excretion NTX 
and CTX. In part the better sensitivity of U-NTX in comparison to free Pyr excretion as 
response to bisphosphonates treatment could be explained by slowing down bone turnover 
which in itself decreases peptide bound crosslink excretion.249 As regards to S-ICTP, the 
explanation to its poor responsiveness to treatment in benign conditions such as osteoporosis 
lies in the action of enzymes degrading bone organic matrix, the action of cathepsin K 
destroying the ICTP antigen and leading to the formation of CTX and NTX.254 Matrix 
metalloproteinases are the enzymes responsible for the formation of immunoreactive ICTP 
antigen, and though functioning also normally, contribute to a lesser extent to bone 
degradation in benign conditions.153 - 156, 162 - 165
Several studies have also shown the poor responsiveness to treatment of S-PICP. In the 
alendronate study mentioned above, S-PICP showed the poorest response of about 20% 
among several bone formation markers studied.300 The upregulation of mannose receptors by 
growth factors during high bone turnover could be the reason for the poorer response in S-
PICP as compared with other formation markers. In our study S-PICP showed no response at 
all. This was probably due to the short follow-up period. In the above mentioned alendronate 
study300 it was shown that a significant response in a resorption markers is seen after about 
one month’s treatment, and the marker values reach their nadir in 3 to 6 months where after 
they remain stable. In formation markers the response is seen later – after about 3 months’ 
treatment they decline significantly, and reach their nadir in 6 to 12 months, a finding that can 
be explained by the sequence of the bone remodeling cycle. 
In addition to significant decrease in urinary NTX, clodronate treatment decreased serum and 
urinary calcium levels and caused compensatory hyperparathyroidism, seen as increase in 
serum intact PTH levels. These findings indicated that clodronate treatment for 4 weeks 
efficiently suppressed osteoclast activity. 
6.4.3 S-TRACP 5b in comparison with U-NTX and S-PINP as a reflector of 
treatment efficacy with clodronate 
Study VIII was planned to compare changes in S-TRACP 5b to changes in urinary excretion 
of NTX and in S-PINP in the follow-up of clodronate treatment of osteopenic 
postmenopausal women. TRACP 5b is an osteoclast-specific enzyme with only non-
significant circardian variation, and therefore it could be expected to reflect bone resorption 
more accurately than do type I collagen-derived markers. 
In comparison to the reference range for premenopausal women, serum TRACP 5b 
concentration was elevated in 42% of the subjects, U-NTX was elevated in 70% of the 
subjects, whereas the marker of bone formation, S-PINP, rose above the reference range in 
only 7% of the subjects. In addition, the median value of U-NTX was above the upper 
reference limit for premenopausal women, but the median of S-TRACP 5b fell within the 
reference range. These findings may indicate uncoupled bone formation and resorption in this 
group of postmenopausal women with vertebral osteopenia. Moreover, urinary excretion of 
NTX seemed to detect osteopenic subjects more efficiently than did S-TRACP 5b. In several 
studies the mean values of U-NTX and S-PINP in postmenopausal healthy women have been 
shown to be somewhat higher than in premenopausal women, but in osteoporotic 
postmenopausal women the marker means are significantly higher.300, 376, 377 In one study S-
TRACP 5b was shown to be elevated in 48% of 29 osteopenic women, a result consistent 
with the result of our study.378
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The changes in the two markers of bone resorption correlated well, but the percentage change 
in TRACP 5b was less than half the percentage change in U-NTX. This may be explained by 
clodronate action. As discussed above, bisphosphonates affect bone resorption at several 
levels:358 They inhibit the adhesion of osteoclasts to bone matrix, preventing the formation of 
actively resorbing cells, and they inhibit osteoclastic proteolytic enzymes. They also cause 
osteoclast apoptosis, the mechanism and kinetics depending on the bisphosphonates in 
concern: the bisphosphonates which contain amino groups do so with slow kinetics by 
preventing protein prenylation. The non-amino bisphosphonates such as clodronate cause 
quick apoptosis by forming complexes with ATP, thus blocking the mitochondrial ADP/ATP 
translocase.379, 380 Depending on which bisphosphonate, different mechanisms may 
predominate in vivo.381 The finding that TRACP 5b was reduced to a lesser extent than U-
NTX could be explained as follows: First, clodronate acts mainly by causing osteoclast 
apoptosis, but does not affect the formation of early osteoclasts, which would still secrete 
TRACP 5b into the circulation. Second, it inhibits the activity of bone resorbing enzymes, 
leading to decreased amounts of type I collagen breakdown products. 
The TRACP 5b changes predicted BMD changes no better than did the type I collagen-
derived markers, and the markers' early changes predicted later changes in BMD at the 
lumbar spine and trochanter only. These results are in agreement with those of several other 
studies showing early marker changes in a response to HRT or bisphosphonates correlating 
with later BMD changes only slightly.28, 311, 324, 331, 332 The markers used in those trials have 
covered all the markers measurable with commercially available reagents. Urinary NTX, 
CTX, DPD, and S-CTXβ changes from baseline to 3 to 6 months have been found to be 
significant predictors of spinal BMD changes only, as have been the changes in serum 
formation markers Bone ALP or OC. In some studies, marker changes have also been 
predictive for BMD changes at other skeletal sites, especially in trials involving elderly 
populations,310 whereas some studies have found no correlations at all between early marker 
changes and later BMD changes.303, 304
Our LSC for S-TRACP 5b, 26.6%, was much smaller than that for U-NTX, 55.1%. However, 
TRACP 5b changes identified somewhat fewer responders to treatment with clodronate than 
did NTX changes, and markedly fewer than did PINP changes. These results are not in 
agreement with results for TRACP 5b changes as a response to HRT in healthy early 
postmenopausal women.27 In that small study a highly significant mean decrease of 48% in S-
TRACP 5b was apparent after six months on HRT, and a decrease larger than an LSC of 
26.2% occurred in 13 of 15 patients on HRT. The difference between the results of these two 
studies may be in part explained by the differing mechanisms of the interventions. Estrogen 
replacement directly affects the number of TRACP secreting osteoclasts by inhibiting 
cytokines essential for osteoclast formation,184 - 186 whereas clodronate treatment influences at 
a later stage of osteoclast development and bone resorption.381
The marker of the greatest value in finding the responders to clodronate treatment was S-
PINP. Although published data on S-PINP as a marker of the efficacy of antiresorptive 
treatment are scanty, some studies support our finding. In a study of subjects with surgical 
menopause,377 among several markers of bone formation (Bone ALP, PINP, PICP, OC), S-
PINP exhibited the highest response to HRT. Of the resorption markers measured (U-CTXβ,
U-CTXα, U-NTX, S- S-ICTP, S-CTXβ, S-TRACP) S-CTXβ was the most efficient, showing 
as high a response as S-PINP. S-PINP was also shown to respond similarly to HRT use in 
natural menopause.376 The reason for S-PINP being superior to U-NTX in detecting the 
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responders to clodronate treatment is mainly the larger intra-individual variability in U-NTX; 
the mean percentage decreases in these markers were of the same magnitude. 
The goal of the treatment or prevention of osteoporosis is to prevent fractures. Therefore, the 
best bone marker would be the one which best predicts the appearance of fractures. For the 
purpose of calculating the efficacy of a treatment in fracture prevention, long-term studies 
with large populations are needed. In a few such studies changes in bone markers have been 
shown to be of more significance than changes in BMD. As a response to raloxifene therapy, 
reduced fracture risk was related to the change in bone turnover but not at all to the change in 
BMD.382 In addition, the bone formation markers S-Bone ALP and S-OC were more 
advantageous than urinary CTX. Also, in one study low carboxylated to total OC ratio was 
shown to be a strong predictor of fracture among elderly population.383 In yet another study, 
the decrease in bone resorption markers predicted up to 40% of the effects of risedronate on 
vertebral fracture risk, whereas the change in BMD explained only 28% of the reduced 
risk.384 In the FIT study, BMD changes predicted only 16% of the effects of alendronate on 
vertebral fracture risk.385
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7 Conclusion
To conclude, the commercially available reagents for measuring type I collagen-derived bone 
markers behave adequately well to be used in routine. The markers tested were robust, and 
the samples could be stored at -20 oC for years without any influence on the results. Diurnal 
variation contributes to the significant intra-individual variation of the markers, and timed 
samples are needed to obtain comparable results in the follow-up. The least significant change 
of serum marker PINP (amino-terminal propeptide of type I procollagen) was much smaller 
than that of urinary marker NTX (crosslinked amino-terminal telopeptide of type I collagen).  
Serum PINP stands out as a sensitive marker reflecting bone formation in a variety of clinical 
situations. In healthy children and young adults it correlated with age, the highest values 
being seen in pubertal boys. During high-dose budesonide treatment of asthmatic children it 
was the most sensitive formation marker measured to reflect the treatment effect on bone 
turnover. In patients with prior thyroid carcinoma, and on thyroxine treatment, S-PINP 
sensitively reflected increased bone formation, and the effect of 5 weeks’ iatrogenic 
hypothyroidism on bone formation was seen only in S-PINP. S-PICP (carboxy-terminal 
propeptide of type I procollagen) increased during hypothyroidism, possibly because of its 
lowered clearance from the circulation due to thyroxine withdrawal. In patients with breast 
cancer S-PINP was prognostic for aggressive disease. 
The PICP-to-PINP ratio is lowered in children and young adults; the lowest ratios in healthy 
population are seen in pubertal boys. Lowered ratios were also seen during thyroxine 
treatment and in patients with aggressive breast cancer, for which the ratio less than 1.74 was 
highly prognostic. The reason for the lowered ratio during growth and in states of high bone 
turnover lies most probably in the clearance of the propeptides from the circulation, the 
clearance of PICP via mannose receptors of liver endothelial cells being sensitive to 
hormones, cytokines and growth factors whereas the clearance of PINP is not. 
Urinary excretion of NTX seems to be the marker which most sensitively reflects bone 
resorption in adults, as judged by the increased excretion after menopause and in osteopenic 
subjects. In children, the most sensitive resorption marker is serum ICTP (crosslinked 
carboxy-terminal telopeptide of type I collagen). S-ICTP showed the largest response to 
inhaled glucocorticoid treatment in asthmatic children among several markers of bone 
resorption; the good correlation between S-PINP and S-ICTP, and their similar magnitude of 
decrease indicated balanced bone formation and resorption even during high-dose treatment. 
S-ICTP reflected increased bone resorption in patients with prior differentiated thyroid 
carcinoma and on thyroxine treatment, and it responded to iatrogenic hypothyroidism. In 
breast cancer patients elevated S-ICTP was indicative of bone metastases. 
In the follow-up of antiresorptive treatment of postmenopausal osteoporosis S-PINP is the 
most efficient one of the markers measured. It decreased to a similar extent as U-NTX, but 
due to its smaller LSC (least significant change), it detected more responders to treatment 
with clodronate than did U-NTX. The serum concentration of TRACP 5b (tartrate resistant 
acid phosphatase isoform 5b) decreased less than the type I collagen-derived markers, but it 
detected about as many responders to treatment as did U-NTX, again due to its smaller LSC. 
Serum ICTP did not change at all as a response to treatment with clodronate for one month, 
whereas urinary NTX decreased significantly. The treatment response in various markers, as 
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well as the magnitude of the response, seems to depend on the therapy and its mechanism of 
action.
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8 Summary
This study was undertaken to evaluate the performance of several commercially available 
immunoassays for measuring type I collagen-derived markers of bone formation and 
resorption, to study factors which affect the interpretation of the results, and to evaluate the 
utility of these markers in different clinical situations. 
The commercially available reagents for measuring type I collagen-derived bone markers 
performed adequately well to be used in routine, the most precise methods being those using 
automated techniques. Most of the type I collagen-derived markers are robust, and the 
samples can be stored at -20 oC for years without any influence on the results. Gross 
hemolysis caused lowering of S-PINP (amino-terminal propeptide of type I procollagen) 
results whereas S-PICP (carboxy-terminal propeptide of type I procollagen) and S-ICTP 
(cross-linked carboxy-terminal telopeptide of type I collagen) were unaffected. Diurnal 
variation is an important contributor to the significant intra-individual variation of the 
markers, and therefore timed samples are needed to obtain comparable results in the follow-
up. The least significant change (LSC) of serum marker PINP was much smaller than that of 
the urinary marker NTX (cross-linked amino-terminal telopeptide of type I collagen). 
In healthy population propeptides S-PINP and S-PICP were high in children, declined to adult 
levels earlier in girls than in boys, and S-PINP somewhat increased in women after 
menopause. In children and in young adults S-PINP correlated negatively with age, and it was 
proportionally higher than S-PICP, leading to lowered PICP-to-PINP ratio during childhood 
and early adulthood. In adults the propeptide concentrations were somewhat higher in men as 
compared to premenopausal women. The resorption markers, urinary excretion of NTX, and 
the excretion of free pyridinolines, U-Pyr, and deoxypyridinolines, U-DPD, changed with age 
similarly to the formation markers. However, the ratio of peptide-bound to free crosslink 
excretion (U-NTX-to-DPD) was age-dependent, the relative proportion of NTX being higher 
in children and young adults. Serum concentration of ICTP, was also high in children, and 
declined to adult levels as did the other markers. In adults, no difference between genders in 
S-ICTP was found. 
In children with newly diagnosed asthma, before treatment the type I collagen-derived 
markers S-PINP, S-PICP, S-ICTP, U-NTX, U-Pyr and U-DPD did not differ from marker 
values in healthy children, but S-OC (osteocalcin) was significantly lower. During treatment 
with high-dose inhaled corticosteroid for one month all markers decreased, S-PINP and S-
ICTP showing the largest responses. The good correlation between formation and resorption 
markers and the similar magnitude of the decrement in S-PINP and S-ICTP indicated 
unchanged balance between bone formation and resorption, despite of decreased bone 
turnover. During low-dose budesonide treatment for five months the marker levels did not 
further change. Type I collagen-derived markers increased to baseline levels after six months 
from withdrawal of the glucocorticoid, and S-OC increased above the baseline level, being 
similar to S-OC in healthy children. As judged by the marker data, inhaled budesonide 
treatment did not have a deleterious effect on bone metabolism and growth in children. 
Markers of bone turnover, S-PINP, S-PICP, S-OC, S-ICTP and U-HOP, indicated increased 
bone turnover in patients with prior differentiated thyroid carcinoma on high-dose thyroxine 
treatment. In spite of increased bone turnover bone mineral densities were similar in patients 
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and in controls. After 5 weeks of iatrogenic hypothyroidism, due to stopping thyroxine 
treatment, bone turnover decreased, as judged by decreased levels of S-PINP, S-OC, S-ICTP 
and U-HOP. On the contrary, S-PICP increased significantly possibly because its altered 
clearance by thyroxine withdrawal via liver endothelial cell mannose receptors, which are 
known to be influenced by hormones and growth factors. S-PINP was the marker which 
reflected altered bone formation whereas S-OC reflected both formation and resorption, as 
judged by the magnitude of changes in the two markers. 
S-ICTP and S-PINP were higher and the PICP-to-PINP ratio was lower in patients with bone 
metastases from breast cancer in comparison to healthy controls and to patients with breast 
cancer without bone involvement. The clinical sensitivities of 50 to 60% of S-ICTP and 
PICP-to-PINP ratio are not high enough for these markers to be used in diagnosing metastatic 
bone disease, despite their good clinical specificities of more than 90%. Increased S-PINP 
and decreased PICP-to-PINP ratio were highly prognostic for aggressive breast cancer. 
S-PINP was similar in postmenopausal smokers and non-smokers, and it was not significantly 
different from S-PINP in premenopausal non-smokers. On the contrary, U-NTX was higher in 
postmenopausal women as compared to premenopausal women, but smoking did not cause 
any difference in U-NTX. However, the correlation of the two markers was poorer in 
postmenopausal smokers in comparison to non-smokers, indicating perhaps unbalance 
between bone formation and resorption, in the favour of resorption, in smokers. In a group of 
postmenopausal osteopenic women, both smokers and non-smokers, U-NTX was elevated 
above the premenopausal reference range in 70% of the subjects whereas the other measured 
resorption marker S-TRACP 5b was elevated only in 40% of the subjects. In this group, S-
PINP was above the premenopausal reference range in 7% of the subjects, indicating 
unbalance between bone formation and resorption in osteopenic women. 
As judged by the BMD and marker results, smoking did not lessen the effect of transdermal 
estrogen replacement therapy (ERT), and the standard dose of estrogen was adequate also in 
smokers for the bone sparing effect of ERT. However, during the second treatment year bone 
formation increased in non-smokers with concomitant stable bone resorption, seen as 
increased S-PINP and stable U-NTX, whereas in smokers both markers were stable, perhaps 
indicating more positive bone balance in non-smokers during extended treatment. 
The response to short-term treatment with oral bisphosphonates clodronate was seen as 
decreased levels of U-NTX and decreased amplitude of diurnal variation of U-NTX. 
Clodronate did not influence the diurnal variation of other measured markers, U-Pyr, S-ICTP 
and S-PICP, nor their levels. The most sensitive marker to find responders to clodronate 
treatment for one and two years in early postmenopausal osteopenic women was S-PINP. The 
change in S-PINP was larger than the LSC of the marker in 79% of the subjects after two 
years on clodronate whereas the changes in markers of bone resorption, U-NTX and S-
TRACP 5b, found only 40% and 34% of the subjects to be responders. Early marker changes 
as response to treatment with transdermal estrogen or oral clodronate predicted later changes 
in bone mineral density at sites where trabecular bone predominates. As judged by the results 
of this study and studies by others, the response of individual markers of bone turnover to 
different treatments varies depending on the mechanism of the intervention. 
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